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Chapter 1
Introduction
1.1 Chemistry of the solid state
1.1.1 Crystal engineering
The term of crystal engineering was rst introduced by Pepinsky in 1955 [1] and
later developed by Schmidt. [2] Crystal engineering is dened as the design of crys-
tal architectures starting from molecular building blocks and it studies the dierent
crystal forms of compounds such as solvates, salts, cocrystals and polymorphs as
possible routes for new functional materials (Fig. 1.1). It has become a key topic
in the last few years, in both academic and industrial research, due to the im-
pact that new crystalline materials have in dierent areas such as supramolecular
chemistry, [3, 4] non-linear optical materials, [5, 6] coordination polymers [7] and
pharmaceutical sciences, [8] usually with the aim of improving the physicochemi-
cal properties and also generating intellectual property. [9, 10] Crystal engineering
permits a rational approach to the investigation of solid forms. [11]
1.1.2 Solid state forms
1.1.2.1 Polymorphs
Over the last decades polymorphism has been an intense area of research in solid-
state chemistry. [12, 13] Polymorphism is dened as "the ability of an element or
compound to exist in dierent crystal forms; with a dierent space disposition of
the molecules which form the crystal". [14] Such dierences in crystal packing and
inter/intramolecular interactions can lead to considerable dierent physical and
chemical properties, such as particle size, shape, hardness, melting point, density,
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Fig. 1.1: Layout of molecular solid forms
solubility, dissolution rate, hygroscopicity, reactivity, heat capacity and stability,
[15{18] which aect drug manufacturing processes [19, 20] and bioavailability, [21]
mainly concerning the pharmaceutical industry. Other areas such as agrochemicals,
pigments, dyes and explosives are also aected by polymorphism. [12, 22{25]
The rst reported example of polymorphism of molecular compounds was ben-
zamide in 1832 [26] and later on the ritonavir's phase transformation [27] alarmed
the pharmaceutical industry (Fig. 1.2). Another similar case has been reported
more recently for rotigotine, a Parkinson's disease drug. [28]
Fig. 1.2: Ritonavir's polymorphs [29]
Polymorphism and crystallization have become essential for research and the
pharmaceutical industry with special importance on generic drugs over the last
decade. About 80 per cent of pharmaceutical API's (Active Pharmaceutical In-
gredient) show polymorphism and it has become a constant concern to the patent
system, since a crystalline modication of a substance represents the existence of a
new solid form with potentially dierent properties, converting it to a competitor
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of a patented compound. [14, 16, 30, 31] Although today polymorphism is a well
known phenomenon, predicting the occurrence and the properties of a particular
polymorph of a given compound, as well as obtaining the desired polymorph are
still a challenge to researchers. [32{38]
1.1.2.2 Thermodynamics of polymorphs
In a polymorphic system it is of great interest to determine the relative stability
of the dierent forms. The ability of a polymorph to crystallize is determined by
thermodynamic and kinetic factors. [39] As a consequence of the dierent disposition
of the molecules in the crystal lattice and the non-covalent interactions, the energies
of the polymorphs are also dierent and in extension the physicochemical properties
of each solid form. Only one of the forms is the thermodynamically stable at
a specic temperature and the rest of the forms may transform into the stable
one. [14] However, it is possible that this transformation needs high activation
energy and consequently the existence of metastable forms which do not transform
during long periods of time is allowed. In the pharmaceutical industry, usually
metastable forms are of special interest since they have advantageous properties
such as high solubility, major bioavailability, and better behaviour in grinding or
milling and compression processes. However, mechanical stress processes and high
humidity conditions can accelerate polymorphic transformations from metastable
to the stable forms, because of the tendency to reduce their free energy. [14, 16]
The knowledge of the thermodynamic and kinetic landscape of a polymorphic
system is crucial to understand the formation of the dierent phases and their
interrelations. The relation among dierent phases of a substance is governed by
the rule of phases established by Gibbs:
P + F = C + 2 : (1.1)
Being C the number of components, P the number of phases in equilibrium and
F the number of degrees of freedom of the system. In case of a pure substance
(C = 1) exhibiting two forms, two phases are in equilibrium (P = 2) and the
system presents one degree of freedom. The conclusion drawn from the rule of
phases is that only one form exists in a determined temperature and pressure, except
in the transition temperature (T
tr
), where the two phases coexist in equilibrium.
According to this rule, the process of transformation of one polymorph into another
(a phase transition) takes place at a specic temperature and pressure.
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Relative stability between polymorphs
In the late nineteenth century, Lehmann classied the polymorphic systems into
monotropic and enantiotropic systems, whereas Ostwald discovered the principles
of thermodynamic and kinetic relationships between polymorphs (Ostwald's Rule
of Stages). [12] If the system is reversible, the two forms are related enatiotropically
and a transition temperature exists, in which the relative stability of the two poly-
morphs is inverted. The low melting form is the most stable below the transition
temperature, and the high melting form is stable over that value. The transition
on heating is always endothermic, whereas on cooling it is exothermic. On the
contrary, if the transition between phases is irreversible, the two forms are related
monotropically and the highest melting form is the most stable at all temperatures
until the melting. In that case, the only possible spontaneous transformation is
from the lowest melting point form to the highest melting point form, and such
transformation is necessarily exothermic. [16, 40, 41]
Determining the relative stability between polymorphs is of great importance,
since in the case of monotropy it will be impossible to obtain a metastable form
starting from the stable one in the solid state. On the other hand, in the case of
enantiotropy it is possible to obtain any of the forms depending on the temperature.
In general, the thermodynamic relationship between two polymorphs is represented
by the Gibbs free energy versus temperature plot. Burger and Ramberger, [42]
proposed alternative plots called energy diagrams, in which free Gibbs energy and
enthalpy of both polymorphs versus temperature are represented.(Fig. 1.3) [12, 14,
34, 40]
Rules for the prediction of the thermodynamic relationship between
polymorphs
Thermodynamic relationships between polymorphs can be deduced experimen-
tally by solubility measurements, solution-mediated polymorphic transformation
studies, calorimetric analyses, density data and spectroscopy analysis. Tamman in
1926 was the rst to develop some rules for predicting the thermodynamic rela-
tive stability between two or more polymorphs. Later, Burger and Ramberger in
1979, Yu in 1995 and Grunenberg et al. in 1996 made extensive their application-
s. [12, 14, 40, 42, 43] The following empirical rules were extracted:
Heat of transition rule: two polymorphs are enantiotropically related if an en-
dothermic phase transition between both forms exists at a temperature below the
lower melting point. [14, 40, 41]
Heat of melting rule: two polymorphs are enantiotropically related if the higher
melting point form presents the lowest enthalpy of melting, otherwise they are
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Fig. 1.3: Burger-Ramberger plots; (a) Enantiotropy and (b) Monotropy
monotropically related. [14, 40, 41]
Entropy melting rule: two polymorphs are enantiotropically related if the higher
melting point form presents the lowest entropy of melting. On the contrary, they
are monotropically related. [14, 43] However, this rule has several exceptions.
Heat capacity rule: two polymorphs are enantiotropically related if the higher
melting point form has the bigger heat capacity, at a specic temperature. This rule
has a limited application since similar heat capacities are diÆcult to be measured
accurately. [14, 40]
Density rule: it is based on the principle established by Kitaigorodskii, taking in-
to account the compact packing of the molecular crystals. [44] The most stable form
of a system without hydrogen bonds in the absolute zero temperature has the high-
est density, since Van der Waals intermolecular interactions are stronger. Therefore,
the crystal structure with the most eÆcient packing will have also the lowest free
energy. However, this rule presents exeptions since energetically favorable hydrogen
bonds can compensate the loss of energy of Van der Waals interactions and they
can stabilize the polymorph with lower density. [12, 14, 44]
Other rules exist, but they are not widely applicable because of their error
percentage.
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1.1.2.3 Solvates and hydrates
Molecular compounds can also exist as solvates, which are solid phases contain-
ing solvent molecules that occupy regular positions in a stoichiometric or non-
stoichiometric ratio in the crystalline structure. [14, 45, 46] Solvates are generally
more soluble and dissolve faster than the pure substance. When the solvent is wa-
ter they are called hydrates and, although they are usually less soluble than the
anhydrous form, [47] they have much more interest in the pharmaceutical industry,
because of its non toxicity and its high stability due to the capacity of the water
molecules to form hydrogen bonds. [16] Moreover, these solid forms are of rellevance
in polymorphism since desolvation may lead to new polymorphs.
1.1.2.4 Amorphous solids
Amorphous solids consist of disordered arrangements, lacking a long-range order
of molecules in the solid phase. Since they are metaestable forms, with a strong
tendency to crystallize even more in contact with moisture, it is diÆcult to commer-
cialize them in the pharmaceutical industry. However, they present a high interest
in terms of solubility and bioavailability. Processes such as liophilisation and spray-
drying are broadly used to produce amorphous solids. [16] An amorphous phase is
named vitreous below a temperature called glass transition temperature (T
g
) and it
tents to behave like a crystalline solid having similar properties such as the plastic
deformation and little order of the molecular disposition. Over this temperature,
the substance is called rubber and it behaves more like a liquid phase, having sim-
ilar molecular mobility, which may facilitate its spontaneous crystallization with
a low exothermic heat variation associated and its subsequent melting at higher
temperature. [40]
1.1.2.5 Salts
There are specic cases when the target compound is ionizable and it is possible
to form a salt with a basic or acidic coformer. [48] Salts are highly soluble in
water and they show higher bioavailability than their corresponding neutral species.
For this reason, they are, in many cases, preferably chosen over the free acid or
base in the formulation of pharmaceutical compounds. Additionally, salt formation
can improve crystallinity and stability. Approximately half of the APIs in the
pharmaceutical market are salts. [14, 18, 49]
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1.1.2.6 Cocrystals
Cocrystals have been known since the late 19th century. Quinhydrone was the rst
reported cocrystal by F. Wohler in 1844. [50] They are an alternative to salts when
these do not have the appropriate solid state properties or cannot be formed due to
the absence of ionizable sites in a chemical compound. The denition of a cocrys-
tal has brought considerable debate regarding them as multicomponent crystals:
"complexes of two or more neutral molecules, each one existing as a solid at room
temperature, interacting in the crystal lattice via non{covalent interactions: mainly
hydrogen bonds, Van der Waals or { interactions". [14, 17, 51, 52] Recently, the
Center for Drug Evaluation and Research of the Food and Drug Administration (F-
DA) has released the latest regulatory classication of pharmaceutical cocrystals:
a cocrystal is a dissociable API-excipient complex classied as a drug product in-
termediate that can improve drug performance. [53]
Whether a compound is a salt or a cocrystal has been an issue of discussion
among solid state chemists. [54,55] Cocrystals and salts may be distinguished by the
absence or not of a proton transfer between components. [56, 57] A pKa dierence
between two reactants (typically  pka > 3) is used as a criterion for selecting
counterions of salt formation. When the  pka < 1 the resulting compound will
almost exclusively be a cocrystal. However, there is a range between 0 and 3 in
which no accurate prediction is possible to make. The dierence between a salt and
a cocrystal is the proton location in the crystal. Nevertheless, there is no sharp
borderline between the two types of multicomponent crystals but a continuum, [54,
55, 58{60] since a molecular cocrystal can transform into a salt on variations in
temperature or pressure. [61{63]
Cocrystals have recently gained the interest of dierent research areas such as
nonlinear optics, solvent free organic synthesis, host{guest chemistry and photo-
graphic lm formulation and they have become an additional tool in the pharma-
ceutical eld. [60] In crystal engineering of pharmaceutical interest, a major goal is
achieved when an API is induced to form a cocrystal by suitable complexation with
another molecule known as a coformer, which is selected on the basis of molecular
recognition through complementary sites with the API [64] from the GRAS (Gener-
ally Regarded as Safe) [65,66] and EAFUS (Everything Added to Food in the United
States) [67] lists published by the FDA. Cocrystallization of pharmaceuticals can
improve some of the solid-state properties of the drugs, such as bioavailability, [68]
dissolution rate, [69] physical stability, [70], owability, chemical stability, [71] com-
pressibility [72], hygroscopicity, [73] and the new solid forms can oer the possibility
of patenting a protected API without infringing the originator's patent. [70, 74, 75]
Cocrystals and salts can also present polymorphism, suggesting additional options
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to modify properties, increase patent protection and improve marketed formula-
tions. [10,76{85] Opposite to what was previously thought, [86] cocrystal polymor-
phism is highly frequent and several examples of pharmaceutycal cocrystals that
show polymorphism have been reported to date. [77, 84, 87{89] Investigating the
polymorphic behaviour of a compound is crucial for determining the solid state
properties of a system and it is equally important when regarding cocrystal forms.
Of several methods, cocrystallization from solution and mechanochemical methods
are the mainly used for cocrystal formation and a combination is needed to identify
as much polymorphic forms as possible. [90] Although several examples of pharma-
ceutical cocrystals are reported in the literature, none has been approved for use
by the FDA yet, therefore much eort needs to be directed to the pharmaceutical
cocrystal research.
A particular class of cocrystals formed by a neutral molecule and an inorganic
salt are named ionic cocrystals and they have recently also received much attention
in the pharmaceutical eld. [91, 92]
1.1.3 Supramolecular chemistry
The term supramolecular chemistry has been dened by the Nobel laureate Jean{
Marie Lehn as "the chemistry of molecular assemblies and of the intermolecular
bond". [93] The principles of self-assembly and molecular recognition are intimate-
ly associated paradigms of supramolecular chemistry. The original research on
supramolecular chemistry remains on synthetic receptors capable of "host{guest"
type behavior in molecular recognition processes in which molecules select each
other via favorable intermolecular interaction to yield a well-dened complex in
solution in a coherent and cooperative manner, without the need to break or form
covalent bonds. [94, 95] Pedersen, [96] Lehn [97] and Cram [98] developed the con-
cepts of molecular recognition and self-assembly as an area of scientic research.
Nowadays, supramolecular chemistry has evolved into an interdisciplinary eld that
bridges biology, chemistry and physics. Crystal engineering has been applied under
the concept of supramolecular chemistry to design cocrystals by means of energy
or structure based rational approaches on the paradigm of intermolecular interac-
tions and molecular recognition to obtain new functional materials with specic
properties. [52] A cocrystal is the consequence of a molecular recognition even-
t between dierent molecular species. The subsequent crystal self-assembly is a
non-equilibrium process via intermolecular interactions subject to the crystalliza-
tion conditions and processes such as association and nucleation take place before
crystal formation. (Fig. 1.4)
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Fig. 1.4: Crystal engineering and supramolecular chemistry
1.1.3.1 Intermolecular interactions
Intermolecular interactions can be characterized by their ability to participate in di-
rectional or non{directional forces. Crystals of supramolecular systems are an exam-
ple of structures that arise from both kind of interactions. On the rst group, hydro-
gen bonding, halogen bonding, ion pair, ion{dipole [99] and dipole{dipole [100{102]
interactions are largely electrostatic interactions. The anisotropic nature of dipoles
provide a degree of directionality, as well as hydrogen and halogen bonding and also
CH{ interactions. [103,104]. On the other hand, induced-dipole interactions such
as ion-induced-dipole and Van der Waals or London dispersion forces are weaker
than permanent dipole interactions and they are the most commonly encountered
non-directional interactions. Although not useful in cocrystal design, they are im-
portant in crystal packing. [105, 106]
The most notable interaction is hydrogen bond. Ubiquitous in science, hydro-
gen bonds are of relevance in assembling processes due to their directionality and
strength. [107] It was in 1931, in a paper describing the nature of the chemical
bond, when Pauling rst used the descriptor "hydrogen bond". [108] A hydrogen
bond may be formed when the electronegativity of A relative to hydrogen in an
A{H covalent bond is suÆcient to cause deshielding of the hydrogen. [109,110] The
hydrogen bond then forms with an acceptor atom B that comprises lone-pair elec-
trons or polarizable {electrons resulting in an A{H  B arrangement. Hydrogen
bonds have the exibility to exist between varieties of functionalities with dierent
lengths and geometries. [111] For pharmaceutical cocrystals, hydrogen bond plays
a signicant role and a graph set notation system introduced by Etter et al. in
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1990 [107, 112] has been used widely to describe and label hydrogen bond motif-
s. For principal motifs: chains C, dimers D, rings R and intramolecular hydrogen
bonds S as descriptors of hydrogen{bonded molecular solids are dened (Fig. 1.5).
Fig. 1.5: Examples of graph sets in hydrogen bond arrays
In parallelism to hydrogen bonding, halogen bonding is a relatively strong and
directional non covalent interaction of the type B{XY where B represents a Lewis
base, commonly nitrogen, oxygen, sulphur or sellinium with a non bonding electron
pair, and X a halogen atom. Another reported type of halogen bonds is X:N. [113{
116]
Electrostatic interactions such as ion pair are dened to exist when a cation and
an anion are close enough in space that the energy associated with their electrostatic
attraction is larger than the available energy to separate them. Ion-dipole and
dipole-dipole is another type of electrostatic interactions in which the positive charge
ends of a dipole interact with the negatively charge ends or ion. The latter forces
are responsible for holding solvent molecules together and raising boiling points.
Other interactions which play a role in supramolecular chemistry and critical bi-
ological processes are those between {surfaces ({ stacking), cation{, anion{
and polar{. [117, 118] { interactions, can exist in dierent conformations: par-
allel displaced, T{shaped or edge{to{face, and tilted{T, [119{121] and all of them
have been reported as part of the complexation of aromatic compounds within struc-
turally diverse hosts in which complementary electrostatic interactions also play a
role. Cation- interactions have been reported to be comparable in nature and
strength to the strongest intermolecular interactions. [122, 123] Theoretical studies
of anion{ interactions support the concept of electron decient aromatic surfaces
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exhibiting favorable interactions towards anions with binding energies comparable
to hydrogen bonds [124] Weaker than cation and anion{ interactions, polar{ in-
teractions take part when a polar molecule interacts with the quadrupole moment
of a  system. Any hydrogen bond donor will experience a favorable electrostat-
ic interaction with the face of a benzene ring. These interactions are observed in
protein structures and contribute to solid state packing forces.
On the other side of electrostatics, the hydrophobic eect is the single most
important component in biologycal molecular recognition processes such as protein
folding, membrane formation, small molecule binding by receptors in water. [118]
A comparison of the main intermolecular interactions is shown in table 1.1.
Tab. 1.1: Non-covalent intermolecular interactions.
2
Interaction Bond Energies Building blocks Products
(kJ/mol)
Covalent 200{400 Atoms Molecules
Hydrogen Bond 4{120
Dipole{Dipole 5{50
    stacking < 50 Molecules Supermolecules
Van der Waals < 5
1.1.3.2 Cocrystals design and prediction
A detailed understanding of the supramolecular chemistry of the present functional
groups is a prerequisite for designing a cocrystal, since it facilitates the appropriate
selection of cocrystal formers. Structure based cocrystal design consists in locat-
ing which functional groups can interact with a coformer using as a reference an
empirical resource such as the Cambridge Structure Database (CSD), [125] which
facilitates statistical analysis of packing motifs and many empirical information con-
cerning common functional groups and how they engage in molecular association
and form supramolecular synthons. [126]
A supramolecular synthon is a probabilistic event that represents directionali-
ty, and it is deeply embedded into the theory and practice of crystal engineering,
since it is the structural unit that conveys the essential features of a crystal struc-
ture. Supramolecular synthons can be classied in two groups: homosynthons and
heterosynthons. [127] Homosynthons occur between identical and complementary
2
Data compiled from [94]
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functional groups and some examples are: carboxylic acids, amide dimers and cate-
mer synthons. On the other hand, heterosynthons occur between two dierent but
complementary functional groups and some examples are: carboxylic{amide and
carboxylic acid{pyridine synthons. [128] (Fig. 1.6)
Fig. 1.6: Examples of supramolecular synthons
The supramolecular synthon approach [60] has its origins in 1894, when Emil
Fischer postulated that an enzyme interacts with its substrate as a key does with
its lock. [129] Later, the term of supramolecular synthon has been dened by De-
siraju [64,126,130] as "structural units within supermolecules which can be formed
and/or assembled by known or conceivable synthetic operations involving inter-
molecular interactions".
Cocrystallization is the result of competing molecular associations between dif-
ferent molecules and hydrogen bonds are mainly the basis of molecular recognition
phenomena and responsible for the generation of a huge variety of molecular net-
works in the crystalline state. Thus, the crystal construction might be seen as a
kinetically sequential event, in which initially the most robust synthon is formed
with strong and directional interactions followed by other synthons involving slight-
ly weaker and less directional interactions. Although competition between synthons
makes it complicated, [64,85] empirical conclusions over the hierarchy of supramolec-
ular synthons and in particular concerning hydrogen bonds are useful guidelines for
cocrystal design. [52,131,132] The identication of reliable supramolecular synthons
is the preliminary step in the design and analysis of multicomponent crystal struc-
tures. The main empirical guidelines described by Etter can be summarized as
follows: [107]
 All good proton donors and acceptors are used in hydrogen bonding
 A six-membered ring with intramolecular hydrogen bonds is formed in pref-
erence to intermolecular hydrogen bonds
 The best proton donors and acceptors remaining after intramolecular hydro-
gen bond formation form intermolecular hydrogen bonds to one another.
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A cocrystal is only expected to form if it is thermodynamically more stable
than its free components. Understanding the relationship between the structure
of a molecule and the preferred pattern of packing during the assembly of a mul-
ticomponent crystalline solid would provide insight into the design of solids with
properties that depend on the relative alignment of the constituent molecules. Thus,
understanding the nature and energetic orderings of non covalent interactions is es-
sential for predicting the structures and properties of complex molecular systems.
Apart from structure based methods for designing cocrystals, computational at-
tempts have been recently exploited to predict cocrystal formation on the basis
of various parameters: lattice energy calculations by Sally Price and coworker-
s, [133, 134] Hansen solubility parameters (HSPs), [135] enthalpies as implemented
in COSMOtherm software. [136] More recently, a new predictive methodology has
been developed by Chris Hunter, based on surface site interaction points calculated
from the ab initio molecular electrostatic potential surface of the molecule in the
gas phase. [137{139]
Unfortunately, cocrystal stoichiometry and additional components, such as sol-
vent or water, which may become incorporated into the structure during synthesis,
are other complications that hinder structure prediction. Therefore, reliable pre-
dictions of which structures will actually crystallize remains a challenging area of
ongoing research and cocrystal synthesis is still limited within the real mode of
trial-and-error experimentation for the foreseeable future. [140{143]
Rationalizing and predicting patterns of packing in molecular solids has proven
to be diÆcult and dierent experimental strategies for engineering the design of
molecular aggregates have been developed. [144{146] However, it still remains a
scientic challenge to understand the nature of crystal packing forces and their
impact upon physicochemical properties of dierent crystal forms.
1.1.3.3 Cocrystals formation
Various experimental methods can be performed to cocrystallize two entities: grind-
ing, drop-grinding, cocrystallization from solution, reaction crystallization and co-
melting are mainly used, and experimental conditions such as temperature, solvent,
solute concentration, additives, vessel design, time heating, cooling rates, pH and
mixing ratios are possible variables to be modied. [10,74,147] A rst step of cocrys-
tal formation is to study the existing equilibrium between the two solid phases and
the solvent.
To depict the phase behavior of cocrystallizing systems, solubility diagrams are
useful: binary phase diagram (BPD) [148] of A and B shows the thermal stability of
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the cocrystal system and the eutectics, phase solubility diagram (PSD) [149] shows
the solubility curves of solid phases as a function of solution concentration of A and
B and ternary phase diagrams (TPD) [150,151] shows the thermodynamic outcome
of a crystallization of cocrystal components (A and B) in a solvent (S) at a given
temperature (Fig. 1.7). Solubilities of the two components are of special interest,
since the dierence in solubility alters the location and the shape of the region in
which a cocrystal is thermodynamically stable.
Fig. 1.7: Schematic (a) BPD, (b) PSD and (c) TPD diagrams [152,153]
After choosing the proper coformers, an experimental cocrystal screening is con-
ducted in order to identify the solid forms obtained and verify if the previous pre-
diction has been true. Since it is diÆcult to automate and labor intensive, high
throughput methods have become of relevance. [154,155] The nal step of cocrystal
preparation is the performance of tests of newly formed compounds which includes
both in vitro and in vivo tests for pharmaceutical cocrystals.
1.2 Squaric acid derivatives
In this phD thesis, the solid state knowledge is applied to dierent squaric acid
derivatives. Squaric acid (3,4-dihydroxy-3-cyclobutene-l,2-dione, (1)) was rst syn-
thesized by Cohen [156] and it is a colorless cyclobutene derivative of unusually
high chemical and thermal stability. It is a strong diprotic acid, which can form
mono- and dianions on deprotonation by amines (Fig. 1.8). [157{159] All the neutral
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and ionic species possess a certain degree of electron delocalization, but it is most
pronounced in (3), which is considered to be aromatic.
Fig. 1.8: Anionic forms of squaric acid
After the discovery of moniliformin, a semisquaric acid salt isolated from maize
molds Fusarium moniliforme and Gibberella Fujikuroi, [160] numerous analogues
derivatives of squaric acid have been synthesized and showed interesting physiolog-
ical properties. [161] For all these abovementioned characteristics and its nature of
small, at and rigid molecule which can self-assemble by strong hydrogen bonds,
squaric acid is a versatile potential molecule frequently used in crystal engineering
to build up multicomponent systems with metals or organic bases to give specif-
ic two- or threedimensional aggregates. [162{166] In bioorganic chemistry, squaric
acid can be used in enzymatic reactions, since its dierent resonance forms can
mimic acidic functions. [167, 168] In other elds, squaric acid has been applied to
the design of photoreceptors, organic solar cells and optical recording. [169]
A family of compound derivatives from squaric acid are cyclobutenediones and,
in particular, squaramides (Fig. 1.9), which exhibit interesting and useful properties
as supramolecular synthons. The presence of two donor and two acceptor hydrogen
bonding groups in a rigid squaric ring have attracted in the past the attention of
researchers in dierent areas such as medicinal chemistry, enantioselective catalysis,
supramolecular chemistry and biochemical processes. [170{172]
N N
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Fig. 1.9: Squaramide scheme
Squaramides have been widely studied in dissolution and various applications
of these compounds have been recently reported. Unsymmetrical squaramides have
been used as pharmaceutically active compounds into the treatment of various
inammatory diseases [173] and they have been also patented for their applica-
tion in the treatment of asthma, multiple sclerosis, and rheumatoid arthritis. [174]
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Still in medicine, other squaramides have been used as carboxylates, sulfonates
and phosphates isosteric groups to enhance biological activity. [175] In biochem-
istry, squaramide-type nucleotide analogues have been studied as potential bio-
logically active compounds such as antiviral and anticancer agents [157, 176{178]
and as transmembrane anion transporters and ion channels for the treatment of a
broad spectrum of disease types, with better properties than analogous ureas and
thioureas. [179] In molecular recognition systems, squaramides are complementary
to cations and anions, such as quaternary ammonium salts, [180, 181] carboxy-
lates, [171] anion sulfates [182] and phospholipids. [171] These properties have been
applied into the design of sensing devices [180, 183, 184] and nanoparticles. [185]
Besides the abovementioned physiological properties of cyclobutenediones, these
compounds have been also proved as powerful synthetic building blocks [170] and
as chiral auxiliaries for asymmetric catalysis [186, 187] and dierent reactions such
as Michael addition, [188] Friedel-Crafts reaction, [189] -amination, [190] dynamic
kinetic resolution [191] and Morita{Baylis{Hillman reaction. [189]
From a structural point of view, squaramides are analogous to squaric acid and
they can be described as viniligous amides. The rigid and planar structure of the
cyclobutendione ring (C
4
N
2
O
2
), containing two coplanar carbonyls and two N-H
almost coplanar, induces a denite orientation of N-H groups, which enhances the
linear hydrogen bonding specicity for some substrates. [192] The hydrogen bond
capabilities are strengthened by the delocalization of the nitrogen lone pair electrons
into the four-member ring to form zwitterionic resonance forms (Fig. 1.10) [193] and
theoretical calculations have demonstrated that its partial aromaticity increments
with the formation of complexes with anions and cations. [194{196]
Fig. 1.10: Zwitterionic resonance forms of squaramides
For all these characteristics, squaramides have been studied in supramolecular
chemistry as an eÆcient alternative to ureas and thioureas in the design of neutral
multisite receptors, since they present advantages in duality binding, rigidity, hydro-
gen bonding, acidity and chemical stability. [197{199] Computational studies have
illustrated the enhanced hydrogen bond donor ability and acidity of squaramides
in comparison to ureas and thioureas. [200] The squaramido functionality shows d-
uality and participates readily in ditopic or polytopic binding (anions and cations)
(Fig. 1.11) even in competitive solvents, more than their counterparts' ureas and
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thioureas. [185, 197, 198, 201] Squaramides have been also proven good substitutes
to thioureas in asymmetric catalysis. [171]
Fig. 1.11: Squaramide anion complex [202]
Previous studies of secondary squaramides in solution demonstrate that these
compounds can exist in several conformations due to the partially restricted rotation
of the C-N bond (anti/anti and anti/syn conformers) (Fig. 1.12). [192, 197, 203]
Fig. 1.12: Squaramide's possible conformations
The low energy barrier of rotation enables squaramides to exist in dierent
conformations, which are geometrically capable to form self-assembling aggregates,
stabilized through intra or intermolecular hydrogen bonds, even in highly competi-
tive polar solvents. [181, 192, 204]
Although the properties of squaramides in solution are well known, to the best
of our knowledge no information has been previously reported about their confor-
mational preferences in the solid state. Only a few crystal structures of disecondary
squaramides have been described. [205, 206]
In this PhD thesis, the solid state properties of squaramides will be investigated,
as well as their applicability into the design of new multicomponent crystals.

Chapter 2
Objectives
This thesis is a multidisciplinary study of the solid state of squaric acid derivatives
by combining approaches from areas such as crystal engineering, organic synthesis,
supramolecular chemistry and crystallography.
The main objectives of this thesis are:
 To analyze the structural preferences in the solid state of the abovementioned
family of compounds, which have been poorly studied in the past.
 To design new crystalline materials derived from squaric acid in order to study
new supramolecular synthons.
 To explore relevant chemical phenomena such as template eect, preorgani-
zation, cooperativity and electrostatic compression.
In order to accomplish these objectives, a series of squaric acid derivatives has
been synthesized and their crystal forms have been analyzed by means of several
experimental techniques. In this sense, a crystal structure solution method based
on powder X-ray diraction has been optimized.
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Chapter 3
Results and discussion
It is well known that squaramides exhibit a dual donor{acceptor hydrogen bonding
ability in solution which make them interesting targets in areas such as supramole-
cular chemistry or medicinal chemistry. However, the lack of information about the
solid state properties of squaramides encouraged us initially to conduct a polymorph
screening of several model compounds with the objective to learn more about the
structural features and conformational preferences of this family of compounds. On
a second stage, this information was used to design new supramolecular architec-
tures through crystal engineering strategies. Finally, the analysis of their crystal
structures, in combination with important associated chemical phenomena such as
cooperativity, preorganization and electrostatic compression, helped us to establish
crystallographic and chemical relations among these compounds.
3.1 Polymorphism of disquaramides
In this chapter the polymorphism of several model compounds are separately dis-
cussed (Fig. 3.1). Each model compound has been carefully designed with its par-
ticular interest: dibenzylsquaramide (1) has no additional hydrogen bond donors/
acceptors apart from the squaramide moiety and it is geometrically restricted com-
pared to other models, the two dipyridyl squaramides (2 and 3) have dierent
alquilic chain lengths and the pyridine groups enhance the hydrogen bond accep-
tor character of the whole compound, as well as the two dimethylamino groups of
dimethylethylenediaminosquaramide (4) which in addition is highly exible.
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Fig. 3.1: Squaramide model compounds: (1) Dibenzylsquaramide, (2) 3,4-bis-
(2-methylaminopyridyl)-1,2-dioxo-3-cyclobutene, (3) 3,4-bis-(2-ethylaminopyridyl)-1,2-
dioxo-3-cyclobutene, (4) 3,4-bis-(2-dimethylamino-ethylamino)-1,2-dioxo-3-cyclobutene
An experimental polymorph screening under dierent thermodynamic and kinet-
ic crystallization conditions was conducted with all compounds in order to obtain as
many crystal forms as possible (Chapter 6.3.6). The dierent crystal modication-
s observed were fully characterized by the combination of calorimetric techniques
(DSC, TGA), powder X-ray diraction (PXRD) and hot-stage microscopy. When
possible, the crystal structures were determined either by single X-ray diraction
(SXRD) or from PXRD.
3.1.1 3,4-Bis-benzylamino-cyclobut-3-ene-1,2-dione (1)
Compound 1 (Dibenzylsquaramide) was obtained according to the literature from
diethylsquarate and benzylamine in ethanol as a white solid (Chapter 6.3.6). Since
it was highly insoluble in all organic solvents, it could only be recrystallized in polar
media such as DMF and DMSO and dierent combinations of those solvents with
polar and non polar antisolvents. The solids obtained revealed a multipolymorphic
system consisting of three forms according to their dierent X-ray diraction pat-
terns (Fig. 3.2). Experimental screening results are summarized in appendix A.12.
Form I was obtained by slow cooling of a DMF saturated solution of 1 from
70
Æ
C to r.t. Forms II and III could be obtained by slow diusion of diethyl ether or
dioxane, respectively, into a DMSO saturated solution at r.t. (See appendix A.12).
DSC analyses of forms I, II and III reveal the melting of the anhydrous form I
at 311
Æ
C(Fig. 3.3). In addition, DSC analyses of forms II and III show a solid-solid
transition at 256
Æ
C into form I, which was conrmed by both variable heating rate
DSC (the endothermic phenomenon is displaced when changing the heating rate)
and variable temperature PXRD analyses. Interestingly, the transition temperature
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Fig. 3.2: PXRD patterns of forms I, II and III of 1
is observed at almost the same value in both cases. Although several polymorphs
can present the same melting point, [207] to the best of our knowledge this is the
rst time that two forms share the same transition temperature.
Fig. 3.3: DSC thermograms of forms I, II and III of 1
Taking into account the prediction rules (see 1.1.2.2) and some calorimetric
experiments, the relative stability of the polymorphs of 1 was deduced. Their DSC
analyses revealed that the two polymorphic forms II and III transform through a
solid-solid transition into form I at the same temperature (Tab. 3.1).
Tab. 3.1: Calorimetric data for the dierent crystal forms of 1
Forms
Transition Melting
Onset (
Æ
C)  H (J/g) Onset (
Æ
C)  H (J/g)
I - - 311 165
II 257 2 - -
III 256 3 - -
Since the transition is endothermic, according to the Burger and Ramberger's
24 Results and discussion
heat of transition rule (section 1.1.2.2), II and III are enantiotropically related
to form I. In an enantiotropic system the phase transition must be reversible so
it might be detectable in a heating-cooling DSC analyses. Figure 3.4 shows a
DSC thermogram of form II in which the reversible phase transition is observed
endothermic while heating and exothermic on cooling.
Fig. 3.4: DSC thermogram of the reversible phase transition of form II on heating and cooling
Single crystals of forms I
1
and III
2
, suitable for X-ray structure determination
(Fig. 6.2), were grown by slow cooling of a saturated solution of 1 in DMF at
70
Æ
C and by slow diusion of dioxane into a saturated solution of 1 in DMSO at
r.t., respectively.
Since no suitable single crystals were obtained for form II
3
, its crystal structure
was determined by means of direct-space methods. Despite the facts of having a
tiny amount of sample and of preferred orientation problems caused by the usual
needle shape crystals, the use of high quality glass capillary, good resolution and
high statistics laboratory powder XRD data lead to a successful structure solution.
The results enabled the following discussion of relevant crystallographic features of
the three polymorphs (Fig. 6.2).
Forms I, II and III crystallize in monoclinic non-centrosymmetric space groups
C2, Pc and C2/c, respectively. All three forms reveal a well dened head-to-tail
hidrogen bonding motif among the squaramide units through two amide hydrogens
and two carbonyl oxygens (N-H/O) with similar intermolecular distances (Tab. 3.2).
Secondary     stacking of the benzene rings in edge-to-face and oset stacked
geometries [121] are also observed in the direction of b axis for form I and c axis
1
CCDC 676071 contains the crystallographic data.
2
CCDC 686074 contains the crystallographic data.
3
CCDC 914675 contains the crystallographic data.
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Fig. 3.5: Crystal structures of forms I, II and III of 1
for forms II and III. CH- interactions are also present in the three forms and the
oset stacked molecules form a zig-zag pattern (Fig. 3.7).
Tab. 3.2: Crystal data for the three polymorphs of 1, being M1 and M2 the two conformers in
the asymmetric unit (*Standard deviations have not been calculated since distances are obtained
from Rietveld renement).
Forms
Space
Z (Z')
d NH  O d
centroids
d
CH 
Group (

A) M1/M2 (

A) M1/M2 (

A)
I C 2 4(1) 2.834(6) 2.838(6) 4.410 3.895
II Pc 4 (2) 2.844 2.900 / 2.837 2.839* 5.271 / 5.181 3.501 2.989
III C 2/c 4 (1) 2.779(3) 2.779(3) 3.263 5.242
The main dierence among them is that the asymmetric unit of form II contains
more than one molecule (Z'=2). Polymorphs, and crystal structures in general,
where the number of molecules in the asymmetric unit is greater than 1 (Z' > 1) are
relatively rare and their occurrence is still the subject of debate, mostly regarding
their thermodynamic stability. [208{211] The two molecules in the asymmetric unit
show two dierent conformations as a result of the aromatic ring rotation (Fig. 3.6).
Since the asymmetric unit contains two dierent conformers, there are two types
of stacking arrangements. On the one hand, for the rst array of molecules, the
centroid-centroid distance is 5.27

A, the lateral displacement distance is 4.86

A and
the interplanar distance is 2.05

A, with an angle between rings of 37.77
Æ
. On the
other hand, for the second array of molecules, the centroid to centroid distance is
5.18

A, the perpendicular distance between the oset stacked rings is 4.63

A with
a displacement angle of 43.80
Æ
and lateral displacement of 2.3

A (Fig. 3.7).
Calculation of Hirshfeld surfaces [212{214] and ngerprint plots [215] is a useful
way to analyze the intermolecular interactions in molecular crystals. The ngerprint
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Fig. 3.6: Overlapped conformers in the asymmetric unit of form II of 1
Fig. 3.7: Zig-zag patterns of forms I, II and III of 1
plots of the two dierent conformers in the asymmetric unit show the same hydrogen
bonding motif (red circles) but subtle dierences of packing, denoting a similar
crystallographic environment for the two conformers (Fig. 3.8).
Fig. 3.8: Hirshfeld surfaces (below) and ngerprint plots (above) of both conformers of form
II of 1, with d
e
(left) and d
i
(right) mapped in colour (in both cases red represents the closest
contacts, and blue the most distant contacts)
It is important to notice the dierent packing direction of the squaramide
columns when comparing the three polymorphs. Self-assembled chains of disec-
ondary squaramides can be oriented in three dierent manners: parallel, antipa-
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rallel, and unparallel alignments with implications in the crystal polarity, which
can produce Non-Linear Optical (NLO) materials, [216{219] interesting for the de-
velopment of technologycal devices. Since the molecular dipole moment of 1 is high
(8.15 Debbyes)
4
, the most likely alignment expected is the antiparallel one, which
minimizes the net dipole moment in the crystal. [220{222] Whereas forms II and III
show an antiparallel alignment in the direction of the head-to-tail alignment, form
I exhibits an unparallel conguration, with an angle of 144
Æ
between the dipole mo-
ment vectors (Fig 3.9) which could present NLO properties. Electronic mycroscopy
experiments were performed to conrm NLO properties of form I, but no signicant
conclusions could be extracted.
Fig. 3.9: Dierent possible combinations of dipole moment alignments; (a) antiparallel,
(b) parallel and (c) unparallel, showing the angle between dipole moment vectors
In conclusion, three forms of dibenzylsquaramide are reported, two of them
sharing a solid-solid transition at the same temperature towards the highest melting
polymorph, which is a rare observation. The same hydrogen bonding head-to-tail
motif is observed in their crystal structures and further insight investigations are
directed to other compounds with additional donor-acceptor functional groups to
reveal their crystal preferences.
3.1.2 3,4-bis-(2-methylaminopyridyl)-1,2-dioxo-3-cyclobutene
(2)
Compound 2 was prepared from diethylsquarate and 2-methylaminopyridine in
ethanol with high yield. An intensive polymorph screening resulted in two poly-
morphs I and II conrmed by PXRD analyses (Fig. 3.10).
4
Calculated with Spartan'10 using a DFT B3LYP/6-31G* functional
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Fig. 3.10: PXRD diagrams of forms I and II of 2
DSC analysis of form I shows its melting at 166
Æ
C together with a simultaneous
crystallization of form II. Finally, the subsequent melting of form II is observed at
186
Æ
C followed by its decomposition (Fig. 3.11).
Fig. 3.11: DSC thermograms of forms I and II of 2
Calorimetric data for crystal forms of 2 are summarized in table 3.3.
Tab. 3.3: Calorimetric data for crystal forms of 2 (*enthalpies are not precise due to overlapped
thermal phenomena)
Forms
Melting Crystallization
Onset (
Æ
C) H (J/g) Onset (
Æ
C) H (J/g)
I 166 >68* - -
II 186 90
~
169 >37*
Form I was obtained during the experimental polymorph screening as plate
shaped crystals from crystallizations under dierent conditions. However, form II
could only be obtained by crystallization from the melt. Form I was heated at
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175
Æ
C(10
Æ
C/min) in the DSC crucible under nitrogen atmosphere to obtain form
II, which remained stable when cooling to r.t. Therefore, it could be characterized
by powder X-ray diraction (See appendix A.12).
Occasionally, an endothermic solid-solid transition was observed by DSC (Fig. 3.12),
starting from form I at low heating rate (1
Æ
C/min), revealing an enantiotropic re-
lationship between the two polymorphs, being form I the stable polymorph below
the transition temperature (ca. 160
Æ
C).
Fig. 3.12: DSC of form I of 2 showing the melting/crystallization phenomena (red)
and the occasionally observed solid{solid transition from form I to II (blue)
This thermal behaviour was corroborated qualitatively by thermomicroscopy.
When heating form I, a partial solid-solid transition to form II was observed around
168-169
Æ
C. Simultaneously, the remaining form I melted and form II crystal-
lized from the melt also at 169
Æ
C. Finally, form II melted with decomposition at
190
Æ
C (Fig. 3.13).
Fig. 3.13: Hot stage photomicrographs of 2, showing the solid-state phase transition
from form I to form II together with melting and crystallization phenomena upon heating
at 10
Æ
C/min
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The crystal structure of form I
5
was determined by single crystal XRD using a
crystal grown by slow diusion of toluene into a solution of 2 in DMF at r.t. Since
single crystals of form II suitable for single-crystal XRD could not be grown, its
crystal structure determination was instead carried out directly from PXRD data,
exploiting the direct-space strategy for structure solution using EAGER software.
6
Fig. 3.14: Crystal structures and Hirshfeld surfaces of forms I and II of 2
The crystal structures of both forms (Fig. 3.14) present a well-dened head-
to-tail hydrogen bonding motif between squaramide units together with secondary
  stacking as for 1. Aryl CHN pyridine interactions are also observed. Crystal
data are shown in table 3.4.
The dominant NH  O hydrogen bonding interactions that give rise to catemeric
assemblies are seen in the Hirshfeld surface plots for both polymorphs (brightest
red areas in gure 3.14 (b)). However, the head-to-tail motif of form II is arranged
5
CCDC 805689 contains the crystallogrpahic data.
6
CCDC 826650 contains the crystallogrpahic data.
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Tab. 3.4: Crystal data of forms I and II of 2 (*Standard deviations have not been calculated
since distances are obtained from Rietveld renement)
Forms Space Z (Z') d NH  O d
centroids
dCH-N
pyridine
(

A)
Group (

A) (

A) (

A)
I Pc 2 (1) 2.834(8) 2.848(6) 3.851 2.578(5)
II P-1 2 (1) 2.804 2.836* - 2.916*
in antiparallel rows of self-associated squaramide molecules whereas form I presents
parallel orientated head-to-tail rows. Dierent secondary interactions are estab-
lished in each case, corresponding to the structural particularities between the two
polymorphs.   stacking interactions in form I are replaced by edge-to-face CH-
interactions in form II. Furthermore, while the aromatic groups are located on the
same side of the squaric ring in form II, they are arranged in a zig-zag manner in
form I (Fig. 3.14(a)).
3.1.3 3,4-bis-(2-ethylaminopyridyl)-1,2-dioxo-3-cyclobutene
(3)
Compound 3 was prepared from diethylsquarate and 2-ethylaminopyridine in ethanol
with high yield. An intensive polymorph screening resulted in four polymorphs
(Fig. 3.15).
Form I was obtained during the experimental polymorph screening in dierent
conditions as a white powder or needle shaped crystals, suitable for single X-ray
diraction analysis. Form II could only be obtained by crystallization from the melt
and forms III and IV were obtained from rapid cooling precipitation of 3 in ethanol
and water, respectively (See appendix A.12).
DSC analysis of form I shows two endothermic phenomena apparently corre-
sponding to the melting of dierent polymorphs (Fig. 3.16). However, various alter-
native hot stage microscopy analyses show a solid-solid transition at the same tem-
perature as the rst endothermic phenomenon registered by DSC (Fig. 3.17). Com-
plementary low heating rate and heating-cooling DSC experiments cannot conrm
the nature of the rst endothermic phenomenon, since no presence of any transition
is detected and no separation of a possible overlaped melting/crystallization process-
es is observed. In a variable temperature PXRD experiment of form I (Fig. 3.18),
peaks of form II are detected at 198
Æ
C and the subsequent melting of form II is
observed at 224
Æ
C together with its decomposition at 250
Æ
C. The DSC analysis of
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Fig. 3.15: PXRD diagrams of forms I, II, III and IV of 3
form III shows a melting and crystallization phenomenon at 168
Æ
C and form IV
melts at 180
Æ
C.
Fig. 3.16: DSC thermogram of form I, II, III, IV of compound 3
Calorimetric data for crystal forms of compound 3 are summarized in table 3.5.
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Tab. 3.5: Calorimetric data for crystal forms of 3
Forms
Thermal phenomena
Onset (
Æ
C) H (J/g)
I 198 69
II 224 92
III 168 22
IV 180 39
Fig. 3.17: Hot stage photomicrographs of 3, showing the solid-state phase
transition from form I to form II and the subsequent melting phenomenon
upon heating at 10
Æ
C/min
Fig. 3.18: Variable temperature PXRD analysis of form I showing the trans-
formation into form II of 3
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The crystal structure of form I is reported in the CCDC (refcode NIZXOK).
Forms III and IV are metastable and no single crystals could be obtained. Broad
powder diraction peaks and low crystallinity hindered the cell indexing attempts.
Form II, however, could only be obtained by hot treatment of form I and it presents
a good quality powder diractogram. Although several attempts of indexing its
powder diractogram were done, no reasonable solution was achieved.
The crystal structure of form I (Fig. 3.19) presents a well dened head-to-tail
hydrogen bonding motif between squaramide units arranged in opposite directions,
together with secondary edge-to-face CH- interactions similar to those described
for form I of 2. Pyridine rings adopt a zig-zag conformation and aryl CH  N
pyridine interactions are also observed. Crystal data are shown in table 3.6.
Fig. 3.19: Crystal structure of form I of 3 (hydrogens not shown)
Tab. 3.6: Crystal data for form I of compound 3
Form Space Group Z (Z') d NH  O (

A) d CH-N
pyridine
(

A)
I Pna2
1
4 (1) 1.795(4) 1.883(2) 2.701(5)
3.1.4 3,4-bis-(2-dimethylamino-ethylamino)-1,2-dioxo-3- cy-
clobutene (4)
Compound 4 was readily prepared from diethylsquarate and dimethylethylenedi-
amine in ethanol with high yield. An intensive polymorph screening resulted in
several polymorphs, not all obtained in pure form (Fig. 3.20).
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Fig. 3.20: Experimental PXRD diagrams of forms I + , II and IV, and
calculated PXRD diagram of form III of 4
Form I was obtained directly from synthesis and other crystallizations with
dierent solvents. Some eorts to index its diractogramwere unsuccesful, probably
due to either the contamination with an unknown phase () or to a poor resolution
diractogram. Although further eorts to purify the sample by recrystallization
were done, no success was achieved and no identication of this unknown phase
could be done.
Form II was obtained pure from an experiment of cocrystallization of 4 with
glutamic acid, in particular, a recrystallization in ethanol. Apart from studying the
polymorphism of squaramides, in this work, special attention has been made on de-
signing cocrystals and analyzing their supramolecular synthons using squaramides
as scaolds (See chapter 3.4). Several cases of new polymorphs obtained by induced
crystallization with additives or using cocrystals as key intermediates are report-
ed in the literature. [223, 224] Other attempts of cocrystallization of 4 with urea
and nicotinamide in ethanol at r.t through reaction crystallization technique have
resulted in form II impuried by the coformer.
Form III could only be obtained from slow cooling recrystallization in acetonitrile
as yellowish needles suitable for SXRD analysis. Finally, form IV has been only
detected by DSC analysis from a solid-solid transition of forms I (+ ) and II
(Fig. 3.21).
DSC analysis of form I (+ , which is hypothesized), shows an endothermic
transition to form IV (m.p.=227
Æ
C) on heating (conrmed by variable tempera-
ture PXRD analysis), starting at about 45
Æ
C with an enthalpy of 4 J/g. When
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Fig. 3.21: DSC thermogram of forms I (+ ), II and III
a cooling-heating DSC analysis is performed, the transition appears at the same
temperature with a lower enthalpy (1.5 J/g), which suggests the possibility of an
incomplete reversible transition (Fig. 3.22) conrmed also by complementary ther-
momicroscopy analyses (Fig. 3.23). Form II presents an endothermic solid-solid
phase transition into form IV, at 150
Æ
C with an enthalpy of 20 J/g, conrmed
by variable temperature PXRD analysis. The DSC analysis of form III shows a
solid-solid transition at 44
Æ
C with an enthalpy of 3 J/g.
Fig. 3.22: DSC thermogram of form I showing a reversible
transition into form IV of 4 on a heating-cooling experi-
ment
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Fig. 3.23: Hot stage photomicrographs of 4, showing the reversible solid-solid phase
transition from form I to IV upon heating at 10
Æ
C/min. (a) T=37
Æ
C on heating, (b)
T=46
Æ
C on heating, (c) T=34
Æ
C on cooling, (d) T=28
Æ
C on cooling
Calorimetric data for crystal forms of compound 4 are summarized in table 3.7.
Tab. 3.7: Calorimetric data for the crystal forms of 4
Form
Solid state transition Melting
Onset (
Æ
C) H (J/g) Onset (
Æ
C) H (J/g)
I 45 4 - -
II 128 20 - -
III 44 3 - -
IV - - 227 137
In terms of this multipolymorphic system's thermodynamic relationship, form I
(+ ) would be enantiotropically related to form IV. Solid samples of form III kept
at r.t. tend to transform irreversibly into form I (+ ). Form II is enantiotropically
related to form IV, since an endothermic solid-solid transition is observed by DSC.
A scheme of the polymorph transformations among the dierent forms is shown in
gure 3.24.
Fig. 3.24: Polymorphic transformations of compound 4
Several crystallization attempts of form II did not result in a crystal with suitable
quality for SXRD analysis, thus, its crystal structure was solved by means of direct
space strategies. The crystal structure of form III
7
was determined by SXRD using
7
CCDC 1015652 contains the crystallogrpahic data.
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needles grown by slow evaporation of an acetonitrile solution of 4 at r.t. The crystal
structures of both forms (Fig. 3.25 and Fig. 3.26) present the typical head-to-tail
hydrogen bonding motif between squaramide units. The main dierence between
both structures is the orientation of the parallel squaramide alignments. Crystal
data are shown in table 3.8. Two cell indexing attempts of form IV obtained by
variable temperature PXRD analysis from form I (+ ) and form II, respectively,
suggested Cc or C2/c space groups. Unfortunately no crystal structure determina-
tion has been possible in spite of big eorts on obtaining high quality diractograms
of form IV. The dierences between cell parameters obtained, as well as the dif-
ferent position of the peaks on the powder diractogram, can be atributted to the
anisotropic dilatation caused by the temperature dierence. The use of synchrotron
radiation together with further purication eorts may be considered in order to
get deeper insight in this multipolymorphic system.
Fig. 3.25: Crystal structures of forms II of 4
Tab. 3.8: Crystal data of 4 (*Standard deviations have not been
calculated since distances are obtained from Rietveld renement)
Form Space Group Z (Z') distance NH  O (

A)
II P2
1
/c 4 (1) 1.975 1.988*
III Fdd2 8 (1) 1.963(13) 1.963(13)
After studing four model disecondary squaramides in the solid state, the exis-
tence of a robust self associating head-to-tail supramolecular synthon is observed in
eight crystal structures solved of the thirteen forms identied in total. They present
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Fig. 3.26: Crystal structures of forms II III of 4
an identical catemer motif in which assemblies of squaramide units interact through
hydrogen bonding and it appears to be unbreakable. The following scheme summa-
rizes the main polymorphic information of the four studied compounds (Fig. 3.27).
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Fig. 3.27: Summary of the polymorphic systems studied in this chapter
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3.2 From solution to the crystal
It is well known that the preferred structure of molecular clusters in supersaturated
solutions can sometimes resemble the mode of aggregation in the crystal structure,
suggesting a possible link between self-aggregation in solution and crystallization
processes. [225, 226] In this section, the structural preferences of a specic dis-
econdary squaramide model compound are analyzed in order to understand the
relationship between the structures of aggregates in solution and in the solid state.
Secondary squaramides present two dierent hydrogen bonding conformations
in solution that can act as double donor-acceptor groups: the anti/anti and the
anti/syn, both suitable to produce a R
2
2
(n) synthon with appropriate donor or
acceptor groups. (Fig. 3.28). [227]
Fig. 3.28: Two diferent conformations of disecondary squaramides
Since dibenzylsquaramide (1) and, in general, disecondary squaramides are
insoluble in apolar organic solvents due to a strong self association, 3,4-bis-(2-
methylaminopyridyl)-1,2-dioxo-3-cyclobutene (2) was chosen as a model compound,
because it is soluble in organic solvents of low polarity, with the objective to study
the interactions of squaramides in solution prior to crystallization. The fact that 2
is soluble in chloroform and other organic solvents allows a broad range of crystal-
lization conditions to be studied.
Initially, 2 was analyzed by
1
H-NMR and its spectrum in CDCl
3
at low tempe-
rature presents three sets of N-H signals, suggesting that 2 is present as a mixture
of two dierent conformers, one symmetric and one asymmetric, since the C-N
amidic
bond rotation is frozen (Fig. 3.29). [228]
42 Results and discussion
Fig. 3.29: Conformational equilibrium and
1
H-NMR spectrum of 2 in CDCl
3
at 240 K, 260 K and 290 K
The three sets of signals (H
a
, H
b
, H
c
), corresponding to three dierent environ-
ments of the amidic hydrogens, are assigned to the anti/anti (Fig. 3.31, 2c) and
anti/syn (Fig. 3.31, 2a or 2b) dimers on the basis of 2D
1
H-NMR COSY dilution
experiments (Fig. 3.30).
8
The shift observed for the amide protons H
a
and H
b
(in-
variability of H
a
and large upeld shift of H
b
) upon dilution (dimer destruction)
gives a strong indication that 2b is the preferred dimer for the asymmetric con-
formation (Fig. 3.30). All possible forms of 2 in solution are related through this
proposed thermodynamic cycle (Fig. 3.31).
The observed
1
H-NMR shifts for H
a
, H
b
and H
c
together with the concentration
and integration values allow the equilibrium constants to be estimated (K
CM
=
2:5; K
CD
= 0:56; K
Dab
= 8600M
 1
; K
Dc
= 790M
 1
).
9
The results indicate that, on increasing concentration at 240 K, the preferred
self-associated form of 2 is 2b. Thus, under circumstances in which the mode of
solution-state aggregation is translated into the crystal structure, it is deducible
that crystals obtained from a supersaturated solution of 2 would contain the 2b
8
Experiments were run on a Bruker DMX500 instrument equipped with an indirect
1
H 
13
C
detection probe with gradients along the z axis. A standard sequence from Bruker software was
used for COSY experiments (cosygpqf); a total of 128 increments, 4 scans each, were collected.
9
The conformational equilibrium constant of the monomer KCM was calculated as the ratio
of the relevant integrals at the lowest concentration, for which > 95% of 2 is monomeric. Dimer-
ization constants were calculated from the variation in chemical shifts with concentration using
the program NMRDil Dimer. [229] The conformational equilibrium constant of the dimer KCD
was calculated from the other three constants: KCD = (KCM)2KDc=KDab.
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Fig. 3.30: 2D
1
H-NMR COSY at 240 K of 2 upon dilution
Fig. 3.31: Proposed thermodynamic cycle for dimerization of 2
motif. In contrast with the polymorph screening carried out, under a broad set of
experimental crystallization conditions, catemeric clusters of 2 crystallize into two
dierent polymorphs with the same head-to-tail motif (based on 2c), with no evi-
dence for any other polymorph with the dimeric motif (2b or 2a) (Chapter 3.1.4).
This observation suggests that, although both dimeric and catemeric modes of in-
teraction are signicant in low polarity solvents such as chloroform, the formation
of clusters with the catemeric motif is only favored due to a possible hydrogen
bonding cooperativity. [230] According to the polymorph screening conducted with
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compounds 1, 2, 3 and 4, these current results may be extrapolated to all dis-
econdary squaramides (on the assumption that other factors do not signicantly
inuence the crystal structure, such as the presence of more strongly competitive
hydrogen bonding groups). Taking into account these ndings in solution, the coop-
erativity phenomenon and its relation to the head-to-tail conformation preference of
these compounds in the solid state was further studied taking dimethylsquaramide
(5) as the simplest model compound.
3.2.1 Cooperativity
Cooperativity of weak interactions plays a crucial role in molecular recognition and
self-assembly events. A good understanding of cooperativity is therefore essential
for obtaining insights into the behavior of both biomolecular systems and synthetic
materials. However, while it is often easy to identify cooperativity at work, it is more
diÆcult to predict how it may inuence the behavior of a particular system. [230,
231] In the simplest case, when a hydrogen bond is formed between two molecules of
water, the redistribution of electron density changes the ability for further hydrogen
bonding. The molecule of water donating the hydrogen atom has increased electron
density on its 'lone pair' region, [232] which encourages hydrogen bond acceptance,
whereas the accepting water molecule has reduced electron density centered on
its hydrogen atoms and its remaining 'lone pair' region, which encourages further
donation, on the one hand, and discourages further acceptance of hydrogen bonds,
on the other hand (Fig. 3.32).
Fig. 3.32: Cooperativity in water molecules
This electron density redistribution, thus, results in cooperativity. In cases for
which hydrogen bonding is the primary intermolecular interaction in the solid state,
cooperativity in the form of mutual hydrogen bond reinforcement within a hydro-
gen bonded chain can play a major role in the supramolecular synthon observed in
the crystal. Price has demonstrated [233] that the induction energy contribution
to the lattice energy of organic compounds is signicant, particularly for molecules
containing hydrogen bonding groups such as carbamazepine; moreover, there is
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evidence that such induction eects are important even in crystals of nonpolar
compounds. It has also been shown in silico that hydrogen bonded amide chains
exhibit a high degree of cooperativity, [234] which arises from the reinforcement of
individual hydrogen bonds through the mutual polarization of acceptors and donors
along the assembly. Such cooperative interactions are signicant in the solid state
but are secondary in the liquid or gas phases because the molecules are separated
too far to interact in a cooperative way and the dynamics of the molecules also lim-
it the eect. [235] Cooperativity is important when self-complementary molecules
assemble into one-dimensional structures by non covalent interactions due to po-
larization (induction) of interacting groups. [230] This phenomenon has been pre-
viously HF, DFT and MP2 studied by Dannenberg et al. with urea and formamide
(Fig. 3.33). [234, 236]
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Fig. 3.33: Cooperativity in (a) Urea and (b) Formamide hydrogen bonding patterns [235]
In this chapter we explore cooperativity as the driving force in disquaramides,
which produces chains in an anti/anti strong self-associating head-to-tail motif in
the solid state, in spite of the fact that other conformations are observed in solution.
First, this nding is theoretically rationalized and then experimentally conrmed.
Thus, dimethylsquaramide (5) (Fig. 3.34 (a)) was chosen as the simplest model to
study the conformational preference in the solid state, because of the fact that no
relevant secondary interactions with other groups are possible. Due to the partial
rotation of the C-N
amidic
squaramide bond, two dierent polymeric structures can
a priori crystallize: chains or ribbons (Fig. 3.34 (b)). In order to predict which
synthon is the most stable, the approach proposed by Hunter [138] to the analysis
of hydrogen bonding interactions was applied.
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Fig. 3.34: (a) Scheme of 5 (b) Chain and ribbon interaction motifs for 5
3.2.1.1 Quantifying intermolecular interactions: Hunter's approach
Dierent approaches have been historically used to understand and predict the core
entity that denes the structure of a particular molecular crystal: Gavezzotti pro-
posed a model based on space group information which reduces the structure to
small molecular clusters and calculates lattice energies, [237] the pioneering model
by Etter is based on strong hydrogen bonding as the driving force in the formation
of a molecular crystal, [107] and the supramolecular synthons model is based on
functional groups complementarity (already described in the introduction of this
thesis). [126] More recently, Hunter proposed a method to quantify intermolecu-
lar interactions through the estimation of relative hydrogen bond donor/acceptor
parameters of most typical functional groups. [138, 238{242]
Hunter's approach is based on the analysis of experimental data on the thermo-
dynamics of hydrogen bonding interactions in carbon tetrachloride and its correla-
tion to the MEP of a wide range of functional groups. It allows estimation of the
free energy of formation of a single hydrogen bond contact based on the calculated
gas phase molecular electrostatic potential (MEP) surfaces of any functional group.
There have been signicant success in using this approach for predicting binding
free energies of molecular complexes and formation of cocrystals. [137,139,243,244]
This theoretical model considers only the electrostatic interactions between the
permanent charge distributions of two molecules that interact in the gas phase to
describe the complex formation. Other components of intermolecular interactions
such as repulsion between the electron densities at close distances, induction and
dispersion interactions between induced dipoles are considered negligible or con-
stant.
Pioneering Abraham's work on experimental binding constants in carbon tetra-
chloride allowed the deduction of hydrogen bonding parameters (
H
2
and 
H
2
) for
many functional groups. Their relation to the binding constant is establish from
the following equation: [245]
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logK = c
1
 
H
2
 
H
2
+ c
2
(3.1)
where c
1
and c
2
are constants that depend on the solvent and 
H
2
and 
H
2
are functional group constants related to the hydrogen bond donor and acceptor
properties of the molecules, respectively.
Hunter demonstrated that these experimental hydrogen bonding parameters
strongly correlate with the maximum and minimum of the MEPs and, thus, any
intermolecular interaction can be analysed like a form of hydrogen bonding, with
some exceptions such as aromatic stacking. [245] Intermolecular interaction between
two molecules will take place between the maximum in the electrostatic potential
on the Van der Waals surface, which is usually located near a hydrogen atom, and
the minimum, usually located over a lone pair or an area of -electron density
(Fig. 3.35).
Fig. 3.35: MEP plotted on the Van der Waals surface of the squaric acid
calculated by using DFT method and a positive point charge. Positive regions
are blue, negative regions red and neutral regions green. [138]
However, there are specic compounds, like carbon tetrachloride, which have no
hydrogen bond donors and their MEP surfaces are strongly positive due to with-
drawing electron eects of neighbouring atoms and the diusion of these electrons.
A linear correlation between maxima and minima in the MEP surfaces and the
experimentally determined values of 
H
2
and 
H
2
parameters of various functional
groups [245] have been found in carbon tetrachloride and a mathematic rescaling
is applied to extrapolate the values to any solvent or the solid state. Thus,  and
 parameters can be calculated from the resulting equations 3.2 and 3.3, using the
second equivalence of the equations when experimental values of 
H
2
and 
H
2
are
available, or using the rst equivalence when experimental data are not available
but calculated AM1 molecular electrostatic potential surface (MEPS) is needed.
 = E
max
=52kJmol
 1
= 4:1(
H
2
+ 0:33) (3.2)
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 = E
min
=52kJmol
 1
= 10:3(
H
2
+ 0:06) (3.3)
An improvement of the hydrogen bonding parameters has been recently reported
by Hunter based on the use of DFT calculations. [238]
In this approach, only neutral molecules have been studied since experimental
values of  and  of salts have not been determined due to the low solubility
of these substances in carbon tetrachloride and other factors such as counterion
association. [246]
In this study, the MEPS of compound 5, was obtained in the gas phase us-
ing ab initio calculations and converted into the corresponding hydrogen bond
donor/acceptor parameters  and .
10
In principle, 5 can exist in three conformations as a result of the rotation of both
C-N bonds: anti/anti, anti/syn and syn/syn. However, only anti/anti and syn/syn
conformations would yield catemeric structures due to cooperativity eects so the
existence of crystals with the anti/syn conformation can be considered unlikely. The
hydrogen bond parameters obtained for the three possible conformers show that
the anti/anti conformation would produce the strongest intermolecular interaction
(Fig. 3.36). Assuming that dispersion and packing eects could be similar for all the
possible polymorphs, crystal structures of disquaramides should prefer this synthon,
as it has been experimentally proven with the results of the previous polymorph
screenings.
The individual interaction of each particular synthon can be estimated as the
sum over both NH  OC contacts with equation (3.6), [225] where 
i
are the hy-
drogen bond donor parameters, 
i
are the hydrogen bond acceptor parameters and
the sum represents the sum over both interactions.
4E =  
n
X
i

i

i
(3.6)
Density functional theory (DFT) calculations were also performed on hydrogen
bonded anti/anti and syn/syn dimers in order to compare with the interaction pair-
10
 and  parameters have been calculated by using the following equations extracted from
reference: [137,247]
 = 0:0000162E
max
E
max
+E
max
 0:00962 (3.4)
 = 0:0000146E
min
E
min
 E
min
 0:00930 (3.5)
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Fig. 3.36: Hydrogen bond parameters for the three conformations of 5
ing energy
11
and counterpoise corrections for basis set superposition error (BSSE)
were used for the calculation of the interaction energy (Tab. 3.9 (a)). [248] Inter-
estingly, the relative DFT interaction energies (56 kJ/mol for the anti/anti versus
73 kJ/mol for the syn/syn) are opposite to those estimated through equation 3.6
(79 kJ/mol for the anti/anti versus 52 kJ/mol for the syn/syn). However, this can
be explained in terms of a mutual induction eect that makes the second hydrogen
bond stronger in the syn/syn dimer and weaker in the anti/anti dimer (Fig. 3.37).
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Fig. 3.37: Induction eects favouring and disfavouring the second hydrogen bond
This eect was roughly simulated by calculating the hydrogen bond parameters
of dimers with only one hydrogen bonding interaction. Geometries of the monomers
were minimized independently and then positioned in such a way that only one in-
teraction is possible and with a distance between the NH proton and the carbonylic
oxygen xed at 2.0

A. In this simulation, once the rst interaction is established,
the remaining free NH and CO groups can interact and then a rough estimation of
the interaction energy can be done using equation (3.6) (Fig. 3.38). Thus, the inter-
action energies for the anti/anti and the syn/syn dimers are -59.2 and -80.2 kJ/mol
respectively (Tab. 3.9 c). These values are closer to those from DFT calculations
11
Geometries were optimized at the B3LYP 6-31G* level of calculation. The interaction energies
were calculated at the B3LYP 6-31+G* level of theory.
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and strongly support our hypothesis (Tab. 3.9).
Fig. 3.38: MEP surfaces and hydrogen bond parameters after the rst inter-
action of anti/anti and syn/syn conformers
Tab. 3.9: Interaction energies calculated by (a) DFT, (b) using equation 3.6
and hydrogen bond parameters for non cooperative dimers and (c) for coop-
erative dimers of 5
Synthon
Interaction Energy (kJ/mol)
a b c
anti/anti -56.0 -78.7 -59.2
syn/syn -73.1 -51.6 -80.2
This eect, however, is compensated as monomers are added to the chain. Inter-
action energies of the terminal monomer are represented in gure 3.39 as a function
of the number of molecules in the chain/ribbon aggregate for 5.
12
As the aggregate
grows, the interaction energy increases in the anti conformation while it remains
practically constant in the syn conformation. Again a cooperative induction eect
explains this phenomenon: once the monomer is linked to the anti/anti aggregate
an electronic polarization takes place, which reinforces the interaction with subse-
quent monomers. Hydrogen bonds increase in strength due to this redistribution
of the electron density along the chain. [249] Dipolar moment reects this eect: it
increases as monomers are added to the anti/anti aggregate but it is constant or
zero in odd or even number of units respectively in the syn/syn aggregate. However,
in the syn/syn aggregate there is neither polarization nor increased interaction as
monomers are added. This suggests an explanation for why dialkyl squaramides,
in abscence of potential additional interacting functional groups, exhibit only the
anti/anti supramolecular synthon.
12
Geometries for the syn/syn aggregates were optimized by DFT (6-31G*) methods while those
for the anti/anti aggregates were taken directly from the crystal structure of 5.
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Fig. 3.39: Interaction energies of the terminal monomer (anti/anti: blue;
syn/syn: red) calculated at the DFT B3LYP 6  31+G level of theory using
Spartan'10 software [247]
In order to validate this hypothesis, a polymorph screening was run with 5
(see appendix A.12), yielding in all cases the same polymorph with the predicted
anti/anti catemeric structure (Fig. 3.40).
Fig. 3.40: Crystal structure of compound 5
Once dimethylsquaramide was studied as the simplest model, Hunter's approach
was applied to compound 2 the previously studied in solution. Calculated  and 
parameters for 2 suggest that 2b and 2c are preferred over 2a in agreement with the
NMR results, and that 2c appears to be slightly more favorable than 2b (Fig. 3.41).
This result is in agreement with the crystal structure grown at r.t. while at 240 K
the NMR experiments show 2b is preferred over 2c. This dierence in behaviour
is attributed to the more important contribution of the intramolecular hydrogen
bonds at 240 K, which tips the balance in favour of 2b at low temperature.
Since no syn/syn conformation was observed in any of the mentioned compound-
s, a covalently forced cyclic disquaramide 6 was designed to study the geometrical
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Fig. 3.41: Aggregation scheme of 2 according to Hunter's approach
features of the catemeric structures with such conguration (Fig. 3.42, (a)). It was
obtained from diethyl squarate and 1,2-diaminoethane in ethanol. In its crystal
structure, the expected NH  OC hydrogen bonding is established between two ad-
jacent molecules forming ribbons with the squaramide rings practically in the same
plane (Fig. 3.42, (b)).
Fig. 3.42: (a) Scheme of 6 (b) Crystal structure and Hirshfeld's surface of 6
in which side interactions in red are shown
Competitive interactions such as    stacking do not aect the anti/anti con-
formation observed in previous disquaramides (1, 2 and 3). In order to check their
inuence over the a priori less strong syn/syn motif, another macrocyclic compound
containing an aromatic group was designed (7, Fig. 3.43, (a)). It was obtained in a
three-step synthetic route from a condensation of 2 aminomethylbenzylamine with
diethyl squarate in ethanol. Needles were grown in the reaction crude and 7 was
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solved by single crystal XRD. Again, the expected NH  OC hydrogen bonding is
established between two adjacent molecules forming ribbons, which are connected
through additional CO  H
aromatic
and     stacking interactions (Fig. 3.43, (b)).
Fig. 3.43: (a) Scheme of 7 (b) Crystal structure and Hirshfeld's surface of
compound 7 in which side interactions in red are shown
The observed lateral oset stack is parallely orientated with a centroid to cen-
troid distance d(   ) of 4.31

A, interplanar distance of 3.55

A and a lateral
displacement of 2.44

A. However, squaramide rings are not coplanar as in the case
of compound 6 (interplane distance of 1.16

A), but they form a zig-zag arrange-
ment which suggests that the competitive     aromatic interactions can disrupt
the formation of an optimal planar hydrogen bond. This phenomenon, which has
not been observed in any of the polymorphs of dibenzylsquaramide (1), suggests
that the cooperativity stabilization in the anti/anti aggregates overcomes possible
disrupting secondary interactions while the non cooperative syn/syn synthon is less
resistant to their presence.
Once the syn/syn conformation was observed in covalently forced disquaramides
we aimed to explore if it could be observed in monosquaramide esters in the solid s-
tate through the design of a simple compound able to form strong dimers (Fig. 3.44).
Thus, the monosquaramide 8 was prepared from diethylsquarate and methylamine
in diethyl ether. Only one polymorph was obtained from a polymorph screening
(appendix A.12), and its crystal structure reveals dimeric aggregates of syn con-
formers. The strong self-complementary squaramide/squaramide dimer is linked to
the following one in the crystal through weaker CO  H
ethyl
interactions (Fig. 3.45).
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Fig. 3.44: Possible supramolecular synthons for compound 8
Fig. 3.45: Dimeric aggregates observed in the crystal structure of 8 together
with the Hirshfeld's surfaces
This suggests that, in absence of competitive donor/acceptor groups, dimers
might be more stable than chains in monosquaramide esters probably due to the
diÆculty to align eÆciently monomers in a head-to-tail manner without losing the
advantage of linear cooperativity. In this sense, another model compound (9) was
designed containing an additional pyridine group in order to explore how compet-
itive groups could aect the R
2
2
10 synthon observed for the very rst time in this
family of compounds.
13
For this reason,  and  parameters were calculated in
this case, in order to compare them with the experimental results (Fig. 3.46, (a)).
The presence of a good hydrogen bond acceptor N
pyridinic
might favor the formation
of a dimeric syn motif dierent from the synthon observed for compound 8.
Experimentally, compound 9 was prepared from diethylsquarate and 2-(amino-
ethyl)pyridine in diethyl ether. A non comprenhensive polymorph screening was
13
A survey at the CCDC shows dierent supramolecular synthons: ACULEP, ACULIT, AC-
ULIT01, CAQRUH, ETIVIM, IXUVAY, JINRAA, MEGNAO, NEMMEX, SIXFIP.
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conducted and only one solid form was obtained (Appendix A.12). The single crys-
tal structure was solved by SXRD and it conrms the prediction that the presence
of a good competitive functional group such as pyridine alters the supramolecu-
lar synthon, but the conformer syn remains. (Fig. 3.46, (b)). The presence of an
ethoxy moiety reduces the electron density around the carbonyl oxygen, and as a
result it favors the formation of the dimer through the hydrogen bonding between
the pyridil nitrogen and the amidic hydrogen.
Fig. 3.46: (a)  and  parameters of 9 (b) Dimers in the crystal structure of 9
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3.3 Crystal engineering: cocrystals design
Next step of this work was to design new materials on the basis of the adquired
solid state knowledge of squaric acid derivatives. As it has been shown in the pre-
vious sections, all attempts to crystallize dierent forms of disquaramides resulted
into the existence of only a robust anti/anti conformational head-to-tail structural
mode, unless being the molecule itself covalently modied. Thus, a rst attempt
was to design cocrystals between disquaramides and strong donor/acceptor com-
plementary functional groups, such as phenols and carboxylic acids, appropriate for
the anti/anti and syn/syn conformers, respectively (Fig. 3.47).
Fig. 3.47: Scheme of possible supramolecular synthons with both donor and acceptor coformers
Although resorcinol and carboxylic acids looked optimal from a geometrical
point of view, calculations suggested that cocrystals were not expected to be ob-
tained in the case of simple compounds such as 5 and 7, because the predicted
interaction energies (from equation (3.6)) of these heterosynthons were lower than
that of the squaramidic homosynthon (Fig. 3.48).
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Fig. 3.48: Predicted interaction energies of heterosynthons and homosyn-
thons for anti/anti and syn/syn conformations of 5 and 7, respectively.
To corroborate this prediction with carboxylic acids and resorcinol, and to ex-
tend it to other good donor or acceptor groups, an experimental cocrystal screening
with 5 and 7 and a set of dierent coformers was conducted (See appendix B.8)
and did not produce any new cocrystal phase (Fig. 3.49).
14
These ndings demonstrate again that the self assembly of squaramide rings is
a very strong binding motif, diÆcult to be perturbed by other competing functional
groups in the solid state.
For this reason, two new crystal engineering strategies were designed. The rst
strategy was to impede the head-to-tail motif via intramolecular interactions and
choose complementary coformers taking into account the Hunter's approach (Fig.
3.50 (a)). [250] The second strategy consisted in taking advantage of such a ro-
bust synthon by designing new crystalline materials with complementary coformers
through the squaramide functionalized secondary chains via peripheral interactions
(Fig. 3.50 (b) and (c)). [251]
14
Evidences of a new phase were identied from a cocrystallization experiment with 7 and
phosphoric acid. However not enough characterization analyses could be done to conrm the
presence of a cocrystal phase.
16
 and  values extracted from [138].
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Fig. 3.49: Coformers used in the cocrystal screening of compounds 5 and 7
16
Fig. 3.50: Scheme of cocrystal design: (a) via intramolecular hydrogen{bonding and
(b, c) via peripheral interactions
3.3.1 First strategy: preorganization
It is well known that the presence of competing hydrogen bond donor/acceptors
in the same molecule can aect the resulting synthons in the crystal. However,
in the case of the disquaramides studied in this work (2, 3 and 4) the head-to-
tail motif remains invariable. For this reason, we decided to study the eect of
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an intramolecular interaction by introducing an extra hydrogen bond acceptor in a
squaramide derivative model compound with the objective to modify the preferred
cooperative self-associating interaction and to generate new synthons. To achieve
this goal two new target compounds (10 and 11) were designed (Fig. 3.51).
Fig. 3.51: Scheme of 10 and 11
The bis squaramide-ester model compound 10 was prepared from diethylsquarate
and 1,4-bis(3-aminopropyl)piperazine in diethyl ether. This amine has been pre-
viously used as a spacer in ditopic thioureas. Piperazine nitrogen establishes in-
tramolecular interactions with thiourea NH protons in the solid state, inducing the
formation of "spiral galaxy" motifs with syn/syn polymerization synthons. [250]
On the other hand, compound 11 was obtained from the addition of butylamine to
a solution of 10 in ethanol, as a very insoluble white solid. A limited polymorph
screening was conducted since only DMF, DMSO (at very high temperature), tri-
uoroethanol and acetic acid could be used for recrystallization and only one form
was obtained (see appendix A.12). Unfortunately, although several eorts were
made to determine its crystal structure from PXRD by direct space methods, no
satisfactory results were obtained. The presence of four amidic NH protons might
be responsible for a strong self-assembling diÆcult to be perturbed, similar to the
previously one seen during this work for other squaramides.
Although squaramides are strong hydrogen bonding donor/acceptors, mono-
squaramide esters are not so previsible and other synthons have been observed
(3.2.1.1). In principle, four dierent supramolecular synthons for 11 in the solid
state were expected: the anti/anti conguration can produce two synthons, the
head-to-tail polymer and the intramolecular monomer (Fig. 6.11 (a) and (b)), while
the syn/syn conguration can produce the ribbon synthon and another intramolec-
ular monomer (Fig. 6.11 (d) and (c)).
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Fig. 3.52: Expected supramolecular synthons for 10 together with their
corresponding graph sets
In order to study which synthons are formed, a polymorphism screening was
conducted and three forms were obtained: two anhydrous forms and one hydrate.
Form I was obtained pure by precipitation from the synthesis process of 10 and
form II could only be obtained pure by heating polymorph I until 160
Æ
C and then
cooling down to r.t. (Fig. 3.53). Solvent mediated transformation experiments at
dierent temperatures, in which a mixture of forms I and II evolved to pure form
II at all temperatures below the melting point of form I, conrmed that both forms
are monotropically related, being form II the most stable. The hydrate form (form
III) was obtained from the solubility study by slow cooling crystallization in water
from 90
Æ
C to r.t.
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Fig. 3.53: PXRD diagrams of forms I, II and III. Form II was obtained
from variable temperature experiments starting from form I (also shown in
this gure)
The thermogram of polymorph I, registered at 10
Æ
C/min, shows an exother-
mic phenomenon at 135
Æ
C which was initially assigned to a solid-solid transition
(Fig. 3.54), but a more accurate analysis with modulated DSC revealed overlapped
melting and crystallization processes. Finally, the melting of form II is registered
at 180
Æ
C. The thermogram of form III shows a wide endothermic double peak
corresponding to water loss and overlapped melting-crystallization phenomena at
160
Æ
C (see appendix C.2.19).
Fig. 3.54: Modulated DSC experiment of form I heating from 30
Æ
C to
220
Æ
C at 0.5
Æ
C/min under nitrogen atmosphere
Since no good quality single crystals of any of the forms could be obtained,
their crystal structures were determined from X-ray powder diraction data by
means of direct space methods (Fig. 3.55). However, no crystal structure could be
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determined for the hydrate form. According to the thermogravimetric analysis, in
which a weight loss of 18% was registered, the hydrate would contain six molecules
of water in its structure (see appendix C.2.19).
Fig. 3.55: Crystal structures of forms I and II showing intermolecular and intramolecular hy-
drogen bonding
Form I
17
presents a six-membered ring formed through intramolecular hydrogen
bonds, roughly perpendicular to the plane dened by the piperazine ring. Strong
hydrogen bonds between the amidic NH and the piperazine nitrogen [N{H  N
2.843(8)

A] make the molecule shrink in a symmetric way. The parallel layers of
molecules are stabilized through     stacking interactions (d
centroids
3.851

A) of
the cyclobutene rings and weak hydrogen bonds between the carbonyl oxygens and
the piperazine hydrogens. A similar hydrogen bonding pattern has been report-
ed in the "spiral galaxy" bis{thiourea derivatives from N,N'-bis(3-aminopropyl)-
piperazine which proved to be very strong. [250] However, in the present case, this
synthon corresponds to the metastable form. Form II
18
, instead, appears relatively
strain-free, showing a head-to-tail hydrogen bonding motif similar to those already
described in some other ester amides of squaric acid. [252] The cyclobutene rings
interact via   stacking, where the interplanar and centroid to centroid distances
are 3.844 and 3.554

A, respectively. In both cases, the piperazine rings adopt a
chair conformation.
Interaction energy calculations of the aggregates resulting from the addition of
dierent monomers for the head-to-tail synthon were performed at the DFT level
of theory and compared with the syn/syn ribbon synthon. A model correspond-
ing to the hydrogen bonding unit for each oligomer was extracted from the crystal
structure, and the interaction energy was calculated (without further geometry
optimization) using the counterpoise correction for basis set superposition error
(BSSE). The extrapolation to a high number of monomers gives roughly an interac-
tion energy of 33 kJ/mol per hydrogen bond, very similar to the 35 kJ/mol for the
17
CCDC 883949 contains the crystallographic data.
18
CCDC 883948 contains the crystallographic data.
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syn/syn dimer (69 kJ/mol for two hydrogen bonds) (Fig. 3.56). The cooperativity
of hydrogen bonding in the catemeric monosquaramide ester is again responsible
for the stabilization of this conformer. In this sense, an experimental polymorph
screening was conducted and, although nding evidences of polymorphism, no sol-
id forms showing the syn/syn ribbon synthon were obtained despite the fact that
it was expected from both geometrically and energetically points of view. Only
the predicted (a) and (c) supramolecular synthons (Fig. 6.11) were experimentally
obtained.
Fig. 3.56: DFT interaction energies for the anti and syn oligomers
Once it was conrmed that the intramolecular hydrogen bond is established in
one of the polymorphs, we decided to use this preorganization eect to drive the
formation of cocrystals with double hydrogen bond donor coformers. In order to
study this possibility, a cocrystal screening was performed between 10 and resor-
cinol. The hydrogen bonding donor abilities of resorcinol and 10 are quite similar
( parameters of 3.7 and 3.5, respectively); thus, a qualitative prediction of the
likeliness of cocrystallization by using the Hunter's approach is particularly diÆcult
in this case. However, resorcinol was chosen due to its geometrical and hydrogen
bonding complementarity (Fig. 3.57), and a cocrystal screening was conducted (see
appendix B.8).
19
Two new crystalline phases were obtained (one anhydrous and
one hydrate), whose crystal structures could also be determined by means of direct
space methods from PXRD.
19
A survey of the November 2011 Cambridge Structural Database has identied over 55 instances
of the synthon R
2
2
(11)
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Fig. 3.57: Donor{acceptor complementarity between the expected cocrystal
of 10 and resorcinol
An anhydrous cocrystal, with a 1:2 (10:resorcinol) stoichiometry, was obtained
from the dehydration of the hydrate cocrystal at 120
Æ
C in an aluminum DSC
crucible under nitrogen atmosphere, whereas the hydrate cocrystal, with a 1:2:2
(10:resorcinol:water) stoichiometry, was obtained by crystallization with dierent
solvents during the cocrystal screening. Good quality crystalline structures could
be achieved after Rietveld renement demonstrating the formation of both cocrys-
tals, although not with the expected synthon. In the anhydrous cocrystal, the
most remarkable feature of the structure is that, besides the fact that the expected
carbonyl{phenol interaction does not take place, each molecule of 10 interacts with
another one via the syn/syn ribbon supramolecular synthon which, although being
expected, had not been previously observed in any of its two polymorphs (Fig. 6.11,
(d)). Moreover, two molecules of resorcinol interact through strong hydrogen bonds
with both piperazine nitrogens and the free carbonyl groups of the squaramidic ring
(Fig. 3.58).
Fig. 3.58: Crystal structures of the resorcinol cocrystals
On the other side, in the hydrate cocrystal, the presence of water produces
a dramatic change in the supramolecular synthons present in the structure. In
this cocrystal, squaramide molecules do not interact with each other; instead, all
its acceptor and donor groups establish hydrogen bonds with water and resorcinol
molecules: carbonylic oxygens bond to water and phenol hydrogens while the amidic
hydrogen bonds to the water oxygen. The other phenolic resorcinol's hydrogen also
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bonds the water oxygen. The structure is completed with piperazine nitrogen{water
interactions.
During the experimental cocrystal screening, evidences of polymorphism in these
multicomponent solids have been observed, but no further studied, therefore, other
supramolecular synthons, including the predicted R
2
2
(10), cannot be discarded.
In order to compare the supramolecular synthons observed with resorcinol, an-
other similar coformer was tested: hydroquinone. Although not being geometrically
complementary for the expected R
2
2
(10) synthon, it is a good double hydrogen bond
donor coformer which might inuence in crystallizing a new supramolecular archi-
tecture. After an experimental screening, three new polymorphic cocrystals were
identied but unfortunately no crystal structure could be determined (see appen-
dices B.8 and C.2.19). Research in this direction is still being conducted.
In summary, we have studied how the formation of an intramolecular hydrogen
bond aects the polymorphism of a bis-squaramide ester compound. However, this
preorganization has been revealed not to be suÆcient to drive the formation of a
cocrystal with the double donor-double acceptor supramolecular synthon that we
expected. On the other hand, three out of the four a priori possible supramolec-
ular synthons predicted for 10 have been observed in its two polymorphs and its
anhydrate cocrystal with resorcinol structures.
3.3.2 Second strategy: cocrystallization with complemen-
tary coformers via peripheral interactions
All the diÆculties in impeding the head-to-tail synthon of the disecondary squaramides
reveal that they can be very attractive to be exploited as molecular scaolds in the
design of new multicomponent crystalline structures because, with a suitable func-
tionalization of the secondary squaramide substituents, complementary coformers
could establish strong peripheral interactions with them. [251] In this sense, further
insight was given to cocrystallization experiments of disquaramides with function-
alized secondary chains with both donor and acceptor groups.
3.3.2.1 Cocrystals with hydrogen bond donor coformers
Two model compounds (2 and 4, Fig. 3.59), which have pyridil and dimethylamino
functional groups, respectively, were selected for performing an intense experimental
cocrystal screening with a set of hydrogen bond donor coformers such as carboxylic
acids, phenols and amides (table 3.10). Three and six multicomponent solid forms
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of 2 and 4 were identied from 56 and 162 cocrystallization experiments performed,
respectively. Evidences of other new phases were detected during the screening.
Fig. 3.59: Scheme of 2 and 4
Tab. 3.10: Cocrystallization experiments with 2 and 4. -: no solid obtained,
0: no cocrystal, 1: evidences of new phases, 2: cocrystal conrmed by SXRD
or PXRD and
1
H-NMR
Coformer Compound 2 Compound 4
Fumaric acid 2 2
p-nitrobenzoic acid 2 1
Glutaric acid 0 1
Glutamic acid 0 1
Oxalic acid 1 1
Citric acid 0 1
Squaric acid 1 2
Resorcinol 0 2
Urea - 1
Nicotinamide 0 1
One crystal structure of 2 with fumaric acid and three crystal structures of 4
with fumaric acid, resorcinol and squaric acid could be determined by means of
direct space methods or SXRD and they are separately discussed as follows.
 Cocrystal of 2 : fumaric acid : ACN
The crystal structure of 2 with fumaric acid
20
shows the catemeric head-to-
tail motif, as expected, together with hydrogen bonds between the pyridil
nitrogen and the carboxylic acid moiety of fumaric acid (N  HO). A cocrys-
tal is formed according to the carboxylate distances obtained from the crystal
structure solved by SXRD as we expected from a dierence of pKas ( pka
< 3, pKa
pyridine
=5.25; pKa
fumaricacid
=3.03) (see chapter 1.2). Moreover, ace-
tonitrile molecules occupy available voids in the crystal structure (not shown)
(Fig. 3.60).
20
CCDC 1015650 contains the crystallographic data.
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Fig. 3.60: Crystal structure of the ACN solvate of 2 and fumaric acid cocrys-
tal, 1:1:2 (ACN molecules not shown)
 Salt of 4 : fumaric acid : MeOH : water
The crystal structure of this solvate,
21
presents a displaced head-to-tail motif
dierent from the previously described. Methanol and water molecules occu-
py the empty channels formed by squaramide units and fumaric acid column-
s. Water molecules connect fumaric acid molecules via hydrogen bonds and
methanol molecules interact with the dimethylamino nitrogen atoms. Ac-
cording to the dierence of pKas between the dimethylamine (pKa: 10.7) and
fumaric acid (pKa: 3.03), this multicomponent solid form was expected to be
a salt, however, surprisingly a cocrystal is conrmed by the carboxylic dis-
tances (d
C O
: 1.20

A, 1.29

A and 1.23

A, 1.28

A) from the crystal structure
solved by SXRD (Fig. 3.61).
21
CCDC 1015651 contains the crystallogrpahic data.
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Fig. 3.61: Crystal structure of the MeOH/Water solvate of 4 and fumaric
acid 2:2:1:3 cocrystal (water molecules not shown)
Interestingly the crystal structures of 2 and 4 with fumaric acid present a
dierent type of head-to-tail synthon. Both scaolds are catemeric, but the
cocrystal of 2 presents a ring motif (R
2
2
(10)) formed by ten atoms, in which
two hydrogen bond donors and two hydrogen bond acceptors participate. On
the other hand, the cocrystal of 4 crystallizes through a displaced head-to-
tail motif, due to fumaric acid interactions, forming a chain (C(6)), in which
one hydrogen bond donor and one hydrogen bond acceptor participate (Fig.
3.62).
Fig. 3.62: Head-to-tail motifs of multicomponent forms of (a) 2 and (b) 4
(Coformers not shown)
 Cocrystal of 4 : resorcinol
In this case, two polymorphic anhydrous cocrystal forms were identied (Fig. 3.63).
Crystal structure of form I, solved by direct space methods, reveals the pre-
viously seen head-to-tail squaramide motif (R
2
2
(10)) through hydrogen bond
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interactions while resorcinol molecules interact with peripheral dimethylamino
groups of 4 via hydrogen bonding (N  HO) linking squaramide columns (Fig.
3.64).
Fig. 3.63: PXRD diagrams of the two polymorphic anhydrous cocrystals of
4 with resorcinol (1:1)
Fig. 3.64: Crystal structure of 4:resorcinol cocrystal, form I
Although tetragonal cell parameters were determined (a = 25:48

A; c =
6:07

A; V = 3943

A
3
) by means of direct-space methods, no acceptable
crystal solution for form II could be deduced, from the two dierent possible
space groups I4 and I-4. Probably, a better denition of the diractogram
is needed for an acceptable crystal structure solution. Synchrotron radiation
source experiments are planned to overcome this problem.
 Salt of 4 : squaric acid : water
The formation of a salt was again expected since squaric acid is a very strong
acid (pKa = 1.5, 3.4) which was conrmed according to the squarate distances
from the crystal structure solved by SRXD. In this case, the head-to-tail is not
observed because of the interaction with the squarate anion (Fig. 3.65). Water
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molecules connect squaramide rings and monosquarate groups via hydrogen
bonding.
Fig. 3.65: Hydrate of the salt between 4 and squaric acid
3.3.2.2 Cocrystals with hydrogen bond acceptor coformers
Since the strategy of using secondary squaramides containing peripheral hydro-
gen bond acceptor functional groups (pyridine and dimethylamine) was successful,
we decided to extend this approach by attaching donor functional groups to the
squaramide peripheral chains (Fig. 3.66). Compound 12 was synthezised from di-
ethylsquarate and tyramine in ethanol.
Fig. 3.66: Scheme of (a) a general disquaramide with peripheral hydrogen
bond donor groups and (b) 12
An experimental cocrystal screening was conducted between 12 and a set of
dierent hydrogen bond acceptor compounds (see appendix B.8). Table 3.11 sum-
marizes the cocrystal screening results.
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Tab. 3.11: Cocrystal experiments with 12. -: no solid obtained, 0: no
cocrystal, 1: evidences of new phases, 2: cocrystal conrmed by SXRD or
PXRD and
1
H-NMR
Coformer Compound 12
oxalic acid 1
resorcinol 0
nicotinamide 1
isonicotinamide 1
bipyridine 1
pyridine 1
As it is shown in table 3.11, some crystallization results suggested the existence
of cocrystals with oxalic acid, nicotinamide, isonicotinamide, bipyridine and pyri-
dine but only two crystal structures of solvate of 12 in ethanol and in DMSO/water
could be determined by single X-ray diraction (Fig. 6.13).
22
Fig. 3.67: Crystal structures of (a) ethanol and (b) DMSO/water solvates of 12
Although the solvents ethanol, DMSO and water, were not intended to be used
as coformers, the two crystal structures depict the general scheme of our strate-
gy: a head-to-tail motif is again formed between squaramide units while ethanol
and DMSO molecules interact via intermolecular hydrogen bonds with the phenol
groups. These crystal structures suggest that our strategy of functionalizing the
peripheral disecondary squaramide chains with hydrogen bond donor functional
groups in order to design new cocrystals could be succesful. However, although
many evidences of new crystal forms have been registered through the cocrystal
screening conducted, further insight is required to elucidate the crystal structures
of the multicomponent solids obtained in order to conrm the success of the design.
22
CCDC 1015653 contains the crystallographic data.
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3.4 Self-assembling and template eect: helical
architectures
Considering that the robust head-to-tail motif can be used as scaold, we de-
signed the non symmetrical squaramide (13) functionalized with donor and ac-
ceptor groups in the same skeleton, with the objective to produce new hydro-
gen bonded self-asssembled architectures with new topological features. Thus,
compound 13 was synthesized through a two-step selective condensation of N,N -
dimethylethylenediamine and tyramine with diethylsquarate in mild conditions. As-
suming that the head-to-tail interaction can act as a template, in principle two types
of interactions are possible: (a) cyclic and (b) polymeric, which could give raise to
helical assemblies (Fig. 3.68).
Fig. 3.68: Possible (a) Cyclic and (b) Polymeric aggregates of 13
The helix is one of the most important structural motifs in nature due to its
ubiquitous presence, from the molecular level to the astronomical scale. [253, 254]
Helicity shows relevant properties such as chirality and other geometric features
which have attracted the attention of the scientic community. [255{257] Examples
of helicity include the double-stranded DNA and the assembly of linear proteins
into multistranded complexes which are responsible for the genetic information and
diverse biological functions. [258] This fascinating natural motif has inspired the
design and synthesis from unnatural backbones of a broad variety of articial he-
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lices in the elds of supramolecular chemistry, asymmetric catalysis, biomimetics,
etc. [259{261] Thus, the use of synthetic building blocks for the supramolecular
assembling into helical polymers [262] has been successfully exploited in the past
with metal coordinated helical complexes [255,263] or self-assembled spiral nanoar-
chitectures from barbituric acid, [264] among many others. [265{267] In this sense,
hydrogen-bonding is a key interaction due to its great directionality and strength
which can be used to design highly stable and selective building blocks able to
cooperatively drive the formation of polymeric assemblies. [268{270]
Since no crystals of 13 suitable for structure determination by SXRD could be
obtained, its crystal structure was solved from laboratory X-ray powder diraction
data by means of direct space methods (Fig. 6.14).
23
Fig. 3.69: Crystal structure of 13
The analysis of the crystal structure reveals that the catemeric head-to-tail ar-
rangement remains and helices are individually packed (following model (a) in gure
3.68), connected to others through weak CH{ interactions between the methy-
lamino group and the aromatic ring, [271,272] with centroid distance of 3.05

A and
C-H centroid angle of 109
Æ
C (Fig. 3.12, (a)). This nitrogen atom is particular-
ly electronegative due to the strong hydrogen bond with the phenol group which
drives the methyl groups to interact eÆciently with the face of the aromatic ring
(Fig. 3.12, (b)).
23
CCDC 953732 contains the crystallographic data.
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Tab. 3.12: (a) Helix-packing motifs via CH   interactions and (b) CH  
interaction between the methylamino group and the aromatic ring in 13
Although helical assemblies from an achiral compound such as 13 can a pri-
ori form chiral crystals, a racemic mixture of alternating clock and anticlockwise
spinning helices has been found (Fig. 3.70).
Fig. 3.70: Clock and anticlockwise rotation of the two dierent helices in the
racemic crystal of 13
This unprecedented helix in a squaramide is driven by a combination of two
dierent head-to-tail interactions and, according to the literature, this example can
be considered remarkable in the eld of crystal engineering and supramolecular
chemistry. The good geometry and donor/acceptor complementarity produces an
optimal packing which excludes the possibility to form cavities.
Once the formation of hydrogen-bonded helical structures in a nanotube fash-
ion was observed with compound 13, another strategy of nanotube formation was
considered through the design of cyclic compounds containing two squaramide u-
nits covalently linked. In this sense, the formation of nanotubes by macrocyclic
squaramides was initially studied and new compounds were synthesized to explore
this possibility (Fig. 3.71), (Chapter 6.3.6). However, this research line has been
abandoned due to experimental diÆculties in crystallizing such compounds. They
are very insoluble in most of the solvents and their powder diraction patterns show
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broad bands, suggesting low crystallinity or likely microcrystalline structures. This
is supported by DSC analysis which shows proles with no dened melting point.
Further research on this issue could be developed in the future.
Fig. 3.71: Macrocyclic squaramides 14, 15 and 16
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3.5 Charged squaric acid derivatives: the electro-
static compression phenomenon
Hydrogen bonding, which combines directionality with strength, -stacking and
their mutual combinations play a key role and have been long and successfully
used in supramolecular chemistry. [119, 120, 273{275] In particular, charge-assisted
hydrogen bonds have been exploited to build periodical supramolecular structures.
[276{278] The electrostatic nature of this type of hydrogen bond usually strengthens
the interaction because of the presence of ionic charges on the hydrogen bonding
donor/acceptor interacting groups. [279] This charge assistance preserves the hy-
drogen bonding directionality while reinforcing the interaction with the help of
coulombic forces. [280] In squarate salts, an inverse relation between length and
strength of charged rings has been observed which is explained by an electrostatic
compression phenomenon. [281] Interionic interactions between anions in the sol-
id state may not correspond to stable intermolecular bonds, in spite of being the
donor-acceptor groups distances shorter than the equivalent neutral groups dis-
tances. [282, 283] In fact, it is a consequence of a stronger attractive interaction
of a next-neighbour anion-cation compared to the repulsive eect of anion-anion
and cation-cation (Fig.3.72). [284] The balance of attractive and repulsive ionic
interactions determines the crystal cohesion. Since electrostatically compressed in-
teractions retain directionality, they are usefool tools in crystal engineering of ma-
terials, in relation to conductive and magnetic properties, [285,286] supramolecular
chemistry [287] and biochemistry. [288]
Fig. 3.72: Scheme of the electrostatic compression phenomenon in squarate assemblies
3.5.1 Zwitterionic squaramide/squarate compounds
Taking into account the abovementioned phenomena recently reported in squarate
salts, [277, 281, 286] we decided to exploit charge assisted hydrogen bonding inter-
actions in zwitterionic squaric acid derivatives in combination with electrostatically
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driven dimerization to design new supramolecular assemblies in the solid state.
With this objective, the zwitterionic squaramide/squarate compound 17 was de-
signed as the building block of a new family of supramolecular assemblies and it was
synthesized in one single step from squaric acid and N,N-dimethylethylendiamine
in water. [184] The strong acidity of the squaric acid moiety ensures the zwitte-
rionic character of 17, which in combination with a geometrical complementarity
produces the optimal conditions to form self-assembling dimers (Fig. 3.73).
Fig. 3.73: Synthesis of the zwitterionic squaramide 17 and the schematic
self-assembling through electrostatic compression
In principle, two dierent supramolecular synthons are geometrically possible
through charge assisted hydrogen-bond interactions if the electrostatically com-
pressed assemblies are formed in the solid state: an R
2
2
(10) motif (in a self-assembling
manner) (Fig. 3.74 (a)) and a head-to-tail C(5) or C(6) motif (Fig. 3.74 (b)).
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Fig. 3.74: Dierent assembling motifs for 17, expected through charge as-
sisted hydrogen bonding
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In order to study this hypothesis a polymorph screening was conducted. Crystals
of three dierent phases were obtained through crystallization of 17 by slow diu-
sion of dioxane in dimethylsulfoxide (form I), of methyltertbutylether in dimethyl-
sulfoxide (form II) and of dichloromethane in water (form III). The structures of
two anhydrate polymorphs (forms I and II)
24
and a hydrate
25
(form III) were solved
by SXRD. Form II crystallized concomitantly with form I in all the experiments,
however, we were able to isolate at needles of form II from the crystallization
mixture.
In the two anhydrous crystal structures, similar electrostatically compressed
dimers establish complementary N-H  O interactions with adjacent dimers. How-
ever, squaramide rings in form I are closer to each other than in form II with
centroids distances of 3.47

A and 3.70

A respectively (Fig. 3.75).
Fig. 3.75: Stacked dimers showing d
centroid centroid
for anhydrous forms I
and II of 17
The most important dierence lies on the carbonylic oxygen which is involved
in the intermolecular hydrogen bond. While in form I the carbonylic oxygen in anti
with respect to the NH is forming the hydrogen bond, in form II this interaction is
established by the oxygen in syn. This is the consequence of two geometrically pos-
sible hydrogen bond donor/acceptor combinations, since hydrogen bond acceptor
ability of the two available carbonyl oxygen atoms are similar (molecular electro-
static potential minima
26
of -330 and -349 kJ/mol, gure 3.76).
Fig. 3.76: MEP surface at the DFT level of computation of the isolated
geometry from the crystal structure of form I
24
CCDC 938373 and CCDC 951985 contain the crystallographic data.
25
CCDC 938372 contains the crystallographic data.
26
MEP surface was computed with Spartan '10 using DFT B3LYP/6  31 + G

ab initio cal-
culations. The molecule was imported from the crystal structure of form I and was not energy
minimized.
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This particularity has important consequences on the connexion of the electro-
statically compressed dimers in the crystal, producing completely dierent supramolec-
ular synthons for both polymorphs: R
2
2
(10) rings in form I and C(5) chains in form
II (Fig. 3.77).
Fig. 3.77: Supramolecular synthon observed in form I (a) and form II (b)
connecting the electrostatically compressed dimers in the crystal
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On the other hand, in the hydrate form III a dierent supramolecular synthon is
observed. Each compressed dimer interacts with the neighbouring dimer in a C(6)
motif with water molecules stabilizing the structure through hydrogen bonding
interactions with the free carbonyls. The electrostatically compressed dimer that is
formed is very similar to the one in form I, with centroid-centroid distance of 3.52

A (Fig. 3.78).
Fig. 3.78: Supramolecular synthons observed together with the stacked dimer
in the hydrate form III
Since the condensation reaction between squaric acid and the N,N -dimethyl-
ethylendiamine is not complete, mixtures of non reacted squaric acid and 17 were
present in the synthesis crude and, unexpectedly, crystals of a dierent phase
were isolated from the reaction mass in one of the crystallization experiments con-
ducted (see appendix B.8). The solved crystal structure
27
revealed that a new
monosquarate/17 salt was obtained. Interestingly, the structure shows another
electrostatically compressed motif which is formed through a combination of a
monosquarate anion and two dierent moieties of 17 in a similar stacked way as in
the anhydrous and hydrate forms of 17, with centroid-centroid distance of 3.51

A
(Fig. 3.79). The most remarkable feature of this structure is that peripheral hy-
drogen bonding squaric/squaric interactions are established with the same R
2
2
(10)
motif previously reported by Mathew et al., [159] suggesting that self-assembled
zwitterionic squaramides could be used as eÆcient coformers for cocrystallization
of a variety of donor/acceptor compounds such as carboxylic acids, ureas, amides,
etc.
27
CCDC 938374 contains the supplementary crystallographic data.
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Fig. 3.79: Crystal structure of monosquarate/17 salt
3.5.2 Squarate salts
Squarate salts have been extensively studied in the solid state [159,169,289] and a -
stacking is observed as a consequence of the electrostatic compression phenomenon.
As it has been reported, aromaticity and hydrogen bonds are the most important
forces driving the interactions in the solid structures of squarate ions, [290] thus we
decided to examine the propensity of squaramide, hydrogen squarate and squarate
salts in the solid state to establish interactions that are typical of aromatic com-
pounds [291] (stacking interactions, [119,292,293] ion-, [294{296] C{H/, [271,297]
etc.). In this sense, a collaborative research with the group of Prof. Frontera was
conducted with the aim to extend the knowledge about the forces that govern these
specic -stacked assemblies by combining X-ray characterization and computation-
al analysis of several squarate and amidosquarate salts (Fig. 3.80),
28
which were
synthesized from squaric acid and the corresponding amine in water (See chapter
6.3.6). In particular, we focused our attention in the analysis of the inuence of
the four-membered ring aromatic character on the solid state architecture of these
mono and di-anion salts directing the type of noncovalent interactions. [298] More-
over, a relation was found between the ability of the squaric acid and its derivatives
to establish hydrogen bonds,     stacking and other -interactions (anion-,
lone pair- and C-H/), which has not been previously analyzed in detail, and the
increase in the aromaticity of the ring.
29
28
CCDC: 987591, 987592, 987593, 987594, 987595 and 987596 contain the crystallographic data.
29
The computational details and further experimental information can be found in the published
article (Prohens, R. et al. Crystal Growth & Design, 2014, 5, 2578-2587.). They are not included
in this Thesis since this research has not been conducted by myself but it is a collaborative work.
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Fig. 3.80: Squarate and amidosquarate salts 18-22 studied in this work
Fig. 3.81: Crystal structures of the amidosquarate salts 18-22 studied in this
collaborative research
In summary, we have studied the electrostatic compression phenomenon in zwit-
terionic squaramides and squarate salts, which is responsible for the formation of
new supramolecular synthons conrming the ability of the squaric acid derivatives
to establish combined hydrogen bond and -stacking interactions in the solid state.
Their potential for the synthesis of new multicomponent solids with both hydrogen
bond donor and acceptor coformers has been tentatively explored.

Chapter 4
Screening Techniques
4.1 Introduction
There are several methods used for screening of solid forms (table 4.1) described
in the literature, either in the solid state or from solution, the latter preferred for
the pharmaceutical industry, in which crystallization conditions can be modied
by using dierent solvents, antisolvents, temperatures, heating and cooling rates,
additives, concentrations, pH, pressure, saturations, etc. [36, 299]
The characterization of the solid forms obtained from the screening is mainly per-
formed by X-ray diraction techniques in combination with thermal analysis such
as dierential scanning calorimetry (DSC, Fig. 4.1), which is also a powerful tool
for obtaining useful information of the polimorphic system properties, and thermo-
gravimetry (TGA). Other complementary techniques widely used are solid{state
NMR spectroscopy, vibration spectroscopy (IR and Raman), thermomycroscopy,
Tab. 4.1: Crystallization methods
Crystallization from solution methods Solid state methods
evaporation cooling from the melt
slurrying expose to solvent vapour
cooling crystallization expose to high or low humidity
antisolvent diusion sublimation
antisolvent addition grinding
reverse antisolvent addition
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moisture sorption analysis and surface energy analysis. [14,23,40] In case of cocrys-
tals characterization, the use of
1
H-NMR and
13
C-NMR spectroscopy is essential.
Fig. 4.1: Thermal phenomena usually observed in a DSC analysis [300]
The preference for a polymorph to crystallize in a specic solvent at a given tem-
perature and pressure is inuenced by solvent-solute interaction phenomena in the
nucleation process, crystal growth, polymorphic transformation and by the intrinsic
solvent properties, such as, viscosity, hydrogen bonding ability, dielectric constant
and surface tension, which aect the crystallization kinetics of polymorphs. [301,302]
Therefore, using solvents with diverse properties increases the probability to nd
new polymorphs. Previous studies have established solvents classication without
including parameters such as acceptor/donor hydrogen bond capacity and viscosi-
ty. [303,304] In the present study, a classication according to the clusters method,
in particular the average linkage method, has been followed. [305,306] This method
classies 96 solvents in 15 groups by taking into account 8 parameters: accep-
tor/donor hydrogen bond capacity, polarity/dipolarity, dipolar moment, dielectric
constant, viscosity, surface tension and cohesive energy density. A parallel classica-
tion is performed, which takes into account just 5 parameters of the aforementioned
(discarding viscosity, cohesive energy density and surface tension, which just aect
solvent-solvent interactions). [307] Finally, a last classication was done with one or
more solvents selected from the coincident solvents from both classications as main
representatives of each group and new groups were created with the non-coincident
solvents, discarding acids, bases and potential toxic solvents. With these general
criteria 13 groups were obtained and 14 solvents have been used to work experimen-
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Tab. 4.2: Solvents classication
Group Solvent b.p.
a

b

c
Æ
d
d
e
V
f

g

h

i
Toxicity
1 Heptane 99 -0.08 0.00 1.91 200 0.39 28.28 0.00 0.00 Low
2 Dioxane 101 0.51 0.00 2.21 372 1.18 47.14 0.00 0.64 Medium
3 Toluene 111 0.54 0.38 2.37 289 0.56 40.20 0.00 0.14 Medium
4 Et
2
O 34 0.27 1.15 4.24 231 0.22 23.96 0.00 0.41 Low
5 THF 66 0.58 1.75 7.43 337 0.46 39.44 0.00 0.48 Low
6 CH
2
Cl
2
39 0.82 1.60 8.93 400 0.41 39.15 0.10 0.05 Medium
7 Acetone 56 0.71 2.88 20.49 362 0.31 33.77 0.04 0.49 Low
8 EtOH 78 0.54 1.69 24.85 619 1.07 31.62 0.37 0.48 Low
9 MeOH 64 0.60 1.70 32.61 808 0.54 31.77 0.43 0.47 Medium
10 ACN 81 0.75 3.92 35.69 523 0.37 41.25 0.07 0.32 Medium
11
DMF 153 0.88 3.82 37.22 464 0.79 49.56 0.00 0.74 Medium
DMSO 189 1.00 3.96 46.83 573 1.99 61.78 0.00 0.88 Low
12 ETG 85 0.92 2.28 41.40 858 16.10 69.07 0.90 0.52 Medium
13 Water 100 1.09 1.87 78.36 2096 0.89 105.0 1.17 0.47 Low
a
Boiling point (
Æ
C)
b
Polarity/dipolarity of the solvent [308]
c
Dipole moment (debye) [309]
d
Dielectric constant [309]
e
Cohesive energy density (Jmol/mL) was calculated from the equation, (H
vap
 RT )=V , where
H
vap
is the enthalpy of vaporization, R is the gas constant, T is temperature of interest and 298.15
K was used in the calculation, and V is the molar volume at 298.15 K. The value of H
vap
and V
was collected from the reference [309]
f
Viscosity of the solvent at 25
Æ
C (mPas) [309]
g
Surface tension of the solvent at 25
Æ
C (cal/(mol

A
2
)) [309,310]
h
Summation of the hydrogen bond donor propensities of the solvent [310,311]
i
Summation of the hydrogen bond acceptor propensities of the solvent [310,311]
tally during the screenings. In particular, dimethylsulfoxide and dimethylformamide
belong to the same group, but we considered working with both solvents since they
are extremely good in dissolving compounds, such as squaramides. Table 4.2 shows
a list of the solvents used in this work for the polymorphic and cocrystal screenings.
Solvents have been used as purchased, without further purication. This classi-
cation has been taken into account with the rst four disquaramides. Additional
solvents have been used in the whole work due to insolubility of the compounds and
other experimental considerations.
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4.2 Polymorphic Screening
In the present work, the polymorphic properties of several reported compounds have
been experimentally investigated through a general procedure for screening [307]
based on previous studies from the literature [12,14,22,312] and our work experience
in the Unit of Polimorphism and Calorimetry of the University of Barcelona. Thus,
for each compound the following general protocol has been follwed:
 Initial solid state characterization of the compounds by PXRD, TGA and
DSC.
 Solvent selection and solubility study.
 Samples generation: crystallizations under kinetic and thermodynamic con-
ditions.
 Analysis and characterization of the solids obtained by PXRD, TGA and
DSC.
 Crystal structure determination from powder X-ray diraction or by single
crystal X-ray diraction when possible.
 Study of the relative thermodynamic stability of the polymorphs obtained for
each compound.
4.2.1 Solubility study
10 mg of the compound were dissolved in the minimum required volum of the select-
ed solvent (up to 1 mL) at r.t. When the solid did not dissolve, the temperature was
raised up to the solvent boiling point. The solubility data of the model compounds
in the current study are summarized in appendix A.12)
4.2.2 Crystallization experiments from the solubility study
The vials containing the solutions obtained from the solubility study are kept closed
overnight at r.t. and if a solid still does not crystallize the tubs are opened for the
solvent to evaporate.
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4.2.3 Solvent mediated transformation experiments (slur-
ries)
The same amount of two polymorphs (10-30 mg of each form) were suspended in the
selected solvent into a sealed vial under stirring at the tested temperature. At higher
temperatures than r.t., the suspension was purged under nitrogen or argon. In case
the solvent was too volatile, small amounts of the solvent were added periodically
to avoid dryness. Aliquots of the suspended solid were analyzed periodically by
PXRD and the diractograms were compared to the starting material until the
transformation was complete. In the present work, this technique has been applied
to the solids of the solubility study which are insoluble and they have been slurried
overnight.
4.2.4 Precipitation experiments under kinetic conditions
4.2.4.1 Precipitation experiments by rapid cooling from high tempera-
ture to low temperature (PHT)
10 mg of the compound were dissolved in the minimum required volume of the
solvent at high temperature and the solution was cooled rapidly to 0
Æ
C or at a
temperature above the solvent freezing point. All the solids obtained were ltered
and air-dried.
4.2.4.2 Precipitation experiments by antisolvent addition (PAD)
10 mg of the compound were dissolved in the minimum required volume of the
selected solvent at r.t. If the compound was insoluble at r.t., the suspension was
heated until it dissolved. Antisolvents
1
at a 1:2 ratio (solvent:antisolvent) were
rapidly added to the solutions at r.t. and if no solid precipitated more antisolvent
was added up to a 1:4 ratio (solvent:antisolvent). Finally, in cases in which no
solid appeared, solutions were cooled down to 0
Æ
C or at a temperature above the
freezing point of the solvent. All the solids obtained were ltered and air-dried.
1
solvents in which the compound is insoluble
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4.2.5 Crystallization experiments under thermodynamic con-
ditions
4.2.5.1 Crystallization experiments by slow cooling from high temper-
ature to r.t. (CHT)
10 mg of the compound were dissolved in the minimum volume of the solvent at
high temperature. Once the solid was completely dissolved, the stirring and heating
were switched o and the solution was allowed to slowly cool down to r.t. The solids
obtained were ltered and air-dried.
4.2.5.2 Crystallization experiments by solvent evaporation at r.t. (CRT)
10 mg of the compound were dissolved in the minimum required volume of the
solvent at r.t. and, once the solid was completely dissolved, the stirring was stopped
and the vial containing the solution was opened to air until a solid crystallized. The
solids obtained were ltered and air-dried.
4.2.5.3 Crystallizations experiments by antisolvent diusion at r.t.(CAD)
10 mg of the compound were dissolved in the minimum required volume of the
solvent at r.t. into a thin vial, which was sealed with a septum and a needle,
through which the antisolvent is allowed to evaporate. The vial was introduced
into a bigger vial containing the selected antisolvent, and the system was sealed.
The solution was mantained at r.t. until a solid crystallized (Fig.4.2).
Fig. 4.2: Antisolvent diusion scheme
4.3 Cocrystal screening
In this section the general procedure of the experimental cocrystal screening tech-
niques used in the present work is described, based on previous studies from the
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literature and our work experience. [52,60,74,313,314] However, no extensive cocrys-
tal screening has been performed for each compound, but specic methods for some
particular compounds in order to study their crystal structures. All the resulting
solids were analyzed by PXRD and new multicomponent phases were conrmed by
1
H-NMR.
4.3.0.4 Grinding/Drop-grinding experiments (G/DG)
20-50 mg of a mixture of the compound and the selected coformer in a 1:1, 1:2 or
2:1 molar ratio were introduced together with two steal balls of 3 mm of diammeter
into a miller. A drop of a selected solvent (5-10L), in case of the drop-grinding,
was added together with two metallic balls and the miller was programmed at 30Hz
for 30 minutes.
4.3.0.5 Reaction Crystallizations (RC)
A saturated solution of the more soluble component was prepared under stirring in
a sealed vial. Small amounts of the other component were added until a suspension
was obtained. The suspension was kept stirring for a week at room temperature,
avoiding the complete evaporation of the solvent by adding little amounts of solvent,
if necessary. Finally, the solid was ltered and air-dried.
4.3.0.6 Precipitation experiments by rapid cooling from high tempera-
ture to low temperature (PHT)
20-50 mg of a mixture of the compound and the selected coformer in a 1:1, 1:2 or 2:1
molar ratio were introduced into a sealed vial with the minimum required volume
of a specic solvent to dissolve the mixture at high temperature. Once the solid
was dissolved, the solution was cooled rapidly to 0
Æ
C or at a temperature above
the solvent freezing point.
4.3.1 Crystallization experiments to obtain single crystals
4.3.1.1 Crystallizations experiments by slow cooling from high temper-
ature to r.t. (CHT)
20-50 mg of a mixture of the compound and the selected coformer in a 1:1, 1:2
or 2:1 molar ratio were introduced into a sealed vial with the minimum required
volume of a specic solvent to dissolve the mixture at high temperature. Once the
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solid was dissolved, the heating was switched o allowing the solution to cool down
slowly to r.t.
4.3.1.2 Crystallization experiments by antisolvent diusion at r.t. (CAD)
An aliquot of a solution containing the compound and the coformer in a 1:1, 1:2
or 2:1 molar ratio at r.t. was introduced into a thin tub sealed with a septum
and a needle, through which the antisolvent was allowed to diuse. It was kept
without stirring into a bigger tub containing the selected antisolvent until a solid
crystallized.
4.3.1.3 Recrystallization experiments from the reaction crystallization
solids (RRC)
A saturated solution of the more soluble component was prepared in the selected
solvent at r.t. and the less soluble component was added until a suspension was
observed. The temperature was raised and additional solvent was added until a
complete dissolution of the solid. Finally, the solutions were slowly cooled down to
r.t.
Chapter 5
Crystal structure determination
from powder X-ray diraction
data
Powder X-ray diraction (PXRD) is now one of the most widely used techniques
available to materials scientists for studying the structure and microstructure of
crystalline solids, specially in cases where suitable single crystals are not avail-
able. [315] In recent years, signicant progress has been made in all aspects of ab
initio crystal structure solution from powder diraction data, [316{320] since or-
ganic compounds named Cimetidine [321] and Fluorescein diacetate, [322] were
rst determined by direct space methods using synchrotron X-ray powder dirac-
tion data. Various methods for the structure determination from powder diraction
data (SDPD) have been used since then and numerous examples of reliable three-
dimensional structures [323{329] have been obtained, of comparable quality to those
from single crystal experiments.
The challenges encountered in crystal structure solution from PXRD data in
the case of molecular crystals are greater compared to non-molecular and frame-
work crystal structures. Molecular crystals tend to have low symmetry, leading to
substantial overlap of peaks in their powder diractograms [330] and specially for
organic molecular crystals, the majority of the atoms in the structure are weak X-
ray scatterers, resulting in little signicant intensity at high diraction angles. [331]
All these issues have been overcome by improving technology, global optimization
algorithms and by using novel strategies, [332{334] which allow high rate of success
even by using conventional laboratory powder diraction data, collected under non
ideal conditions. [335{338]
During the development of this PhD thesis, various crystal structures have been
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solved by means of direct space methods from PXRD data following a methodology
which has been optimized in the Polymorphism and Calorimetry Unit in collabo-
ration with the X-ray Diraction Unit of the Scientic and Technological Centers
(CCiT-UB). The procedure is based on a sequential process [316,339] which mainly
consists in: (I) indexing and space group determination, (II) structure solution and
(III) structure renement. Each step will be separately presented next. (Fig. 5.1)
Fig. 5.1: SDPD using direct-space methods
(I) Indexing and space group determination
The rst and crucial step in a structure determination from powder diraction
data is indexing, i.e. to nd the unit cell dimensions (a, b, c, ,  and ) of the
material under investigation. This stage is the key of the whole procedure because
a wrong unit cell leads to unsatisfactory structures and in some cases the unit cell
cannot be found due to low intensity peaks, peak shoulders, textured samples, extra
peaks from unknown impurities or peak overlapping. In the indexing process, low-
angle peaks are critical, since peak overlap at high diraction angles is usually very
extensive and consequently high-angle region of X-ray diraction laboratory data
cannot be used reliably.
The most widely used programs for indexing are ITO, [340] TREOR [341] and
DICVOL [342,343], which typically consider the maximum peak position of about 20
selected peaks at low diraction angles of all available diraction lines. In particular,
DICVOL is explained next as it is the program used in this work.
Crystal structure determination from powder X-ray diraction data 95
Through automatic peak search and then through careful manual inspection,
the diraction patterns of the crystal structures reported in this work were indexed
by using DICVOL04, a trial and error method based on the variation of parameters
by successive dichotomy. The impurity tolerance 'imp' is related only to the 20 lines
used for searching the solution (additional unindexed lines can be found among the
extra input lines in the reviewing process). However, spurious lines increase the
risk to miss the correct solution. DICVOL04 oers also the possibility to analyze
the presence of a zero-point error and it can suggest more than one solution, due
to uncertainty in searching harmonic diraction lines. Solutions are searched for
the smallest cell volumes and they have to be evaluated according to their gures
of merit M20 and F20. [344] As a result, the set of d-spacings (d's) and intensities
(I's) of peaks can be derived from the pattern and used further in the identication
of the space group, according to systematic extinctions in the intensity data, which
are shown as a lack of diraction peaks with certain conditions in its Miller indices.
To help in this process, density () considerations and space group multiplicities
are used to check whether the obtained cell parameters correspond to an integer
number of a chemical formula in the cell (Z) (Eq. 5.1),
 =
M  Z
N
A
 V
c
(5.1)
whereM is the molecular weight, N
A
is the Avogadro number and V
c
the volume
cell.
If the space group cannot be uniquely assigned, structure solution calculations
should be carried out separately for each of the possible space groups and the correct
structure will be decided at the end of the process.
After indexing and space group assignment, the intensity data are prepared for
structure solution by using the prole matching technique, through Le Bail [318]
or Pawley [345] tting methods. Thus, the unit cell parameters obtained from
the indexing step are used in the renement without any structural model; in this
step, the intensities are rened as mathematic variables only to give optimal t to
the experimental powder diraction pattern. In this work, the pattern matching
process was followed as developed by Le Bail. The calculated intensities of every
2 point of the powder diraction diagram are initially taken equal to an arbitrary
value and successively rened to minimize by least squares the 
2
function through
the following equation:

2
=
N
X
i=1
!
i
(y
obs
i
  y
calc
i
)
2
(5.2)
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where y
obs
i
and y
calc
i
are, respectively, the intensities of the i
th
point in the digital-
ized experimental and calculated powder diraction patterns, and !
i
is a weighting
factor for the ith point (1/y
i
in our case).
The aim of this process is to obtain reliable values of the variables that describe
(a) the peak positions (unit cell parameters and zero-point shift), (b) the back-
ground intensity distribution, (c) the peak widths, (d) the peak shape (typically
described by a pseudo-Voigt function i.e., a mixture of Gaussian and Lorentzian
functions) [346, 347] and (e) the peak intensities. All aforementioned rened pa-
rameters will be used as input information in a subsequent stage of the structure
determination process.
Following a Le Bail multi-step procedure, the integrated intensities, lattice pa-
rameters and zero-point shift parameters of the crystal structures determined in
this work were rened. The quality of the Le Bail t is established from the com-
parison of the simulated and the experimental powder diraction patterns and it
is quantied by the weighted powder prole R-factor (R
wp
) and 
2
that considers
the entire powder diraction prole point by point, taking peak overlap implicitly
under consideration (Eq 5.3).
R
wp
= 100
s
P
i
!
i
(y
obs
i
  y
calc
i
)
2
P
i
!
i
y
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i
2
(5.3)
(II) Structure solution
The aim of structure solution is to obtain the best initial approximation of the
crystal structure by using the unit cell, the space group, the background and the
prole variables determined in the rst step, but without previous knowledge of the
actual position of the molecules within the unit cell.
Ab initio structure determination from powder diraction data methods can
be divided into two groups depending on the powder pattern treatment: recip-
rocal space methods, (the most commonly used are the so called direct method-
s)
1
[315, 350, 351] and direct-space methods. [331, 352{356] The rst methods con-
sider the observed individual peaks, whereas the latter ones are based on modelling
the observed pattern as a whole. [353] (Fig. 5.2)
A. Reciprocal space methods: They require the extraction of structure factor ampli-
tudes from individual reection intensities in the powder pattern, analogously
to single-crystal methods, and they are successfully applied to single crystal
1
Other procedures are also used like Patterson synthesis [348] or charge ipping. [349].
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Fig. 5.2: Structure determination methods
data, however, this methodology is much more limited in SDPD. A prelimi-
nary decomposition of the experimental prole into the single peaks is required
to obtain the integrated intensity (area under each peak) for each reection.
In this sense, various experimental limitations make diÆcult to apply direct
methods: strong overlap of the diraction peaks generated by the problem of
projecting the 3D reciprocal space on a single dimension, which is particularly
severe in molecular solids because of their large and low symmetry unit cells;
the fact that organic compounds do not usually have dominant strong scat-
tering atoms; the need for a background estimation; the preferred orientation,
crystal defects which cause broadening peaks, etc. Signicant improvement in
overcoming the aforementioned limitations has been achieved using synchrotron-
based powder diractometers to enhance resolution and intensity together with
advanced mathematical approaches. [355,357{359] However, insuÆcient resolu-
tion in powder patterns or limiting crystal size and quality, twinning and other
intrinsic structural features still make direct space methods an indispensable
technique to solve crystal structures from PXRD data.
B. Direct-space methods: The method is based on the location of building blocks in
the cell and the comparison of the calculated and observed diraction patterns
as a whole. Its greatest advantage is that they do not deal with the "phase
problem" since the extraction of structure factors is not required. In general
terms, it is a global optimization problem of a great complexity in which the
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agreement between the observed and calculated diraction patterns is maxi-
mized by a continuous movement of the molecular model around the unit cell,
constantly adjusting its conformation, position and orientation. Starting from a
random conguration, the free parameters in the structure are varied random-
ly. In general, the global optimization process in direct space consists of (i)
parametrization, (ii) ergodic algorithm and (iii) cost function. [353]
(i) Parametrization: Any direct space search requires the denition of the de-
gree of freedom (DoF) which describes the structure. Structures are de-
scribed by continuous or discrete parameters; comprising a list of atoms re-
lated to each other by bond distances and bond angles and their respective
restraints, [360, 361] or by using the Z-matrix approach. [362] In order to ac-
celerate the structure solution process, it is necessary to reduce the number of
space parameters that describe the molecular model by grouping atoms with
prior knowledge of chemical information such as the identity of the molecule
and the atomic connectivity. Thus, molecular models can be treated as rigid
bodies in which bond lengths and bond angles are xed at the standard values
during the direct-space structure solution calculation and the torsion angles
that dene the molecular conformation are left as the unique variables to be
determined.
(ii) Ergodic algorithm: parameters vary to eventually explore the entire congura-
tion space and the algorithm evaluates if the global minimum path to the true
structure is correct. Several optimization algorithms commonly used are Grid
Search, [320,363,364] Monte Carlo (MC), [365] MC with Simulated Annealing
(SA), [366{369] MC with Parallel Tempering (PT), [370] Genetic Algorith-
m (GA) [371, 372] and Dierential Evolution (DE). [373] MC, SA and PT
are based on the evaluation of the probability of a given conguration by a
Boltzman type distribution known as Metropolis algorithm [374] depending
on temperature, which decreases during the optimization to make MC pro-
cess converge, since lower temperature favors better congurations. In SA,
the temperature is slowly decreased after each trial conguration, whereas in
PT a single chain of congurations is used with a decreasing temperature. A
small number of parallel optimizations is made, each with a dierent temper-
ature and periodically the algorithm tests an exchange of congurations. PT
algorithm is invariant with the number of trials and at all times during the
optimization there is the possibility to reach any conguration. PT or multi-
ple SA have been proven to better succeed in overcoming the main drawback
of SA, which is to be trapped in a local minimum due to a possible premature
decrease of temperature. All the abovementioned algorithms evaluate individ-
Crystal structure determination from powder X-ray diraction data 99
ual trials whereas with GA a population of congurations is tested as a group.
TOPAS, [375] DASH, [376] FOX (Free objects for crystallography) [360, 361]
and EAGER [377] among others [378] are the main computer programs of
direct space methods using MC algorithm with SA or PT.
(iii) Cost function (CF): it is the penalty or tness associated with each trial
structure and it is evaluated by several criteria (
2
or R
wp
, [379] crystal ener-
gy, atomic coordination, etc). [353] Congurations are compared using a cost
function, which is characteristic of how good the structure is (the smaller val-
ue the better conguration). However, other validation of structural models
can be applied in addition, such as quantum-chemical stability calculation-
s, [380] combined with local or global energy minimization [381{383] or the
application of crystallographic rules derived from crystal chemistry of known
structures. [384]
The following gure summarizes the procedure of the global optimization algo-
rithm in structure solution using direct space methods.
Fig. 5.3: Global optimization algorithm in SDPD
In this work, structure solution has been conducted by means of direct space
methods with a reverse Monte-Carlo approach [385] implemented in FOX. Although
this program has been in principle designed to solve non-molecular structures better
than molecular ones, its use has expanded to small, discrete organic compounds with
satisfactory results. [353,386{389] FOX has its own advantages, which are presented
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next. The crystal structure can be described using any combination of isolated
atoms, molecules or polyhedra. The molecular model can be encoded in two ways:
as a molecule, comprising a list of atoms related to each other by bond distances and
bond angles and their respective restraints, or as a Z-matrix. The use of a exible
parametrization [361] improves optimization speed and it allows the use of several
optimization algorithms (SA or PT). A cost function is dened by each optimized
object and any combination of CFs can be used as a particular criterion, moreover,
maximum likelihood principles for a correct evaluation of the approximate models
have been recently implemented. It is also possible to use jointly all available data
sets from dierent radiation sources and dynamical occupancy correction (DOC)
simplies the problem with special positions when solving non-molecular crystals.
Extending the program structure algorithms criterion for validating the structure
is easy. It has its own algorithms of indexing and a very intuitive user-friendly
graphical interface. [360, 361] In order to obtain the starting structural models of
the dierent phases determined during this work, Monte Carlo calculations were
performed with the parallel tempering algorithm implemented in the program FOX
and the initial starting molecular models were introduced by Z-matrices approach
using the molecular modeling software package Spartan. [247] Optimized structural
models at molecular mechanics level of calculation were converted from protein data
bank format (.pdb) to a Fenske hall Z-matrix format (.fh) using an opensource
OpenBabel program. [390] During the calculations, the observed and calculated
intensities were compared generally only in the 2 range between 2 and 70deg and
the molecules were allowed to translate and rotate randomly.
(III) Structure renement: Rietveld
The nal step on SDPD is the structure renement carried out by the Rietveld
method [347, 391], which considers every point in the powder diraction diagram
as an individual intensity measurement, instead of using the integrated intensi-
ties I(hkl). During Rietveld renement the variables dening the structural model
(atomic positions and atomic displacement parameters) and the powder diraction
prole (unit cell, zero shift error and shape parameters) are adjusted by least-squares
methods (Eq. 5.2) so that an optimal t between the experimental and calculated
powder diraction patterns is achieved. The calculated powder pattern is obtained
based on the crystalline structures, instrumental characteristics, optic parameters
related with diraction phenomenon and other sample features able to be modeled
such as microstructure of the considered phases.
Each diraction peak is characterized by its angular 2 position, by the medium
high width function (FWHM or H) and by its gaussian and lorentzian contribu-
tions of the pseudo Voigt function, which best describes the shape of the diraction
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pattern. Texture is usually taken into account through the March-Dollase func-
tion. [392] It is generally necessary to use geometric restraints based on standard
molecular geometries to avoid problems of instability during Rietveld renement
and to achieve stable convergence of least-squares calculations. The evaluation of
the t is performed according to the Rietveld graphics and mathematic residual
indices: the Rietveld graphics represent both diagrams observed and calculated to-
gether with the dierences diagram, and the mathematic residual indices allow a
subsequent following of the adjustment during the renement (
2
and R
wp
are the
most considered factors). The most common programs to perform Rietveld rene-
ment are GSAS [318] and FULLPROF, [393] the latter being used to rene the
crystal structures presented in this work.
The Finger's treatment of the axial divergence [394] was taken into account to
model the asymmetry of the peak prole. The background was linearly interpolated
between a set of selected 2 points. During Rietveld renement, the scale factor, zero
shift error, cell parameters, peak shape, background points, isotropic temperature
factors (rened by types of atoms: C, N, O, H, etc.) and, at last, atomic coordinates
of the atoms considered not restricted for moving were adjusted. Planar molecular
fragments and hydrogen atoms coordinates were maintained xed.

Chapter 6
Experimental Section
6.1 Materials and equipment
The characterization of the synthesized compounds during the development of this
thesis has been performed using technical instrumentation from the Centres Cien-
tcs i Tecnologics of the Universitat de Barcelona (CCiT-UB).
 Nuclear magnetic resonance (NMR). Proton nuclear magnetic reso-
nance (
1
H-NMR) spectra and carbon nuclear magnetic resonance (
13
C-NMR)
spectra have been recorded on a Varian Mercury 400 (400 MHz). Variable-
Temperature NMR studies have been performed on a Bruker DMX500 (500
MHz) instrument equipped with an indirect
1
H{
13
C detection probe with gra-
dients along the z axis. A standard sequence from Bruker software has been
used for COSY experiments (cosygpqf): a total of 128 increments, 4 scans
each, have been collected. Chemical shifts for proton are reported in parts per
million (ppm) downeld from tetramethylsilane and are referenced to residual
protium in the NMR solvent (CDCl
3
: Æ 7.26, DMSO: Æ 2.50). Chemical shifts
for carbon are reported in parts per million downeld from tetramethylsilane
and are referenced to the carbon resonances of the solvent (CDCl
3
: Æ 77.0,
DMSO: Æ 39.43). Data are represented as follows: chemical shift, multiplicity
(br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet),
coupling constants in Hertz (Hz) and integration.
 Mass spectrometry (MS). Mass spectra have been obtained on dierent
spectrometers: API 365 and API 150 from PE SCIEX, and LTQ Orbitrap
Velos from Thermo Scientic tted with an electron spray ionization (ESI)
source via Flow Injection Analysis (FIA) in (+) and (-) polarity ionization
mode depending on the sample.
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 Powder X-ray diraction (PXRD). Laboratory X-ray powder diraction
data have been collected in dierent instruments and congurations depending
on the required type of information:
A) Panalytical X'Pert PRO MPD = of 240 mm of radius powder dirac-
tometer transmission conguration, using CuK
1+2
radiation ( = 1.5418

A)
with a focalizing elliptic mirror, dening a beam height of 0.4 mm, a PIX-
cel detector working at a maximum detector's active length of 3.347 deg 2
and 0.01 or 0.02 radians Soller slits. The instrument has worked at 45 kV
and 40 mA. Capillary geometry has been used with the samples placed in
0.5 or 0.7 mm of diameter Lindemman capillaries measuring 2 scans from 2
to 70 deg 2, with a step size of 0.013 deg 2 and a measuring data collec-
tion time of 16 hrs (when using 0.02 soller slit) or 60 hrs (when using 0.01
soller slit). When temperature dependent analyses have been performed, an
Oxford Cryosystems 700 series Cryostream liquid nitrogen criostat, enabling
temperature control of the analysed capillary sample from 90 to 500 K has
been used.
B) Panalytical X'Pert PRO MPD = of 240 mm of radius powder dirac-
tometer transmission conguration, using CuK
1+2
radiation ( = 1.5418

A)
with a focalizing elliptic mirror, dening a beam height of 0.4 mm, a PIXcel
detector working at a maximum detector's active length of 3.347 deg 2 and
0.02 radians Soller slits. The instrument has worked at 45 kV and 40 mA. Flat
geometry has been used with the samples sandwiched between low absorbing
lms (poliester lms of 3.6 micrometers of thickness) measuring 2= scans
from 2 to 40 deg 2 with a step size of 0.026 deg 2 and a measuring time of
80 seconds per step.
C) Debye-Scherrer INEL CPS-120 powder diractometer with capillary con-
guration and curved position sensitive detector of 120 deg with horizontal
goniometer of 250 mm of radius in transmission geometry has been used.
CuK
1
radiation ( = 1.54056

A) by means of Ge (111) primary monochro-
mator has been selected. A parabolic multilayer mirror 'OSMIC Gutman
optics 13B{413' was placed between the tube and the monochromator. The
instrument has worked at 40 kV and 30 mA. Samples were placed in 0.5 mm.
diameter glass Lindemann capillaries. Each sample was measured from 2 to
115 deg 2, with a step size of 0.029 deg 2 and a measuring time of 3600 sec-
onds per step. When temperature dependent analyses have been performed,
a FURCAP device from INEL that enables to heat capillary samples from
r.t. to 523 K has been used. Data acquisition was carried out at several
temperatures in a range of r.t. to melting temperature.
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 Single crystal X-ray diraction (SCXRD). Laboratory single crystal X-
ray diraction data have been collected in two dierent instruments depending
on the quality of the crystal:
A) MAR345 diractometer with an image plate detector has been used. In-
tensities have been collected with graphite monochromatized MoK radiation
using  {scan technique. Oxford cryosystems 700 series cryostream (80 to
500 K) has been required to record low temperature diraction data. After
data collection the crystal structure solution has been attempted by direct
methods, using SHELXS97 computer program for determination and rened
by full-matrix least-squares method with SHELX97 computer program. [395]
Reections have been assumed as observed applying the condition I > 2(I).
When H atoms have been computed and rened, a riding model with an
isotropic temperature factor equal to 1.2 time the equivalent temperature
factor of the atom which are linked has been applied.
B) D8 Venture air-cooled system equipped with a multilayer monochromator
and a Mo ( = 0.71073

A) or Cu ( = 1.5418

A) microfocus has been used. A
2D area detector PHOTON 100: active area 10x10 cm
2
and CMOS technology
with 1024x1024 pixels, 4 circle goniometer, Kappa geometry with pinhole
collimators of 0.8 millimetres, motorized diracted beam arm with distances
sample-detector from 30 to 240 mm and cryogenic system (nitrogen liquid jet)
Bruker Cryoex working in a temperature range of 80 to 400 K has been used.
Frames have been integrated with the Bruker SAINT software package using
a SAINT algorithm. Data have been corrected for absorption eects using the
multi-scan method (SADABS). The structures have been solved and rened
using the Bruker SHELXTL Software Package, [396] a computer program
for automatic solution of crystal structure and rened by full-matrix least-
squares method with SHELXLe Version 4.8.0: a Qt graphical user interface for
SHELXL computer program, [397] a program for crystal structure renement.
Reections have been assumed as observed applying the condition I > 2(I).
When H atoms have been computed and rened, a riding model with an
isotropic temperature factor equal to 1.2 time the equivalent temperature
factor of the atom which are linked has been applied.
 Dierential scanning calorimetry (DSC). Experiments have been per-
formed in three dierent calorimeters: Mettler-Toledo DSC-822e, Mettler
Toledo DSC-30 and Perkin Elmer Diamond equipped with a model ULSP90
intracooler. The samples have been placed in aluminum crucibles of 40 L
volume and they have been analyzed under atmosphere of dry nitrogen with
50 mL/min ow rate. The calorimeters has been calibrated with standards
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of indium, n-decane and benzene of 99.99% purity. Standard heating rates of
10
Æ
C/min have been used on the range of 30 to 350
Æ
C. Occasionally, other
special experimental conditions have been required, such as aluminum cru-
cibles of 20 or 100 L volume, helium or air atmosphere and variable heating
rates on the range of 1 to 120
Æ
C/min.
 Modulated dierential scanning calorimetry (MDSC). Experiments
have been performed in a TA Instruments MDSC Q2000 calorimeter. The
samples have been placed in aluminum crucibles of 40 L volume and they
have been analyzed under atmosphere of dry nitrogen with 50 mL/min ow
rate at 0.5
Æ
C/min on the range of 30 to 200
Æ
C. Periods of 60 seconds and
amplitude of 0.08
Æ
C to satisfy Only Heat conditions.
 Thermogravimetry (TGA). Thermogravimetric experiments have been
performed in two dierent instruments.
- A thermo balance Mettler-Toledo TGA-851e. The samples have been placed
in alumina crucibles of 70 L volume and they have been analyzed under
atmosphere of dry nitrogen with 50 mL/min ow rate. The microbalance has
been calibrated with indium and aluminum of 99.99% purity. A standard
heating rate of 10
Æ
C/min has been used in all experiments.
- A Perkin Elmer TGA7. The samples have been placed in alumina crucibles of
70 L volume and they have been analyzed under atmosphere of dry nitrogen
with 50 mL/min ow rate. A standard heating rate of 10
Æ
C/min has been
used in all experiments.
 Thermomicroscopy (Hot-stage). A Nikon polarization microscope (Nikon
Eclipse 50i) equipped with a Linkam LTS350 hot stage which can operate
in the temperature range of -196-600
Æ
Cand digital video recorder facilities
have been used. Dierent experimental heating and cooling rates have been
required in order to record the particularities of each polymorphic system's
thermal events.
 Milling: Retsch ball mill MM2000 equipped with two metal vessels, each one
having four 2 mL cavities is used. Two tungsten balls (diammeter 3mm) are
used in each experiment which is performed at 30Hz for 15 or 30 minuts.
6.2 Synthesis of squaramides
Commercial reagents were purchased from Sigma Aldrich and used as received.
Synthesis grade quality solvents were used.
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Substituted squaramides can be accessed via modular synthesis under relative-
ly mild conditions. In this work, a modular synthesis via condensation [172, 398,
399] has been used to prepare a wide variety of symmetrical and unsymmetrical
squaramides and monosquaramides, enabling the exploration of diverse structures.
Ester derivatives of squaric acid, especially diethyl esters (i), undergo a conden-
sation with 1 equivalent of a primary amine in a solvent such as diethyl ether to
generate a monosquaramide product: squaramide{ester (ii). This is possible due
to the dierence of solubility among the products of the reaction. The squaramide
ester has a low solubility in diethyl ether so it precipitates avoiding a second con-
densation, which has slower kinetics than the rst one. This is a case of kinetic
regioselectivity and dierent solubility of squaramide-ester in the media. Since di-
ethylsquarate reactivity is higher than a conventional ester it does not require previ-
ous activation. [398] In other cases, when the product to be obtained is a symmetric
disquaramide (iv), diethylsquarate undergo a condensation with 2 equivalents of a
primary amine in ethanol. Since the product of condensation is soluble in the medi-
a, it can further react until the disquaramide is formed and precipitates in ethanol.
If an asymmetric disquaramide is required, a two-step synthesis is performed: the
product of the rst condensation with 1 equivalent of amine in ether is isolated and
it reacts through a second condensation with 1 equivalent of a dierent amine in
ethanol. The products are obtained by insitu crystallization and they can be iso-
lated and puried by ltration and subsequent washes with ethanol or diethylether.
Their purity was conrmed by NMR comparing with data from the literature when
possible. A scheme summarizing the synthesis is shown in gure 6.1.
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Fig. 6.1: Scheme of squaramides' synthesis
6.2.1 Synthesis of compound 1
NH2
OO
OO
OO
N
H
N
H
+
1
Fig. 6.2: Synthesis of Dibenzylsquaramide
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Benzylamine (3.09 mL, 28.0 mmol) was added to a solution of diethylsquarate
(1.60 g, 9.43 mmol) in absolute ethanol (66 mL) at r.t. under vigorous stirring and
argon atmosphere. After 24 hours, the resulting white solid was ltered and it was
washed with absolute ethanol (2 x 10 mL). The solid was dried under vaccum to
yield 99 % (2.72 g).
Characterization of 1:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.70 (s, 2H); 7.24 (m, 10 H), 4.02 (d, J = 7
Hz, 4H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 186.6; 171.5; 142.9; 132.6; 131.5;
131.4 ; 50.8 ppm. MS: (ESI) m/z (%): 293.13 (M+H
+
, 100).
6.2.2 Synthesis of compound 2
N
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2
Fig. 6.3: Synthesis of 3,4-Bis(2-methylaminopiridyl)-1,2-dioxo-3-cyclobutene
2{methylaminopyridine (2.92 mL, 28 mmol) was added to a solution of diethyl-
squarate (1.60 g, 9.43 mmol) in absolute ethanol (66 mL) at r.t. under vigorous
stirring and argon atmosphere. After 24 hours the resulting yellowish solid was
ltered and washed with absolute ethanol (2 x 10 mL). The solid was dried under
vacuum to yield 83% (2.30 g).
Characterization of 2:
1
H-NMR (CDCl
3
, 400 MHz) Æ: 8.49 (d, J = 4 Hz, 2H); 7.70 (m, 2H); 7.38 (d,
J = 10 Hz, 2H); 7.22 (m, 2H); 4.87 (br s, 4H) ppm.
13
C-NMR (CDCl
3
, 100 MHz)
Æ: 184.3; 169.3; 157.4; 149.9; 138.2; 123.6 ; 49.9 ppm. MS: (ESI) m/z (%): 295.12
(M+H
+
, 100).
6.2.3 Synthesis of compound 3
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Fig. 6.4: Synthesis of 3,4-Bis(2-ethylaminopiridyl)-1,2-dioxo-3-cyclobutene
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2-ethylaminopyridine (2.14 mL, 17.6 mmol) was added to a solution of diethyl-
squarate (1.02 g, 6.0 mmol) in absolute ethanol (42 mL) at r.t. under vigorous
stirring and argon atmosphere. After 24 hours, the resulting white solid was l-
tered and washed with absolute ethanol (2 x 5 mL). The solid was dried under
vaccum to yield 90% (1.76 g).
Characterization of 3:
1
H-NMR (CDCl
3
, 400 MHz) Æ: 8.45 (d, J = 4 Hz, 2H); 7.70 (m, 2H); 7.24 (br s,
4H); 4.02 (d, J = 5 Hz, 4H); 3.14 (t, J = 6,4 Hz, 4H) ppm.
13
C-NMR (CDCl
3
, 100
MHz) Æ: 183.9; 168.3; 122.6; 124.5; 44.0; 38.1 ppm. MS: (ESI) m/z (%): 323.15
(M+H
+
, 100).
6.2.4 Synthesis of compound 4
+NH2N
OO
OO
OO
N
H
N
H
N N
4
Fig. 6.5: Synthesis of 3,4-Bis(2-dimethylamino-ethylamino)-cyclobut-3-ene-1,2-dione
2-N,N -ethylendiamine (3.09 mL, 28.29 mmol) was added to a solution of diethyl-
squarate (1.60 g, 9.43 mmol) in absolute ethanol (66 mL) at r.t. under vigorous
stirring and argon atmosphere. After 24 hours, the resulting white solid was l-
tered and washed with cold absolute ethanol (2 x 10 mL). The solid was dried under
vacuum to yield 84% (2.01 g).
Characterization of 4:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.45 (s, 2H); 3.59 (m, J = 4 Hz, 4H); 2.37 (t,
J = 4 Hz, 4H); 2.15 (s, 6H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 184.2, 169.7,
58.5, 43.1, 38.4 ppm. MS (ESI) m/z (%): 255.3 (M+H
+
, 100).
6.2.5 Synthesis of compound 5
A solution of methylamine 33% in ethanol (3.1 mL, 24 mmoL, 0.75 g/mL) was
added to a solution of diethylsquarate (1.39 g, 8 mmol) in ethanol (10 mL), at
r.t. under vigorous stirring and argon atmosphere. A yellowish solid precipitated
immediately and after 24 hours the solid was ltered and washed with ethanol (2 x
5 mL). The resulting solid was dried under vacuum to yield 87% (0.99 g).
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OO
OO
NH2-CH3
OO
NN
HH
+
5
Fig. 6.6: Synthesis of 3,4-Bis-methylamino-cyclobut-3-ene-1,2-dione
Characterization of 5:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.3 (br, NH), 3.09 (d, J = 4 Hz, 6H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 183.3, 169.0, 30.9 ppm. MS (ESI) m/z (%):
141.1 (M+H
+
, 100).
6.2.6 Synthesis of compound 6
OO
HN
O
OO
O
NH+
NH2 NH2
6
Fig. 6.7: Synthesis of 2,7-Diaza-bicyclo(6.2.0)dec-1(8)-ene-9,10-dione
A solution of 1,4-diaminobutane (0.27 g, 3 mmol) in ethanol (30 mL) was added
dropwise to a stirring solution of diethylsquarate (0.52 g, 3 mmol) in ethanol (62
mL) at r.t. under nitrogen atmosphere. After stirring overnight, a white pale solid
was ltered, washed with ethanol (2 x 10 mL) and dried under vacuum to yield
78% (0.39 g).
Characterization of 6:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 8.31 (br, 2H), 3.19 (m, 4H), 1.25 (m, 4H)
ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 183.1, 169.1, 40.6, 24.8 ppm. MS (ESI)
m/z (%): 167 (M+H
+
, 100).
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6.2.7 Synthesis of compound 7
Br Br N3 N3 NH2 NH2
N N
OO
HH
7
i ii
iii
7a 7b 7c
O O
OO
NH2 NH2
7c
+
Fig. 6.8: Synthesis of 3,4,9,10-Tetrahydro-3,10-diaza-benzocyclobuta-cyclooctene-1,2-dione
Compound 7 was obtained in a three-step synthetic route. Dibromide 7a was
converted into the corresponding diazide 7b in toluene/DMF, then reduced to the
amine 7c with LiAlH
4
, and nally condensed with one equivalent of diethyl squarate
in ethanol. (ii) Sodium nitride (3.72 g, 0.07 mol) was added to a stirring solution
of ; 
0
-Dibromo-o-xylene 7a (5.02 g, 0.02 mol) in toluene (125 mL) and DMF (125
mL) and the mixture was reuxed at 110
Æ
C for 1.5 hours under nitrogen atmo-
sphere. The red suspension was cooled down to r.t., ltered, and washed with cold
toluene (30 mL). After washing with water (3 x 50 mL) and drying with anhydrous
sodium sulfate, the combined organic phases were evaporated under vacuum yield-
ing a viscous brown tinge oil 7b (88%). (ii) In a second step synthesis, LiAlH
4
(20
mL, 1M in THF) was added dropwise to a solution of 1,2-Bis(azidomethyl)benzene
7b (3 g, 0.016 mol ) in THF (180 mL). After adding water (10 mL), the mixture
was stirred for 15 min and the suspension was ltered over celite. The solid was
washed with THF (3 x 20 mL) and the combined organic fractions were evaporated
under vacuum yielding a viscous yellowish oil 7c (90%). (iii) In the last step of the
synthesis, a solution of 2-aminomethylbenzylamine 7c (2g, 0.015 mol) in ethanol
(550 mL) was added to a stirring solution of diethylsquarate (2.5 g, 0.015 mol) in
ethanol (10 mL) at r.t. under nitrogen atmosphere. The solid was ltered, washed
with acetone (2 x 10 mL), and dried under vacuum to yield 30%.
Characterization of 7:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 8.81 (s, br, 2H), 7.21 (m, J = 4 Hz, 4H), 4.37
(s, 4H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 187.9, 173.6, 143.3, 136.2, 134.4,
50.1 ppm. MS (ESI) m/z (%): 215.3 (M+H
+
).
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6.2.8 Synthesis of compound 8
OO
OO
NH2-CH3
OO
NO
H
+
8
Fig. 6.9: Synthesis of 3-ethoxy-4-methylamine-cyclobut-3-ene-1,2-dione
2-ethylaminopyridine (0.69 mL, 5.9 mmol) diluted in diethylether (60 mL) was
added dropwise for three hours to a stirred solution of diethylsquarate (1.01 g,
5.9 mmol) in diethylether (5 mL), at r.t. under argon atmosphere. A white solid
precipitated immediately and after 24 hours of stirring it was ltered and washed
with diethylether (2 x 20 mL). The resulting solid was dried under vacuum to yield
72% (1.04 g)
Characterization of 8:
1
H-NMR (CDCl
3
, 400 MHz) Æ: 7.61 (br, 1H), 4.62 (q, J = 8Hz, 2H), 3.08 (s,
3H), 1.35 (t, J = 8 Hz, 3H) ppm. MS (ESI) m/z (%): 156.1 (M+H
+
, 50), 178.1
(M+Na
+
, 50).
6.2.9 Synthesis of compound 9
+
NH2N
OO
NO
OO
OO
9
H
N
Fig. 6.10: Synthesis of 3-ethoxy-4-(2-pyridin-2-yl-ethylamino)-cyclobut-3-ene-1,2-dione
A solution of 1,4-bis(3-aminopropyl)piperazine (0.68 g, 3.4 mmol) in diethylether
(60 mL) was added dropwise for three hours to a stirred solution of diethylsquarate
(1.72 g, 10.1 mmol) in diethylether (10 mL), at r.t. under argon atmosphere. A
white solid precipitated immediately and after 24 hours of stirring it was ltered
and washed with diethylether (3 x 10 mL). The resulting solid was dried under
vacuum to yield 87% (3.95 g).
Characterization of 9:
1
H-NMR (CDCl
3
, 400 MHz) Æ: 8.45 (br, 1H), 7.75 (br, 1H), 7.29 (br, 1H), 7.19
(br, 1H), 4.76 (m, 2H), 4.10 (s, 1H), 3.89 (m, 1H), 3.08 (m, 2H), 1.46 (m, 3H) ppm.
MS (ESI) m/z (%): 247.25 (M+H
+
, 100).
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6.2.10 Synthesis of compound 10
N
N
N
N
O
O O
O O
O
H
H
O
O O
O
+N
N
H2N
NH2
10
Fig. 6.11: Synthesis of 1,4-Bis-(3-aminopropyl)piperazine-bis-monosquaramide ester
A solution of 1,4-bis(3-aminopropyl)piperazine (0.68 g, 3.4 mmol) in diethylether
(60 mL) was added dropwise for three hours to a stirred solution of diethylsquarate
(1.72 g, 10.1 mmol) in diethylether (10 mL), at r.t. under argon atmosphere. A
white solid precipitated immediately and after 24 hours of stirring it was ltered
and washed with diethylether (3 x 10 mL). The resulting solid was dried under
vacuum to yield 87% (3.95 g).
Characterization of 10:
1
H-NMR (CDCl
3
, 400 MHz) Æ: 8.21 (br, 1H), 8.01 (br, 1H), 7.94 (br, 1H), 7.75
(br, 1H), 4.76 (q, J = 8 Hz, 4H), 3.82 (m, 2H), 3.60 (m, 2H), 2.61 (m, 12H), 1.79
(m, 4H), 1.46 (t, J = 8 Hz, 6H) ppm.
13
C-NMR (CDCl
3
, 100 MHz) Æ: 183.4, 182.2,
69.6, 57.7, 53.1, 45.7, 25.1, 16.1 ppm. MS (ESI) m/z (%): 449.25 (M+H
+
, 100).
6.2.11 Synthesis of compound 11
N
N
N
N
O
O O
O O
O
H
H
+
11
NH2 N
N
N
N
N
O O
O O
N
H
HH
H
Fig. 6.12: Synthesis of 1,4-Bis-(3-aminopropyl)piperazine-bis-squaramide
Butylamine (0.25 g, 3.42 mmol) was added to a solution of compound 10 (0.5
g, 1.11 mmol) in ethanol (60 mL) at 50
Æ
C under stirring and argon atmosphere. A
white solid precipitates after 10 minutes and the suspension. After three hours, it
114 Experimental Section
was ltered, washed with absolute ethanol (3 x 10 mL) and dried under vacuum to
yield 87% (0.49 g).
Characterization of 11:
1
H-NMR (DMSO-d
6
, 100 MHz) Æ: 8.8 (br, 1H), 8.6 (br, 1H), 8.4 (br, 1H), 7.8
(br, 1H), 4.6 (q, J=8Hz), 1.25 (m, H), 1.37 (m, H), 1.50 (m, H), 0.89 (6H, J=8Hz)
ppm. MS (ESI) m/z (%): 503.3 (M+H
+
).
1
6.2.12 Synthesis of compound 12
N
H
N
H
OH
+
OH
H2N O O
HOO O OO
12
Fig. 6.13: Synthesis of 3,4-Bis-(2-(4-hydroxy-phenyl)-ethylamino)-cyclobut-3-ene-1,2-dione
A solution of tyramine (1.25 g, 8.85 mmol) in 15 mL of dicloromethane/MeOH
(3:2) was added to a stirring solution of diethylsquarate (0.5 g, 2.94 mmol) in
ethanol (20 mL), at r.t. under argon atmosphere. After stirring the suspension
overnight, the white solid was ltered, washed with ethanol (2 x 5 mL) and dried
under vacuum to yield 97% (1.01 g).
Characterization of 12:
1
H-NMR (DMSO-d
6
, 100 MHz) Æ: 7.28 (br, 1H), 6.98 (d, 4H, J = 8 Hz), 6.67 (d,
4H, J = 8 Hz), 3,63 (br, 1H), 3.2 (br, 1H), 2.67 (t, 4H, J = 8 Hz) ppm.
13
C-NMR
(DMSO-d
6
, 400 MHz) Æ: 183.11, 168.3, 156.5, 130.2, 129.2, 115.8, 45.6, 36.9 ppm.
MS (ESI) m/z (%): 354.1 (M+H
+
).
6.2.13 Synthesis of compound 13
Compound 13 was synthesized through a two-step selective condensation of N,N -
dimethylethylenediamine and tyramine with diethylsquarate under mild conditions.
A solution of N,N -dimethyletilenediamine (0.42 g, 4.76 mmol) in diethylether (60
mL) was added dropwise to a solution of diethylsquarate (0.81 g, 4.76 mmol) in
diethylether (5 mL) at r.t. under stirring and argon atmosphere. A white solid pre-
cipitated and the suspension was stirred overnight. The solid was ltered, washed
with diethylether (2 x 5 mL) and dried under vacuum to yield 56 %. In a second
step, a solution of tyramine (0.45 g, 3.3 mmoL) in 5 mL of MeOH:DCM (2:3) was
1
No
13
C-NMR analysis was performed due to the very low solubility of 11 in DMSO-d
6
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+NH2N
OO
OO
OO
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H
N
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N
H
N
H
N
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+
OH
H2N
13
O OOO
ONN
H
13a
Fig. 6.14: Synthesis of 3-(2-Dimethylamino-ethylamino)-4-(2-(4-hydroxy-phenyl)-ethylamino)
cyclobut-3-ene-1,2-dione
added to a solution of squaramide ester 13a (0.35 g, 1.6 mmol) in ethanol (10 mL).
After ve minutes a solid precipitated and the suspension was stirred overnight
under argon atmosphere. The solid was ltered, washed with diethyleter (3 x 10
mL) to yield 89% (0.30 g).
Characterization of 13a:
1
H-NMR (CDCl
3
, 400MHz) Æ: 6.45 (br, 1H), 6.39 (br, 1H), 4.75 (m, 2H), 3.77
(s, 1H), 3.50 (s, 1H), 2.53 (m, J = 8 Hz, 2H), 2.27 (s, 6H), 1.44 (t, J = 8 Hz, 3H)
ppm.
13
C-NMR (CDCl
3
, 400MHz) Æ: 183.2, 183.1, 168.3, 156.5, 130.3, 129.2, 115.9,
59.9, 45.7, 45.5, 36.9 ppm. MS (ESI) m/z (%): 213.2 (M+H
+
, 100).
Characterization of 13:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 9.17 (br, 1H), 7.43 (br, 1H), 7.34 (br, 1H),
7.0 (d, J=8Hz, 2H) 6.67 (d, J=8Hz, 2H), 3.66 (m, 4H), 2.69 (t, J=8Hz, 2H), 2.35
(t, J=8Hz, 2H) ppm.
13
C-NMR (DMSO-d
6
, 400 MHz) Æ: 183.2, 183.1, 168.3, 156.5,
130.3, 129.2, 115.9, 59.9, 45.7, 45.5, 36.9 ppm. MS (ESI) m/z (%): 304.2 (M+H
+
,
100).
6.2.14 Synthesis of compound 14
A solution of aminobutane (0.55 g, 6 mmol) in ethanol (3 mL) was added to a
stirring solution of diethylsquarate (1.07 g, 6 mmol) in ethanol (25 mL) under
argon atmosphere. A white solid precipitated in a few minutes and the suspension
was stirred overnight. The white solid was ltered, washed with diethyleter (2 x 5
mL) and dried in the oven under vacuum to yield 89% (0.93 g).
Characterization of 14:
MS (ESI) m/z (%): 333.2 (M+H
+
), 355.1 (M+Na).
2
2
No
1
H-NMR nor
13
C-NMR was performed due to insolubility of 14 in DMSO-d
6
and D
2
O.
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+
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Fig. 6.15: Synthesis of 2,7,12,17-Tetraaza-tricyclo(16.2.0.0
8;11
)eicosa-1(18),8(11)-diene-
9,10,19,20-tetraone
6.2.15 Synthesis of compound 15
+
O O
O O
15
N
H
N
H
O O
N N
H
N
H
N
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NN
N
N
H2N
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Fig. 6.16: Synthesis of cycloaminopropylpiperazinesquaramide
A solution of 1,4-bis(3-aminopropyl)-piperazine (2.13 g, 10.63 mmoL) in ethanol
(3 mL) was added to a stirring solution of diethylsquarate (1.09 g, 6.4 mmol) in
ethanol (41 mL) under argon atmosphere. A white solid precipitated in a few
minutes and the suspension was stirred overnight. The white solid was ltered,
washed with ethanol (2 x 10 mL) and dried in the oven under vacuum to yield 49%
(0.87 g).
Characterization of 15:
MS (ESI) m/z (%): 557.1 (M+H
+
).
3
3
No
1
H-NMR nor
13
C-NMR was performed due to insolubility of 15 in DMSO-d
6
and D
2
O.
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6.2.16 Synthesis of compound 16
N
NH HN
NH
N
HN
O
O
O
O
OO
OO
+ NH2N NH2
N
NH HN
O O
O
O
O
O
+ NH2N NH2
N
NH HN
O O
O
O
O
O
16a
16a 16
Fig. 6.17: Synthesis of cycloaminopropylpiperazinesquaramide
A solution of N,N -diethylethylenediamine (0.57 g, 3.9 mmoL) in diethyl ether
(85 mL) was added dropwise to a stirring solution of diethylsquarate (2.01 g, 11.8
mmol) in diethyl ether (2 mL) under argon atmosphere. A white solid precipitated
and the suspension was stirred overnight. The white solid was ltered, washed with
ethanol (2 x 10 mL) and dried in the oven under vacuum to yield 92% (1.43 g).
A solution of N,N -diethylethylenediamine (0.49 g, 3.4 mmoL) in ethanol (30 mL)
was added dropwise to a stirring solution of 16a (1.34 g, 3.40 mmol) in ethanol (130
mL) under argon atmosphere. A white solid precipitated and the suspension was
stirred overnight. The white solid was ltered, washed with ethanol (2 x 10 mL)
and acetone (2 x 10 mL) dried in the oven under vacuum to yield 82% (1.25 g).
Characterization of 16:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.20 (br, NH), 2.41 (m, 8H), 2.21 (m, 4H),
2.10 (s, 6H), 1.68 (m, 14H) ppm. MS (ESI) m/z (%): 448.2 (M+H
+
, 100).
6.3 Synthesis of squarate salts and amidosquaric
acid derivatives
In this work, derivatives of squaric acid have also been synthesized in order to ana-
lyze their solid state properties and interesting chemical eects. Since squaramides
are very diÆcult to hydrolize and diethylsquarate hydrolizes easily to squaric acid,
amidosquaric acids were synthesized from squaric acid under aqueous condition-
s. [184, 400] Squaric acid (i) reacts with 1 equivalent of a primary amine in water
under reux (it is insoluble in water at r.t.) for minimum three hours to generate
a monoamidosquaric acid (ii). It has been noted that the salt formation between
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squaric acid and the corresponding amine (iii) [401] is a kinetically competitive
reaction which is faster and in some cases longer periods of time were required
to obtain amidosquaric acid instead of the salt. All the products are obtained by
insitu crystallization and they can be isolated and puried by ltration and sub-
sequent washes with ethanol or diethylether. Their purity was conrmed by NMR
comparing with data from the literature when possible. A scheme summarizing the
synthesis is shown in gure 6.18.
OO
OHO
R NH2
OO
OHHO
R NH2
H2O, ∆
OO
N
H
HO
R
1eq.1eq.
i ii
H2O, ∆
+R NH3+
iii
-
Fig. 6.18: Scheme of hydrolized squaramides' synthesis and their salts
6.3.1 Synthesis of compound 17
OO
N
H
HO N
+
OO
OHHO
H2N
N
17
Fig. 6.19: Synthesis of 3-(2-Dimethylamino-ethoxy)-4-hydroxy-cyclobut-3-ene-1,2-dione
Compound 12 was prepared from a mixture of N,N -dimethylethylenediamine
(0.47 g, 7.34 mmol) and squaric acid (0.84 g, 8.86 mmol) in water (25 mL). After
reuxing the solution at 100
Æ
C for three hours, the yellowish solution was cooled
down to r.t. and yellowish needles crystallized in 24h. The solid was ltered and
washed with diethylether (3 x 2 mL) to yield 90% (1.47 g).
Characterization of 17:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.97 (t, J = 8 Hz, 1H), 3.70 (q, J = 8Hz,
2H), 3.25 (q, J = 8 Hz, 2H), 2.80 (s, 6H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ:
194.8, 190.3, 176.8, 57.7, 43.2, 40.0 ppm. MS (ESI) m/z (%): 185.1 (M+H
+
, 100).
6.3.2 Synthesis of compound 18
A mixture of squaric acid (2.01 g, 17.6 mmol) and benzylamine (1.89 g, 17.6 mmol)
in water (25 mL) was reuxed for three hours at 100
Æ
C and after that time it was
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OO
OH-O
+
OO
OHHO
18
NH2 NH3+
Fig. 6.20: Synthesis of squarate : dibenzylamine salt
slowly cooled down to r.t. The resulting crystals were ltered, washed with acetone
(2 x 5 mL) and dried under vacuum overnight to yield 97% ( 3.21 g).
Characterization of 18:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 8.18 (br, NH), 7.42 (m, 6H), 4.03 (s, 2H)
ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ: 197.1, 134.7, 129.3, 43.1 ppm. MS (ESI)
m/z (%): 108.2 (C
7
H
9
N+H
+
, 100), 112.1 (C
4
H
2
O
4
-2H
+
, 100).
6.3.3 Synthesis of compound 19
OO
O--O
+
OO
OHHO
19
N
N
H2N
NH2
N
N
+H3N
NH3+
Fig. 6.21: Synthesis of squarate : 1,4-bis(3-aminopropyl)piperazine salt
Amixture of squaric acid (0.50 g, 4.4 mmol) and 1,4-bis(3-aminopropyl)piperazine
(0.44 g, 2.2 mmol) in water (25 mL) was reuxed for three hours at 100
Æ
C and
after that time it was slowly cooled down to r.t. The resulting crystals were ltered,
washed with acetone (2 x 5 mL) and dried under vacuum overnight to yield 80%
(0.54 g).
Characterization of 19:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 4.65 (s, 8H), 3.06 (m, 8H), 2.92 (t,J=8 Hz,
4H), 2.85 (t, J=8 Hz, 4H), 1.89 (m, 4H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ:
202.5, 53.7, 37.2, 22.6 ppm.
6.3.4 Synthesis of compound 20
A mixture of squaric acid (0.20 g, 1.7 mmol) and diethylamine (1.28 g, 1.7 mmol)
in water (10 mL) was reuxed for four hours at 100
Æ
C and it was slowly cooled
down to r.t. The resulting yellowish oil was recrystallized in water at 70
Æ
C and the
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OO
OO
N
H
OO
O-N+
20
+H2N
Fig. 6.22: Synthesis of diethylamidosquaric acid : diethylamine salt
solution was slowly cooled down to 5-8
Æ
C. Single crystals of 20 were ltered and
analyzed by SXRD.
Characterization of 20:
By single X-ray diraction (see appendix C.2.19).
6.3.5 Synthesis of compound 21
OO
O-HO
+
OO
OHHO
21
OH
H2N
OH
+H3N
Fig. 6.23: Synthesis of squarate : tyramine salt
A mixture of squaric acid (1.09 g, 9.6 mmol) and tyramine (0.94g, 8.7 mmol)
in water (25 mL) was reuxed for three hours at 100
Æ
C and it was slowly cooled
down to r.t. The resulting crystals were ltered, washed with acetone (2 x 5 mL)
and dried under vacuum overnight to yield 80% (1.93 g).
Characterization of 21:
1
H-NMR (DMSO-d
6
, 400 MHz) Æ: 7.91 (br, OH), 7.0 (d, J = 8Hz, 1H), 6.7 (d,
J = 8 Hz, 2H), 2.9 (m, 2H), 2.5 (m, 2H) ppm.
13
C-NMR (DMSO-d
6
, 100 MHz) Æ:
197.0, 156.9, 130.3, 127.8, 116.0, 32.9 ppm.
6.3.6 Synthesis of compound 22
Compound 22 was obtained by recrystallization of 18 and it was characterized only
by SXRD.
Chapter 7
Conclusions
This thesis has contributed to a better understanding of the solid state structural
issues of squaric acid derivatives and their applicability to the design of new materi-
als. A multidisciplinary work has been developed combining approaches from areas
such as crystal engineering, supramolecular chemistry and crystallography. 47 poly-
morphs, solvates, cocrystals and salts from 22 squaric acid derivative compounds
have been obtained and 31 crystal structures have been solved and analyzed. The
optimization of a metodology for solving crystal structures from laboratory powder
diraction data by means of direct space methods has permitted to overcome the
diÆculty of disecondary squaramides to crystallize as good quality single-crystals.
The following conclusions can be extracted:
 Cooperativity in hydrogen-bonded catemers plays a crucial role in den-
ing the robust solid-state synthon in anti/anti conguration of disecondary
squaramides, overriding the preferred association mode in solution. Conse-
quently, the self assembling of the squaramide rings is a very strong binding
motif, which has been proven diÆcult to be perturbed by other competing
functional groups in the solid state.
 Secondary squaramides can act as molecular scaolds in the design of new
cocrystals with a suitable functionalization of the secondary squaramide sub-
stituents.
 Self-assembling squaramides can be used for the formation of new helicoidal
topologies in the solid state.
 Electrostatic compression phenomenon observed in zwitterionic squaramides
is responsible for a robust supramolecular synthon which allows the formation
of multicomponent solids.
121
122 Conclusions
In summary, all these conclusions show that the squaric/squaramide functional
group, poorly studied in the solid state, has interesting properties which can be
exploited for the design and synthesis of new and diverse crystalline materials.
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Appendix A
Experimental polymorph
screening
The experiments performed in the polymorph screening for each squaric acid deriva-
tive are summarized in this appendix, in which an experimental method example
for each new solid form is also described. Their PXRD, DSC, TGA,
1
H-NMR and
crystallographic data are shown in appendix C.2.19. In all tables the following
nomenclature has been used; X: no experiment was performed, - : experiment per-
formed but no solid crystallized, 1: evidences of a new phase, 2: single crystal,
CSS: crystallization experiments of the dissolutions obtained from the solubility
study, PHT: precipitation experiments by rapid cooling from high to low temper-
ature, CHT: crystallization experiments by slow cooling from high temperature to
r.t., CRT: crystallization experiments by evaporation at r.t., CSE: crystallization
experiments by seeding at r.t., PAA: precipitation experiments by rapid addition of
antisolvent at r.t. and CAD: crystallization experiments by antisolvent diusion at
r.t. In the solubility tables the following nomenclature has been used; S: soluble, I:
insoluble and PS: partially soluble.
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A.1 Compound 1
Tab. A.1: Solubility of 1
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 I
EtOH 78 1.0 I
ETG 197 1.0 I
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 S (r.t.)
DMF 153 1.0 S (70
Æ
C)
DMSO 189 1.0 S (40
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.2: Slurry experiments of 1
from the solubility study
Solvent Result
MeOH Forms II/III
a
EtOH Forms II/III
ETG Forms II/III
ACN Forms II/III
Acetone Forms II/III
H
2
O Forms II/III
Heptane Forms II/III
Toluene Forms II/III
Et
2
O Forms II/III
THF Forms II/III
Dioxane Forms II/III
DCM Forms II/III
CHCl
3
Forms II/III
a
Result from DSC analysis
Tab. A.3: Precipitation and crystallization ex-
periments of 1
Solvent PHT CHT CRT
DMF Form I Form I 2 (Form I)
DMSO Form II/III Form II/III Form I
Tab. A.4: Precipitation and crystallization experiments
of 1 by antisolvent addition
Antisolvent PAA CAD
H
2
O Form II/III Form II/III Form I X
DCM Form I Form I X 1
Dioxane Form I Form I X 2 (Form III)
Toluene Form I Form I X 2 (Form III)
ETG Form I Form II/III X X
EtOH Form I Form II/III X X
THF Form I Form I X X
ACN Form I Form II/III X X
Acetone Form I Form II/III Form I X
MeOH Form I Form I Form I X
Et
2
O Form I Form II/III X 2 (Form II)
Solvent DMF DMSO DMF DMSO
Preparation of the new forms of 1
 Form I
Compound 1 (10.2 mg, 0.03 mmol) was dissolved in DMF (0.5 mL) at 70
Æ
Cand
the solution was slowly cooled down to r.t. Needle-shaped crystals of form I
appeared after 13 days.
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 Form II
Diethyl ether (2 mL) was let to diuse into a solution of 1 (10.9 mg, 0.03
mmol) in DMSO (1.0 mL) at r.t. Needle-shaped crystals of form II appeared
after 15 days.
 Form III
Dioxane (2 mL) was let to diuse into a solution of 1 (10.1 mg, 0.03 mmol)
in DMSO (1.0 mL) at r.t. Needle-shaped crystals of form III appeared after
30 days.
A.2 Compound 2
Tab. A.5: Solubility of 2
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 S (40
Æ
C)
EtOH 78 1.0 S (40
Æ
C)
ETG 197 1.0 S (70
Æ
C)
ACN 82 1.0 S (70
Æ
C)
Acetone 56 1.0 I
H
2
O 100 1.0 S (70
Æ
C)
DMF 153 0.4 S (r.t.)
DMSO 189 0.4 S (r.t.)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 S (50
Æ
C)
Dioxane 101 1.0 S (80
Æ
C)
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.6: Slurry experi-
ments of 1 from the solubility
study
Solvent Result
Acetone Form I
Heptane Form I
Toluene Form I
Et
2
O Form I
DCM Form I
CHCl
3
Form I
Tab. A.7: Precipitation and crystallization experiments of 2
Solvent CSS PHT CHT CRT CSE
MeOH Form I Form I Form I X X
EtOH Form I Form I Form I X X
ETG - - Form I X X
ACN Form I Form I Form I X X
H
2
O Form I Form I Form I X X
DMF - - - Form I X
DMSO - - - Form I X
THF Form I Form I Form I X 2 (Form I)
Dioxane Form I Form I Form I X X
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Tab. A.8: Precipitation and crystallization experiments
of 2 by antisolvent addition
Antisolvent PAA CAD
H
2
O Form I Form I Form I -
DCM - - X X
Dioxane Form I - X X
Toluene Form I - - 2 (Form I)
ETG - - X X
EtOH Form I - - -
THF - - X X
ACN Form I - - -
Acetone - - X X
MeOH - - X X
Et
2
O Form I - - Form I
Solvent DMF DMSO DMF DMSO
Preparation of the new forms of 2
 Form I
Toluene (2 mL) was let to diuse into a solution of 2 (10.3 mg, 0.03 mmol) in
DMF (1.0 mL) at r.t. Plate-shaped crystals of form I appeared after 15 days.
 Form II
Form II of 2 could only be obtained by heating form I from r.t. to 175
Æ
Cin
the DSC crucible under nitrogen.
A.3 Compound 3
Tab. A.9: Solubility of 3
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 S (35
Æ
C)
EtOH 78 1.0 S (70
Æ
C)
ETG 197 1.0 S(50
Æ
C)
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 PS (90
Æ
C)
DMF 153 0.5 S (r.t.)
DMSO 189 0.5 S (r.t.)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.10: Slurry experi-
ments of 3 from the solubility
study
Solvent Result
Acetone Form I
ACN Form I
Heptane Form I
Toluene Form I
Et
2
O Form I
THF Form I
Dioxane Form I
DCM Form I
CHCl
3
Form I
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Tab. A.11: Precipitation and crystallization experiments of 3
Solvent CSS PHT CHT CRT CSE
MeOH Form I Form I Form I Form I X
EtOH Form I Form III Form I Form I X
ETG Form I - Form I Form I X
H
2
O X Form IV Form I Form I X
DMF - Form I Form I Form I -
DMSO - Form I Form I Form I 2 (Form I)
Tab. A.12: Precipitation and crystallization experiments
of 3 by antisolvent addition
Antisolvent PAA CAD
H
2
O - Form I - Form I
DCM - - - -
Dioxane Form I - - -
Toluene Form I Form I Form I -
THF - Form I - -
ACN Form I Form I - Form I
Acetone Form I - Form I Form I
Et
2
O Form I - - -
Solvent DMF DMSO DMF DMSO
Preparation of the new forms of 3
 Form I
A solution of 3 (10.5 mg, 0.03 mmol) in DMSO (0.5 mL) was kept in an
opened vial at r.t. Needle-shaped crystals of form I crystallized after 21 days.
 Form II
Form II of 3 could only be obtained by heating form I from r.t. to 215
Æ
Cin
the DSC crucible under nitrogen.
 Form III
A solution of 3 (10.3 mg, 0.03 mmol) in ethanol (1.0 mL) at 70
Æ
Cwas rapidly
cooled down to 0
Æ
C. The solid was ltered and dried under vacuum.
 Form IV
A solution of 3 (10.3 mg, 0.03 mmol) in water (1.5 mL) at 90
Æ
Cwas rapidly
cooled down to 5-10
Æ
C. The solid was ltered and dried under vacuum.
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A.4 Compound 4
Tab. A.13: Solubility of 4
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 S (r.t.)
EtOH 78 1.0 S (r.t.)
ETG 197 1.0 S (60
Æ
C)
ACN 82 1.0 S (70
Æ
C)
Acetone 56 1.0 I
H
2
O 100 0.5 S (r.t.)
DMF 153 0.5 S (r.t.)
DMSO 189 0.5 S (r.t.)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 PS (50
Æ
C)
Tab. A.14: Slurry experi-
ments of 4 from the solubility
study
Solvent Result
Acetone Forms I+
Heptane Forms I+
Toluene Forms I+
Et
2
O Forms I+
THF Forms I+
Dioxane Forms I+
DCM Forms I+
CHCl
3
Forms I+
Tab. A.15: Crystallization experiments of 4
Solvent CSS CHT
MeOH Forms I+ Forms I+
EtOH Forms I+ Forms I+
ETG Forms I+ Forms I+
ACN Forms I+ 2 (Form III)
H
2
O Forms I+ Forms I+
DMF Forms I+ Forms I+
DMSO Forms I+ Forms I+
Tab. A.16: Crystallization experiments of 4 by antisolvent addition
Antisolvent CAD
DCM Forms I+ Forms I+ -
17
X Forms I+ -
(form III)
THF Forms I+ Forms I+ X
17
- Forms I+ Forms I+
(form III)
Acetone Forms I+ Forms I+ - - X Forms I+ Forms I+
Et
2
O Forms I+ - Forms I+ X X Forms I+ Forms I+
Pentane X X Forms I+ X X X X
Heptane X X X - - X X
Dioxane X X X - - X X
Toluene X X X - - X X
Solvent ACN EtOH MeOH H
2
O ETG DMF DMSO
Preparation of the new forms of 4
 Form II
1
Form II of 4 was obtained from the cocrystallization experiments. (See ap-
pendix B.8).
1
Form I could not be obtained pure.
A.5 Compound 5 153
 Form III
A solution of 4 (10.1 mg, 0.03 mmol) in ACN (1.0 mL) at 70
Æ
Cwas slowly
cooled down to r.t. The vial containing the solution was kept sealed until
needle-shaped crystals appeared after 15 days.
 Form III of 17
Interestingly, form III of 17 was obtained from the polymorph screening of 4.
DCM or THF (2 mL) were let to diuse at r.t. into a solution of 4 in water
(10.4 mg, 0.04 mmol). After 18 months needle-shaped crystals appeared.
2
A.5 Compound 5
Tab. A.17: Solubility of 5
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 I
EtOH 78 1.0 I
ETG 197 1.0 S (90
Æ
C)
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 S (70
Æ
C)
DMF 153 1.0 S (60
Æ
C)
DMSO 189 1.0 S (40
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.18: Slurry experi-
ments of 5 from the solubility
study
Solvent Result
MeOH Form I
EtOH Form I
ACN Form I
Acetone Form I
Heptane Form I
Toluene Form I
Et
2
O Form I
THF Form I
Dioxane Form I
DCM Form I
CHCl
3
Form I
Tab. A.19: Precipitation and crystallization ex-
periments of 5
Solvent CSS PHT
a
CHT
DMSO Form I Form I Form I
DMF Form I Form I X
ETG - - X
H
2
O Form I Form I Form I
a
Precipitations from high T to 10
Æ
C
2
Since disquaramides are so diÆcult to hydrolyze, we suspect that traces of squaric acid reacted
with traces of amine to produce 17 contaminated with 4 in the same batch.
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Tab. A.20: Precipitation and crystallization ex-
periments of 5 by antisolvent diusion
Antisolvent PAA CAD
DCM Form I Form I
Dioxane Form I Form I
Toluene Form I Form I
CHCl
3
Form I Form I
THF Form I Form I
ACN Form I Form I
MeOH Form I Form I
Et
2
O Form I Form I
MEK Form I Form I
AcOEt Form I 2 (Form I)
MTBE Form I Form I
Pentane Form I Form I
Solvent DMSO
Preparation of the new form of 5
 Form I
AcOEt was let to diuse at r.t. into a solution of 5 (5.1 mg, 0.03 mmol) in
DMSO (0.5 mL), which was prepared at 40
Æ
Cand cooled down to r.t. Needle-
shaped crystals of form I appeared after 30 days.
A.6 Compound 7
Tab. A.21: Solubility of 7
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 I
EtOH 78 1.0 I
ETG 197 1.0 I
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 I
DMF 153 1.0 S (r.t.)
DMSO 189 0.2 S (r.t.)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 I
Acetic acid 118 0.1 S (r.t.)
TFE 74.0 0.5 S (r.t.)
Tab. A.22: Slurry experi-
ments of 7 from the solubility
study
Solvent Result
MeOH Form I
EtOH Form I
ETG Form I
ACN Form I
Acetone Form I
H
2
O Form I
Heptane Form I
Toluene Form I
Et
2
O Form I
THF Form I
Dioxane Form I
DCM Form I
CHCl
3
Form I
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Tab. A.23: Crystallization experi-
ments of 7 by antisolvent diusion
Antisolvent CAD
DCM Form I Form I
Dioxane Form I Form I
Toluene Form I Form I
EtOH - X
ACN - 2 (Form I)
Acetone Form I Form I
MeOH - Form I
Et
2
O Form I Form I
DIE - X
MEK Form I X
AcOEt Form I Form I
Solvent DMSO Acetic acid
Preparation of the new form of 7
 Form I
Acetonitrile was let to diuse at r.t. into a solution of 7 (6.5 mg, 0.046 mmol)
in acetic acid (0.5 mL). Needle-shaped crystals of form I appeared after 60
days.
A.7 Compound 8
Tab. A.24: Solubility of 8
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 0.1 S (r.t.)
EtOH 78 0.1 S (r.t.)
ACN 82 1.0 PS (70
Æ
C)
DMF 153 0.1 S (r.t.)
DMSO 189 0.1 S (r.t.)
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.25: Slurry experi-
ments of 8 from the solubility
study
Solvent Result
DCM Form I
CHCl
3
Form I
Tab. A.26: Precipitation and crystallization ex-
periments of 8
Solvent CSS PHT CHT
MeOH Form I Form I Form I
EtOH Form I Form I 2 (Form I)
ACN Form I Form I Form I
DMSO Form I X Form I
DMF Form I X Form I
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Tab. A.27: Crystallization experi-
ments of 8 by antisolvent diusion
Antisolvent PAA CAD
Et
2
O Form I Form I
Pentane Form I Form I
Solvent MeOH
Preparation of the new form of 8
 Form I
A solution of 8 (20.1 mg, 0.13 mmol) in ethanol (0.1 mL) at 50
Æ
Cwas cooled
down to r.t. Needle-shaped crystals of form I appeared after 3 days.
A.8 Compound 9
Tab. A.28: Solubility of 9
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 S (r.t.)
EtOH 78 1.0 S (50
Æ
C)
ETG 197 1.0 S (r.t.)
ACN 82 1.0 PS (80
Æ
C)
Acetone 56 1.0 PS (50
Æ
C)
H
2
O 100 1.0 S (60
Æ
C)
DMF 153 1.0 S (70
Æ
C)
DMSO 189 1.0 S (40
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 PS (90
Æ
C)
Et
2
O 34 1.0 I
THF 66 1.0 PS (60
Æ
C)
Dioxane 101 1.0 PS (90
Æ
C)
DCM 39 1.0 PS (r.t.)
CHCl
3
61 1.0 S (r.t.)
MIBK 116 1.0 I
Cyclohexane 81 1.0 I
Pentane 36 1.0 I
MTBE 55 1.0 I
Xylene 138 1.0 I
i
pOH 82 1.0 PS (80
Æ
C)
AcOEt 77 1.0 PS (80
Æ
C)
n-BuOH 118 1.0 S (80
Æ
C)
MIBK 116 1.0 PS (90
Æ
C)
Tab. A.29: Slurry experi-
ments of 9 from the solubility
study
Solvent Result
Et
2
O Form I
Heptane Form I
Cyclohexane Form I
Pentane Form I
MEK Form I
MIBK Form I
MTBE Form I
Xylene Form I
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Tab. A.30: Precipitation and crystallization ex-
periments of 9
Solvent CSS PHT CHT
MeOH Form I Form I X
EtOH Form I Form I 2 (Form I)
ETG - X X
ACN Form I Form I Form I
Acetone Form I Form I Form I
H
2
O Form I X Form I
DMF Form I X Form I
DMSO Form I X Form I
Toluene Form I Form I Form I
THF Form I Form I Form I
DCM Form I X Form I
CHCl
3
Form I - Form I
Dioxane Form I X Form I
i
pOH Form I Form I Form I
AcOEt Form I Form I Form I
n-BuOH Form I X Form I
MIBK Form I Form I Form I
Preparation of the new form of 9
 Form I
Compound 9 (10.1 mg, 0.041 mmol) was dissolved in ethanol (1.8 mL) at
50
Æ
C. The solution was slowly cooled down to r.t. Needle-shaped crystals
appeared after two days.
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A.9 Compound 10
Tab. A.31: Solubility of 10
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 S (r.t.)
EtOH 78 1.0 S (40
Æ
C)
ETG 197 1.0 S (90
Æ
C)
ACN 82 1.0 S (40
Æ
C)
Acetone 56 1.0 S (40
Æ
C)
H
2
O 100 1.0 S (90
Æ
C)
DMF 153 1 S (r.t.)
DMSO 189 1 S (70
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 S (60
Æ
C)
Dioxane 101 1.0 S (70
Æ
C)
DCM 39 1.0 S (r.t.)
CHCl
3
61 1.0 S (r.t.)
i
pOH 82 1.0 S (50
Æ
C)
t
BuOH 82 1.0 S (90
Æ
C)
n-BuOH 118 1.0 S (50
Æ
C)
MIBK 116 1.0 S (90
Æ
C)
DME 85 1.0 S (70
Æ
C)
MEK 55 1.0 PS (60
Æ
C)
Tab. A.32: Slurry experi-
ments of 10 from the solubil-
ity study
Solvent Result
Heptane Form I
Et
2
O Form I
Toluene Form II
Cyclohexane Form I
MEK Form I
Pentane Form I
MIBK Form I
AcOEt Forms I+II
DIE Forms I+II
Xylene Forms I+II
MTBE Form II
Tab. A.33: Precipitation and crystallization ex-
periments of 10
Solvent CSS PHT CHT
MeOH Form II Form I X
EtOH Form II Form I Form II
ETG 1 - X
ACN Form II Form I X
Acetone Form II Form I X
H
2
O Form III X X
DMF - X X
DMSO 1 X X
THF Form I Forms I+II X
Dioxane X X Form II
DCM Forms I+II Form I X
CHCl
3
Form I Forms I+II X
i
pOH Form II Form I Form I
t
BuOH Form II X X
n-BuOH Form II Form I Form I
MIBK Form II 1 X
DME Form II Form I X
MEK Form II Form I X
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Tab. A.34: Crystallization experi-
ments of 10 by antisolvent diusion
Antisolvent CAD
Et
2
O Form II
Pentane Form II
AcOEt Form II
MEK Form II
MTBE Form II
DIE Form II
Solvent EtOH
Preparation of the new forms of 10
 Form I
Form I was obtained from the synthesis of 10. (See 6.3.6)
 Form II
Diethyl ether was let to diuse into a solution of 10 (10.1 mg, 0.02 mmol) in
ethanol (1.5 mL) at r.t. The solid was ltered and dried under vacuum.
A.10 Compound 11
Tab. A.35: Solubility of 11
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 I
EtOH 78 1.0 I
ETG 197 1.0 I
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 I
DMF 153 1.0 S (120
Æ
C)
DMSO 189 1.0 S (120
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
CHCl
3
61 1.0 I
i
pOH 82 1.0 I
t
BuOH 82 1.0 I
n-BuOH 118 1.0 I
MIBK 116 1.0 I
DME 85 1.0 I
MEK 55 1.0 I
TFE 78 1.0 S (r.t.)
Acetic acid 118 1.0 S (70
Æ
C)
Tab. A.36: Slurry experi-
ments of 11 from the solubil-
ity study
Solvent Result
MeOH Form I
EtOH Form I
ETG Form I
ACN Form I
Acetone Form I
H
2
O Form I
Heptane Form I
Toluene Form I
THF Form I
Dioxane Form I
CHCl
3
Form I
i
pOH Form I
t
BuOH Form I
n-BuOH Form I
MIBK Form I
DME Form I
MEK Form I
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Tab. A.37: Precipitation and crystal-
lization experiments of 11
Solvent/s CSS CHT
DMSO Form I X
ETG/DMF X Form I
DMF Form I Form I
DMSO/DMF X Form I
Acetic acid Form I Form I
TFE Form I Form I
Acetic acid/H
2
O X Form I
Tab. A.38: Crystallization experiments of
11 by antisolvent diusion
Antisolvent PAA CAD
Et
2
O X Form I Form I
DCM X Form I Form I
MIBK X Form I X
Pentane X Form I Form I
MeOH X Form I Form I
MEK X X Form I
Acetone X X Form I
THF X X Form I
CHCl
3
X X Form I
DMSO Form I X Form I
Solvent TFE Acetic acid TFE
Preparation of the new form of 11
 Form I
A solution of 14 (10.3 mg, 0.02 mmol) with DMSO (2 mL) was prepared at
120
Æ
Cand it was let to cool down to r.t. The solid was ltered and dried under
vacuum.
A.11 Compound 12
Tab. A.39: Solubility of 12
Solvent B.p. (
Æ
C) V (mL) Result
MeOH 65 1.0 I
EtOH 78 1.0 I
ETG 197 1.0 I
ACN 82 1.0 I
Acetone 56 1.0 I
H
2
O 100 1.0 PS (90
Æ
C)
DMF 153 1 S (90
Æ
C)
DMSO 189 1 S (60
Æ
C)
Heptane 98 1.0 I
Toluene 111 1.0 I
Et
2
O 34 1.0 I
THF 66 1.0 I
Dioxane 101 1.0 I
DCM 39 1.0 I
CHCl
3
61 1.0 I
Tab. A.40: Slurry experi-
ments of 12 from the solubil-
ity study
Solvent Result
MeOH Form II
EtOH Form II
ETG Form II
ACN Form II
Acetone Form II
Heptane Form II
Toluene Form II
Et
2
O Form II
THF Form II
Dioxane Form II
DCM Form II
CHCl
3
Form II
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Tab. A.41: Crystallization experi-
ments of 12 by antisolvent diusion
Antisolvent CAD
MeOH 1
DIE 1
THF 1
Et
2
O 1
Pentane 1
AcOEt -
MEK 1
MTBE -
DIE 1
DCM 1
CHCl
3
1
THF -
ACN -
i
pOH 1
H
2
O 1
EtOH 2 (Form III)
Solvent DMSO
Preparation of the new forms of 12
 Form I
Form I was obtained from the cocrystallization experiments with pyridine (See
appendix B.8).
 Form II
Form II was obtained from the synthesis of 12 in ethanol (See chapter 6.3.6).
 Form III
Ethanol (2 mL) was let to diuse into a solution of 12 in DMSO at r.t.
Needle-shaped crystals appeared after three months.
 Form IV
Form IV was obtained from the cocrystallization experiments (See appendix B.8).
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A.12 Compound 17
Tab. A.42: Solubility of 17
Solvent B.p. (
Æ
C) V (mL) Result
H
2
O 100 1.0 S (80
Æ
C)
DMSO 189 1.0 S (r.t.)
Tab. A.43: Crystallization experiments of 17
Solvent CSS CHT
H
2
O Form I 1
DMSO Form I Form I
Tab. A.44: Crystallization experi-
ments of 17 by antisolvent diusion
Antisolvent CAD
MeOH -
THF Form I
Et
2
O Form I
Pentane -
AcOEt Form I
MEK Forms I+II
MTBE 2 (Form II)
DIE 1
DCM 1
CHCl
3
1
ACN Form I
Toluene 1
Dioxane 2 (Form I)
Solvent DMSO
Preparation of the new forms of 17
 Form I
Dioxane (2 mL) was let to diuse at r.t. into a solution of 17 (5.0 mg, 0.03
mmol) in DMSO (0.5 mL), which was prepared at 40
Æ
Cand cooled down to
r.t. Needle-shaped crystals of form I appeared after 15 days.
 Form II
MTBE (2 mL) was let to diuse at r.t. into a solution of 17 (5.0 mg, 0.03
mmol) in DMSO (0.5 mL), which was prepared at 40
Æ
Cand cooled down to
r.t. Needle-shaped crystals of form II appeared after 15 days.
 Form III
Form III of 17 was obtained during the polymorph screening of 4 (See A.4).
Appendix B
Experimental cocrystal screening
The experiments performed in the cocrystal screening for each squaric acid deriva-
tive are summarized in this annex, in which an experimental method example for
the obtention of each new solid form is also described. Their PXRD, DSC, TGA,
1
H-NMR or
13
C-NMR and crystallographic data are shown in annex III. The crys-
tal structure solution of the new forms is described in annex IV. In all tables the
following nomenclature has been used; X: no experiment was performed, - : exper-
iment performed but no solid crystallized, 0: no cocrystal obtained, 1: evidences
of a new phase or mixture of phases, 2: single crystal, DG: drop grinding experi-
ments, RC: reaction crystallization experiments, CHT: crystallization experiments
by slow cooling from high temperature to r.t., CAD: crystallization experiments by
antisolvent diusion at r.t., PHT: precipitation experiments by rapid cooling from
high T to r.t., CRT: crystallization experiments by evaporation at r.t.
Each new form is conrmed by SXRD or PXRD and
1
H-NMR and it is identied
by the number of squaric acid derivative (1,2...), number of coformer (I, II...) and
polymorphic form (A, B...).
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B.1 Coformers
Fig. B.1: List of coformers used in this work (Description according to Sigma Aldrich)
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B.2 Compound 2
Tab. B.1: Drop grinding experiments
of 2 and selected coformers (DG)
Solvent
Coformer
FA RE NA
EtOH 1 0 -
Tab. B.2: Reaction crystallization experiments of 2 and selected coformers (RC)
Solvent
Coformer
FA PNBA GRA GMA OA CA SQA RE
EtOH 2-I-A 2-II - 0 1 - 1 0
Tab. B.3: Crystallization experiments of 2 and
selected coformers from high temperature to r.t.
(CHT)
Solvents
Coformer
FA NA
MeOH 0 X
EtOH 0 -
ACN
2
X
(2-I-A)
H
2
O 0 X
ratio (2:coformer) 1:1 1:2
Tab. B.4: Crystallization experiments of 2 and selected coformers
by antisolvent diusion at r.t. (CAD)
Antisolvent
Coformer
FA RE NA
MEK 1 1 - - 0
Acetone - - - X -
Pentane X X X - X
Et
2
O 1 1 0 - 0
THF X X X - X
MTBE 1 1 0 0 0
DIE 1 1 1 - 0
DCM - 1 - - 0
ACN X X X - X
Solvent
THF/ THF/ THF/ EtOH/ THF/
CHCl
3
CHCl
3
CHCl
3
DMSO CHCl
3
ratio (2:coformer) 1:1 1:2 1:1 1:1 1:1
Tab. B.5: Recrystallization experiments from reaction crystallization solids
of 2 and selected coformers from high temperature to r.t. (RRC)
Solvent
Coformer
FA PNBA GRA GMA OA CA SQA RE UR NA
EtOH 0 - X X 0 X 0 0 - -
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Preparation of the new multicomponent forms of 2
 Cocrystal of 2:fumaric acid, form A (2-I-A)
Compound 2 (13 mg, 0.04 mmol) was added to a saturated solution of fumaric
acid in ethanol (2.0 mL) and the suspension was stirred during one day at r.t.
The solid was ltered and dried under vacuum.
 Cocrystal of 2:fumaric acid, form B (2-I-B)
A mixture of 2 (20.2 mg, 0.07 mmol) and fumaric acid (15.7 mg, 0.14 mmol)
were dissolved in ACN (30 mL) at 60
Æ
C. The heater was switched o and
thin needles crystallized overnight.
 Cocrystal of 2:p-nitrobenzoic acid (2-II)
Compound 2 (10 mg, 0.03 mmol) was added to a saturated solution of p-
nitrobenzoic acid in ethanol (2.0 mL) and the suspension was stirred during
one day at r.t. The solid was ltered and dried under vacuum.
B.3 Compound 4
Tab. B.6: Drop grinding experiments of 4 and selected coformers (DG)
Solvent
Coformer
FA PNBA GRA GMA OA CA SQA RE UR NA
MeOH X X X X X X X 4-VIII-A
a
X X
EtOH 1 0 - 0 1 - 1 1 1 1
IPA X X X X X X X 1 X X
THF X X X X X X X 4-VIII-B
a
X X
H
2
O X X X X X X X 1 X X
ACN X X X X X X X 4-VIII-B
a
X X
DMF X X X X X X X 1 X X
DMSO X X X X X X X 1 X X
a
No single crystals were obtained from recrystallization of these samples
Tab. B.7: Reaction crystallization experiments of 4 and selected coformers (RC) (FII of 4
meaning polymorph II of 4)
Solvent
Coformer
FA PNBA GRA GMA OA CA SQA RE UR NA
MeOH X X X X X X X 4-VIII-A X X
EtOH 4-I-A 1 1 FII of 4 1 1 4-VII-A X FI+FII of 4 FI+FII of 4
ACN X X X X X X X 4-VIII-B X X
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Tab. B.8: Crystallization experiments of 4 and selected coformers from high
temperature to r.t. (CHT)
Solvent/s
Coformer
FA PNBA GRA GMA OA UR NA
ACN/DMSO X X X 0 X X X X - X X
ACN/TFE X X X X 1 X 1 X X - -
EtOH/DMSO 1 0 X X X X X 1 X X X
ACN/TFE/DMSO X X 1 X X X X X X X X
H
2
O X X X X X X X 2 (4-VII-B) X X X
ratio 4:coformer 1:1 1:1 1:2 1:2 1:2 1:1 1:2 1:1 1:2 1:2 1:2
Tab. B.9: Recrystallization experi-
ments of the solids obtained by drop
grinding between 4 and resorcinol
Solvent Result
MeOH 4-VIII-A
EtOH 4-VIII-A
IPA 1
THF 0
Chloroform 4-VIII-A
Acetone 0
Dioxane 4-VIII-B
MEK 1
ETG -
Tab. B.10: Crystallization experiments of 4 and selected coformers by antisolvent diusion at
r.t. (CAD)
Antisolvent
Coformer
FA PNBA RE UR NA
MeOH 2 (4-I-B) - - X X X X X 0 X 0
MEK needles
a
- - X X - - - 0 - 0
Acetone 0 - - X X - - X 0 X 0
Pentane 0 - 0 4-VIII-A - 0 - 0 0 - 0
Et
2
O 0 - - 4-VIII-A - 0 - - 0 1 0
THF 0 - - X X 0 - 0 0 0 0
MTBE 0 - - 1 - 4-VIII-A - 0 0 - 0
DIE 0 - 0 4-VIII-A - - - - 0 - 0
DCM 0 - - 4-VIII-A - 4-VIII-A - 0 0 - 0
ACN - - - 4-VIII-A - X X 0 0 1 0
- twins
a
- - X - - - 0 0 - 0
Solvent/s EtOH/H
2
O/ EtOH/ EtOH/ EtOH EtOH ACN ACN EtOH EtOH EtOH EtOH
DMSO DMSO DMSO
ratio (4:coformer) 1:1 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2
a
No good quality single crystals
Tab. B.11: Crystallization experiments of the reaction crystallization
solids of 4 and selected coformers by antisolvent diusion at r.t. (CAD)
Solvent Antisolvent
Coformer
FA PNBA GMA OA RE
EtOH - 1 1 0 1 -
ACN - X X X X 4-VIII-A
Toluene - X X X X 0
EtOH DCM X X X X -
ACN DCM X X X X -
Toluene DCM X X X X -
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Preparation of the new forms of 4
 Form II of 4
Compound 4 (55 mg, 0.21 mmol) was added to a saturated solution of glu-
tamic acid in ethanol (1.0 mL) and the suspension was stirred overnight. The
solid was ltered and dried under vacuum.
 Cocrystal of 4 : fumaric acid, form A (4-I-A)
Compound 4 (10 mg, 0.04 mmol) was added to a saturated solution of fumaric
acid in ethanol (1.0 mL) and the suspension was stirred overnight. The solid
was ltered and dried under vacuum.
 New phase 4 : fumaric acid, form B (4-I-B)
A solution of 4 (50.2 mg, 0.20 mmol) and fumaric acid (22.8 mg, 0.20 mmol)
in ethanol (6 mL) was prepared. Since the solid did not completely dissolve,
DMSO (8 mL) and water (1mL) were added at 40
Æ
Cuntil a total dissolution.
An aliquot was placed at r.t. in a thin vial and it was sealed with a septum
and a needle, through which methanol was let to diuse into the solution.
After one month thin needles crystallized.
 Salt of 4 : squaric acid, form A (4-VII-A)
Compound 4 (12 mg, 0.05 mmol) was added to a saturated solution of squaric
acid in ethanol (1.0 mL) and the suspension was stirred overnight. The solid
was ltered and dried under vacuum.
 Salt of 4 : squaric acid, form B (4-VII-B)
Compound 4 (12 mg, 0.05 mmol) and squaric acid were dissolved in water
(1.0 mL) at 80
Æ
Cand the solution was slowly cooled down to r.t. Crystals
were isolated and analyzed by SXRD.
 Cocrystal of 4 : resorcinol, form A (4-VIII-A)
Resorcinol (30.7 mg, 0.28 mmol) was added to a saturated solution of 4 in
ACN (0.5 mL) and the suspension was heated to 50
Æ
C. Since it did not
completely dissolve, ACN (0.5 mL) was added and the solid was ltered at
r.t. The solution was kept in a sealed vial with a needle at r.t. until a solid
crystallized. It was ltered and dried under vacuum.
 Cocrystal of 4 : resorcinol, form B (4-VIII-B)
Resorcinol (8.7 mg, 0.08 mmol) was added to a saturated solution of 4 in ACN
(0.2 mL) and the suspension was stirred overnight. The solid was ltered and
dried under vacuum.
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B.4 Compound 5
Tab. B.12: Drop grinding experiments of 7 and selected
coformers in a 1:1 molar ratio (DG)
Solvent/s
Coformer
FA PNBA RE NA CBZ DMU DBS
DMF 0 0 0 0 0 0 0
EtOH 0 0 0 0 0 0 0
DMSO 0 0 0 0 0 0 0
Tab. B.13: Reaction crystallization experiments of 5 and
selected coformers (RC)
Solvent/s
Coformer
FA PNBA RE NA CBZ DMU DBS
ACN/DMF 0 0 0 0 0 0 0
EtOH 0 0 0 0 0 0 0
B.5 Compound 7
Tab. B.14: Drop grinding experiments of 7 and selected
coformers (DG)
Solvent/s
Coformer
SQA RE TPPO
DMF 1 0 0 0 0
DMSO 0 0 0 0 0
Acetic acid 0 0 0 0 0
TFE 1 0 0 0 0
MeOH/DCM 0 0 0 0 0
ratio (7:coformer) 1:1 1:2 2:1 1:1 1:1
Tab. B.15: Reaction crystallization experiments of 7 and selected co-
formers (RC)
Solvent
Coformer
FA PNBA GRA GMA OA CA SQA DHBA
DMF X X X X X X 0 X
DMSO X X 0 0 X X 0 X
Acetic acid X X X X X X 0 X
TFE X X X X X X 1 0
MeOH/DCM X X 0 0 X X 0 X
EtOH 0 0 0 0 0 0 0 0
Tab. B.16: Crystallization experiments of 7
and oxalic acid in a 1:1 molar ratio by antisol-
vent diusion (CAD)
Antisolvent Solvent Result
DCM DMSO 0
Et
2
O DMSO 0
EtOH DMSO 0
Acetone DMSO 0
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Tab. B.17: Crystallization experiments of 7 and selected coformers
in a 1:1 molar ratio from high temperature to r.t. (CHT)
Solvent
Coformer
GRA GMA PA LA GLA FRA IA PHA
DMSO 0 0 X X X X X X
TFE 0 0 X X X X X X
- X X - - - 0 - 1
Tab. B.18: Crystallization experiments of 7
and phosphoric acid (PHA) in a 1:1 molar ratio
by antisolvent diusion (CAD)
Antisolvent Result
AcOEt 1
MTBE 1
B.6 Compound 10
Tab. B.19: Drop grinding experiments of 10 and selected coformers (DG)
Solvent
Coformer
RE HI
MeOH 10-VIII-A,B
FI of 10 +
10-XI-A
10-XI-A
EtOH 10-VIII-A,B X X
Acetone 10-VIII-A,B
FI of 10 + FI of 10 +
10-XI-A 10-XI-A
CHCl
3
FI of 10 +
X X
10-VIII-B
Dioxane 10-VIII-A,B X X
Toluene
10-VIII-A,B
FI of 10 +
10-XI-A
10-XI-A
DCM
FI of 10 +
X X
10-VIII-B
t
BuOH
1 FI of 10 X
ACN 10-VIII-A,B
FI of 10 + FI of 10 +
10-XI-A 10-XI-A
MEK 10-VIII-A,B X X
THF 10-VIII-A,B X X
IPA 10-VIII-A,B X X
MIBK 10-VIII-A,B X X
H
2
O 10-VIII-B X X
TFE
FI of 10 +
X X
10-VIII-A
ratio (10:coformer) 1:2 1:1 1:2
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Tab. B.20: Reaction crystallization experi-
ments of 10 and selected coformers (RC)
Solvent
Coformer
RE HY
MeOH 0 10-XI-B
EtOH 0 X
Acetone 0 0
CHCl
3
0 1
DMF - X
Toluene 1 1
DCM 0 X
t
BuOH 1 1
ACN X 10-XI-B
IPA X X
Tab. B.21: Precipitation experiments of 10 and
resorcinol by rapid cooling from high tempera-
ture to 0
Æ
C(PHT)
Solvent/s Result
MeOH 0
EtOH 0
Acetone 0
CHCl
3
/MeOH 0
THF 0
Toluene 0
DCM/MeOH 10-VIII-B
IPA 0
ACN 0
ratio (10:coformer) 1:2
Tab. B.22: Crystallization experiments of 10
and selected coformers from high temperature to
r.t. (CHT)
Solvent
Coformer
RE HI
MeOH 0 X X 0
Acetone 0 X X 0
DCM 1 X X X
H
2
O 0 X X X
THF X X 0 X
CHCl
3
X X 1 X
H
2
O X 10-VIII-B X X
ratio (10:coformer) 1:1 1:2 1:1 1:2
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Tab. B.23: Crystallization experiments of 10
and selected coformers by solvent evaporation at
r.t. (CRT)
Solvent
Coformer
RE HY
MeOH 1 - X
Toluene 1 1 X
ACN X X 0
t
BuOH X X 0
Dioxane X X -
ratio (10:coformer) 1:1 1:2 1:1
Tab. B.24: Crystallization experiments of 10 and resorcinol in a 1:2 molar ratio by antisolvent
diusion (CAD)
Antisolvent
Solvent
MeOH Acetone EtOH IPA THF
DCM/ CHCl
3
/
ACN H
2
O
MeOH MeOH
Pentane 0 0 0 0
FI of 10 +
10-VIII-A 10-VIII-A 10-VIII-B 1
10-VIII-B
Tab. B.25: Crystallization experiments of 10 and hydroquinone
by antisolvent diusion (CAD)
Antisolvent
Solvent
THF ACN MeOH
MEK 1 X X X
Pentane 1
FI of 10 + 1
-
10-XI-A
Et
2
O 1 0 - -
MTBE 1 X 1 -
DIE 10-XI-A X 0 -
DCM - - - -
ratio (10:coformer) 1:1 1:2 1:2 1:2
Preparation of the new multicomponent forms of 10
 Cocrystal of 10 : resorcinol, form A (10-VIII-A)
A mixture of 10 (20.1 mg, 0.04 mmol) and resorcinol (10.0 mg, 0.09 mmol)
was dissolved in a solvent mixture of DCM/MeOH 10:1 (1 mL) at 50
Æ
C. The
solution was cooled down to r.t. and pentane (2 mL) was rapidly added. A
white powder precipitated immediately.
 Cocrystal of 10 : resorcinol, form B (10-VIII-B)
A mixture of 10 (10.1 mg, 0.02 mmol) and resorcinol (4.8 mg, 0.04 mmol)
was dissolved in a water (1.0 mL) at 70
Æ
C. The solution was slowly cooled
down to r.t. and a white powder crystallized.
 Cocrystal of 10 : hydroquinone, form A (10-XI-A)
A mixture of 10 (10.2 mg, 0.02 mmol) and hydroquinone (5.1 mg, 0.04 mmol)
with a drop of toluene was grinded for 30 minutes at 30Hz.
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 Cocrystal of 10 : hydroquinone, form B (10-XI-B)
Compound 10 (12 mg, 0.02 mmol) was added to a saturated solution of hy-
droquinone in methanol (0.1 mL) at r.t. The suspension was stirred for two
days and the solid was ltered and dried under vacuum.
B.7 Compound 12
Tab. B.26: Drop grinding experiments of 12 and selected coformers (DG)
Solvent
Coformer
OA RE NA ISNA BIP
DMSO - - 0 0 1 1 1 X 1 1
DMF 1 1 0 0 1 1 X X 1 1
ACN X X X X 1 1 X X 1 X
THF X X 0 0 X X X X 1 X
H
2
O X X X X X X X X 1 1
Dioxane X X X X X X X X 1 X
Acetone X X X X X X X X 1 X
ratio (12:coformer) 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2
Tab. B.27: Reaction crystallization experi-
ments of 12 and selected coformers (RC)
Solvent
Coformer
NA ISNA BIP
DMSO 1 1 X
ACN 1 0 X
H
2
O X X 1
TFE X X 0
Tab. B.28: Crystallization experiments of 12
and selected coformers from high temperature to
r.t. (CHT)
Solvent Result
BIP 1 1 X
BIP 1 1 X
PY X X FI of 12
Solvent DMSO DMF -
ratio (12:coformer) 1:1 1:2 -
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Tab. B.29: Crystallization experiments of 12
and selected coformers in a 1:2 molar ratio in
DMSO by antisolvent diusion (CAD)
Antisolvent
Coformer
OA BIP
MeOH 1 1
DIE - 2 FIV of 12
THF 1 1
Et
2
O - -
Pentane 1 -
MTBE 1 1
DCM 1 1
MEK 1 -
AcOEt 1 1
CHCl
3
0 1
Preparation of the new forms of 12
 Form I of 12
Form I was obtained from a cocrystallization experiment of 12 with pyridine.
Compound 12 (10.0 mg, 0.03 mmol) was dissolved in pyridine (0.5 mL) at
50
Æ
Cand the solution was cooled down slowly to r.t. A white solid crystallized
after one month.
 Form IV of 12
The single crystal of form IV was obtained from a cocrystallization experiment
of 12 with 4,4'-bipyridine. A mixture of 12 (10.6 mg, 0.03 mmol) and 4,4'-
bipyridine (8.8 mg, 0.06 mmol) was dissolved in DMSO (0.8 mL) at 50
Æ
C.
The vial containing the solution was kept sealed at r.t. and DIE (2 mL) was
let to diuse through a needle. Needle-shaped crystals were obtained after
four months.
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B.8 Compound 17
Tab. B.30: Crystallization experiments of 17 and selected coformers by
antisolvent diusion (CAD)
Antisolvent
Coformer
CA RE
ACN - 1 0 0
THF X X 0 0
MEK X X 0 0
AcOEt
2
- 0 0
17-VII
a
Toluene X X 0 0
ratio (17:coformer) 1:1 1:2 1:1 1:2
Solvent H
2
O DMSO
a
Single crystal needles of 17 with squaric acid were obtained
possibly due to traces of squaric acid from the synthesis of 17
Preparation of the new forms of 17
 Salt of 17 : squaric acid (17-VII)
The single crystal of this form was obtained from a cocrystallization experi-
ment of 17 (containing traces of squaric acid) with citric acid. A mixture of
17 (10.1 mg, 0.09 mmol) and citric acid (17.3 mg, 0.09 mmol) was dissolved
in water at 70
Æ
C. The vial containing the solution was kept sealed at r.t. and
AcOEt (2 mL) was let to diuse through a needle. Needle-shaped crystals
were obtained after one month.

Appendix C
Figures
C.1 Polymorphs
The powder X-ray diractogram, DSC and TGA thermograms,
1
H-NMR or
13
C-
NMR spectra and crystallographic data of the new forms obtained in the present
work are included in this appendix. In some cases,
1
H-NMR,
13
C-NMR or TGA data
are missing due to lack of sample availability or because the form was suÆciently
characterized by the rest of the techniques.
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C.1.1 Compound 1, form I
N
H
N
H
OO
1
Fig. C.1: Crystallographic data of form I of 1 obtained by
SXRD
Fig. C.2: Powder X-ray diractogram of form I of 1
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Fig. C.3: DSC thermogram of form I of 1
Fig. C.4: TGA thermogram of form I of 1
Fig. C.5:
1
H-NMR spectrum of form I of 1
180 Figures
C.1.2 Compound 1, form II
N
H
N
H
OO
1
Fig. C.6: Crystallographic data of form II of 1 solved by
PXRD
Fig. C.7: Powder X-ray diractogram of form II of 1
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Fig. C.8: DSC thermogram of form II of 1
Fig. C.9: TGA thermogram of form II of 1
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C.1.3 Compound 1, form III
N
H
N
H
OO
1
Fig. C.10: Crystallographic data of form III of 1 obtained by
SXRD
Fig. C.11: Powder X-ray diractogram of form III of 1
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Fig. C.12: DSC thermogram of form III of 1
Fig. C.13: TGA thermogram of form III of 1
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C.1.4 Compound 2, form I
N
H
N
H
OO
N N
2
Fig. C.14: Crystallographic data of form I of 2 obtained by
SXRD
Fig. C.15: Powder X-ray diractogram of form I of 2
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Fig. C.16: DSC thermogram of form I of 2
Fig. C.17: TGA thermogram of form I of 2
Fig. C.18:
1
H-NMR spectrum of form I of 2
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C.1.5 Compound 2, form II
N
H
N
H
OO
N N
2
Fig. C.19: Crystallographic data of form II of 2 solved by
PXRD
Fig. C.20: Powder X-ray diractogram of form II of 2
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Fig. C.21: DSC thermogram of form II of 2
Fig. C.22: TGA thermogram of form II of 2
Fig. C.23:
1
H-NMR spectrum of form II of 2
188 Figures
C.1.6 Compound 3, form I
N
H
N
H
OO
NN
3
Fig. C.24: Powder X-ray diractogram of form I of 3
Fig. C.25: DSC thermogram of form I of 3
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Fig. C.26: TGA thermogram of form I of 3
Fig. C.27:
1
H-NMR spectrum of form I of 3
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C.1.7 Compound 3, form II
N
H
N
H
OO
NN
3
Fig. C.28: Powder X-ray diractogram of form II of 3
Fig. C.29: DSC thermogram of form II of 3
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C.1.8 Compound 3, form III
N
H
N
H
OO
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3
Fig. C.30: Powder X-ray diractogram of form III of 3
Fig. C.31: DSC thermogram of form III of 3
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C.1.9 Compound 3, form IV
N
H
N
H
OO
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3
Fig. C.32: Powder X-ray diractogram of form IV of 3
Fig. C.33: DSC thermogram of form IV of 3
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C.1.10 Compound 4, form II
N
H
N
H
OO
N N
4
Fig. C.34: Crystallographic data of form II of 4 solved by
PXRD
Fig. C.35: Powder X-ray diractogram of form II of 4
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Fig. C.36: DSC thermogram of form II of 4
Fig. C.37: TGA thermogram of form II of 4
Fig. C.38:
1
H-NMR spectrum of form II of 4
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C.1.11 Compound 4, form III
N
H
N
H
OO
N N
4
Fig. C.39: Crystallographic data of form III of 4 obtained by
SXRD
Fig. C.40: Calculated powder X-ray diractogram of form III of 4
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Fig. C.41: DSC thermogram of form III of 4
Fig. C.42: TGA thermogram of form III of 4 (The weight loss registered in the TGA analysis
is attribuited to a wet solid)
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C.1.12 Compound 5, form I
5
Fig. C.43: Crystallographic data of form I of 5 obtained by
SXRD
Fig. C.44: Powder X-ray diractogram of form I of 5
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Fig. C.45: DSC thermogram of form I of 5
Fig. C.46: TGA thermogram of form I of 5
Fig. C.47:
1
H-NMR spectrum of form I of 5
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C.1.13 Compound 6, form I
6
Fig. C.48: Crystallographic data of form I of 6 obtained by
SXRD
Fig. C.49: Powder X-ray diractogram of form I of 6
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Fig. C.50: DSC thermogram of form I of 6
Fig. C.51: TGA thermogram of form I of 6
Fig. C.52:
1
H-NMR spectrum of form I of 6
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C.1.14 Compound 7, form I
7
Fig. C.53: Crystallographic data of form I of 7 obtained by
SXRD
Fig. C.54: Powder X-ray diractogram of form I of 7
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Fig. C.55: DSC thermogram of form I of 7
Fig. C.56: TGA thermogram of form I of 7
Fig. C.57:
1
H-NMR spectrum of form I of 7
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C.1.15 Compound 8, form I
8
Fig. C.58: Crystallographic data of form I of 8 obtained by
SXRD
Fig. C.59: Powder X-ray diractogram of form I of 8
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Fig. C.60: DSC thermogram of form I of 8
Fig. C.61: TGA thermogram of form I of 8
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C.1.16 Compound 9, form I
OO
NO
H
N
9
Fig. C.62: Crystallographic data of form I of 9 obtained by
SXRD
Fig. C.63: Powder X-ray diractogram of form I of 9
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Fig. C.64: DSC thermogram of form I of 9
Fig. C.65: TGA thermogram of form I of 9
Fig. C.66:
1
H-NMR spectrum of form I of 9
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C.1.17 Compound 10, form I
10
Fig. C.67: Crystallographic data of form I of 10 solved by
PXRD
Fig. C.68: Powder X-ray diractogram of form I of 10
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Fig. C.69: DSC thermogram of form I of 10
Fig. C.70: TGA thermogram of form I of 10
Fig. C.71:
1
H-NMR spectrum of form I of 10
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C.1.18 Compound 10, form II
10
Fig. C.72: Crystallographic data of form II of 10 solved by
PXRD
Fig. C.73: Powder X-ray diractogram of form II of 10
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Fig. C.74: DSC thermogram of form II of 10
Fig. C.75: TGA thermogram of form II of 10
Fig. C.76:
1
H-NMR spectrum of form II of 10
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C.1.19 Compound 10, form III
10
Fig. C.77: Powder X-ray diractogram of form III of 10
Fig. C.78: DSC thermogram of form III of 10
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Fig. C.79: TGA thermogram of form III of 10
Fig. C.80:
1
H-NMR spectrum of form III of 10
214 Figures
C.1.20 Compound 11, form I
11
Fig. C.81: Powder X-ray diractogram of form I of 11
Fig. C.82: DSC thermogram of form I of 11
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Fig. C.83: TGA thermogram of form I of 11
Fig. C.84:
1
H-NMR spectrum of form I of 11
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C.1.21 Compound 12, form I
N
H
N
H
OO OHHO
12
Fig. C.85: Powder X-ray diractogram of form I of 12
Fig. C.86: DSC thermogram of form I of 12
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Fig. C.87: TGA thermogram of form I of 12
Fig. C.88:
1
H-NMR spectrum of form I of 12
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C.1.22 Compound 12, form II
N
H
N
H
OO OHHO
12
Fig. C.89: Powder X-ray diractogram of form II of 12
Fig. C.90: DSC thermogram of form II of 12
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Fig. C.91: TGA thermogram of form II of 12
Fig. C.92:
1
H-NMR spectrum of form II of 12
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C.1.23 Compound 12, form III
12
Fig. C.93: Crystallographic data of form III of 12 obtained
by SXRD
Fig. C.94: Calculated powder X-ray diractogram of form III of 12
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Fig. C.95: DSC thermogram of form III of 12
Fig. C.96: TGA thermogram of form III of 12
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C.1.24 Compound 12, form IV
12
Fig. C.97: Crystallographic data of form IV of 12 obtained
by SXRD
Fig. C.98: Calculated powder X-ray diractogram of form IV of 12
C.1 Polymorphs 223
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C.1.25 Compound 13, form I
N
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N
H
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13
Fig. C.99: Crystallographic data of form I of 13 solved by
PXRD
Fig. C.100: Powder X-ray diractogram of form I of 13
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Fig. C.101: DSC thermogram of form I of 13
Fig. C.102: TGA thermogram of form I of 13
Fig. C.103:
1
H-NMR spectrum of form I of 13
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C.1.26 Compound 17, form I
OO
N
H
HO N
17
Fig. C.104: Crystallographic data of form I of 17 obtained by
SXRD
Fig. C.105: Powder X-ray diractogram of form I of 17
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Fig. C.106: DSC thermogram of form I of 17
Fig. C.107: TGA thermogram of form I of 17
Fig. C.108:
1
H-NMR spectrum of form I of 17
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C.1.27 Compound 17, form II
OO
N
H
HO N
17
Fig. C.109: Crystallographic data of form II of 17 obtained by SXRD
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Fig. C.110: Calculated powder X-ray diractogram of form II of 17
Fig. C.111: DSC thermogram of form II of 17
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C.1.28 Compound 17, form III
OO
N
H
HO N
17
Fig. C.112: Crystallographic data of form III of 17 obtained by SXRD
Fig. C.113: Calculated powder X-ray diractogram of form III of 17
Fig. C.114: DSC thermogram of form III of 17

C.2 Multicomponent solids 233
C.2 Multicomponent solids
The powder X-ray diractogram, DSC and TGA thermograms,
1
H-NMR or
13
C-
NMR spectra and crystallographic data of the new multicomponent forms obtained
in the present work are included in this appendix. In some cases,
1
H-NMR,
13
C-
NMR or TGA data are missing due to lack of sample availability or because the
form was suÆciently characterized by the rest of the techniqu'oles.
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C.2.1 Cocrystal of 2 : fumaric acid, form A
2 : fumaric acid
Fig. C.115: Powder X-ray diractogram of form A of 2:fumaric acid cocrystal
Fig. C.116: DSC thermogram of form A of 2:fumaric acid cocrystal
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Fig. C.117: TGA thermogram of form A of 2:fumaric acid cocrystal
Fig. C.118:
1
H-NMR spectrum of form A of 2:fumaric acid cocrystal
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C.2.2 Cocrystal of 2 : fumaric acid, form B
2 : fumaric acid
Fig. C.119: Crystallographic data of form B of 2:fumaric acid cocrystal obtained by SXRD
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Fig. C.120: Powder X-ray diractogram of form B of 2:fumaric acid cocrystal
Fig. C.121: DSC thermogram of form B of 2:fumaric acid cocrystal
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C.2.3 Cocrystal of 2 : p-nitrobenzoic acid
2 : p-nitrobenzoic acid
Fig. C.122: Powder X-ray diractogram of 2:p-nitrobenzoic acid salt
Fig. C.123: DSC thermogram of 2:p-nitrobenzoic acid salt
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Fig. C.124: TGA thermogram of 2:p-nitrobenzoic acid salt
Fig. C.125:
1
H-NMR spectrum of 2:p-nitrobenzoic acid salt
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C.2.4 Cocrystal of 4 : fumaric acid, form A
4 : fumaric acid
Fig. C.126: Powder X-ray diractogram of form A of 4:fumaric acid salt
Fig. C.127: DSC thermogram of form A of 4:fumaric acid salt
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Fig. C.128: DSC thermogram of form A of 4:fumaric acid salt
Fig. C.129:
1
H-NMR spectrum of form A of 4:fumaric acid salt
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C.2.5 Cocrystal of 4 : fumaric acid, form B
4 : fumaric acid
Fig. C.130: Crystallographic data of form B of 4:fumaric acid salt obtained by SXRD
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Fig. C.131: Calculated powder X-ray diractogram of form B of 4:fumaric acid salt
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C.2.6 Salt of 4 : squaric acid, form A
4 : squaric acid
Fig. C.132: Powder X-ray diractogram of form A of 4:squaric acid salt
Fig. C.133: DSC thermogram of form A of 4:squaric acid salt
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Fig. C.134: TGA thermogram of form A of 4:squaric acid salt
Fig. C.135:
13
C-NMR spectrum of form A of 4:squaric acid salt
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C.2.7 Salt of 4 : squaric acid, form B
4 : squaric acid
Fig. C.136: Crystallographic data of form B of 4:squaric acid salt obtained by SXRD
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Fig. C.137: Calculated powder X-ray diractogram of form B of 4:squaric acid salt
Fig. C.138: DSC thermogram of form B of 4:squaric acid salt
Fig. C.139:
13
C-NMR spectrum of form B of 4:squaric acid salt
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C.2.8 Cocrystal of 4 : resorcinol, form A
4 : resorcinol
Fig. C.140: Crystallographic data of form A of 4:resorcinol cocrystal obtained by SXRD
Fig. C.141: Powder X-ray diractogram of form A of 4:resorcinol cocrystal
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Fig. C.142: DSC thermogram of form A of 4:resorcinol cocrystal
Fig. C.143: TGA thermogram of form A of 4:resorcinol cocrystal
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C.2.9 Cocrystal of 4 : resorcinol, form B
4 : resorcinol
Fig. C.144: Powder X-ray diractogram of form B of 4:resorcinol cocrystal
Fig. C.145: DSC thermogram of form B of 4:resorcinol cocrystal
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Fig. C.146: TGA thermogram of form B of 4:resorcinol cocrystal
Fig. C.147:
1
H-NMR spectrum of form B of 4:resorcinol cocrystal
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C.2.10 Cocrystal of 10 : resorcinol, form A
10 : resorcinol
Fig. C.148: Crystallographic data of form A of 10:resorcinol cocrystal obtained by SXRD
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Fig. C.149: Powder X-ray diractogram of form A of 10:resorcinol cocrystal
Fig. C.150: DSC thermogram of form A of 10:resorcinol cocrystal
Fig. C.151: TGA thermogram of form A of 10:resorcinol cocrystal
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C.2.11 Cocrystal of 10 : resorcinol, form B
10 : resorcinol
Fig. C.152: Crystallographic data of form B of 10:resorcinol cocrystal obtained by SXRD
Fig. C.153: Powder X-ray diractogram of form B of 10:resorcinol cocrystal
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Fig. C.154: DSC thermogram of form B of 10:resorcinol cocrystal
Fig. C.155: TGA thermogram of form B of 10:resorcinol cocrystal
Fig. C.156:
1
H-NMR spectrum of form B of 10:resorcinol cocrystal
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C.2.12 Cocrystal of 10 : hydroquinone, form A
10 : hydroquinone
Fig. C.157: Powder X-ray diractogram of form A of 10:hydroquinone cocrystal
Fig. C.158: DSC thermogram of form A of 10:hydroquinone cocrystal
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Fig. C.159: TGA thermogram of form A of 10:hydroquinone cocrystal
Fig. C.160:
1
H-NMR spectrum of form A of 10:hydroquinone cocrystal
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C.2.13 Cocrystal of 10 : hydroquinone, form B
10 : hydroquinone
Fig. C.161: Powder X-ray diractogram of form B of 10:hydroquinone cocrystal
Fig. C.162: DSC thermogram of form B of 10:hydroquinone cocrystal
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Fig. C.163: TGA thermogram of form B of 10:hydroquinone cocrystal
Fig. C.164:
1
H-NMR spectrum of form B of 10:hydroquinone cocrystal
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C.2.14 Salt 18
squaric acid : benzylamine
Fig. C.165: Crystallographic data of 18 salt obtained by SXRD
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Fig. C.166: Powder X-ray diractogram of 18 salt
Fig. C.167: DSC thermogram of 18 salt
Fig. C.168:
13
C-NMR spectrum of 18 salt
262 Figures
C.2.15 Salt 19
squaric acid:1,4-bis(3-aminopropyl)piperazine
Fig. C.169: Crystallographic data of 19 salt obtained by SXRD
Fig. C.170: Powder X-ray diractogram of 19 salt
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Fig. C.171: DSC thermogram of 19 salt
Fig. C.172: TGA thermogram of 19 salt
Fig. C.173:
13
C-NMR spectrum of 19 salt
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C.2.16 Salt 20
diethylamidosquaric acid : diethylamine
Fig. C.174: Crystallographic data of 20 salt obtained by SXRD
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Fig. C.175: Powder X-ray diractogram of 20 salt
Fig. C.176: DSC thermogram of 20 salt
266 Figures
C.2.17 Salt 21
squaric acid:tyramine
Fig. C.177: Crystallographic data of 21 salt obtained by SXRD
Fig. C.178: Powder X-ray diractogram of 21 salt
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Fig. C.179: DSC thermogram of 21 salt
Fig. C.180: TGA thermogram of 21 salt
Fig. C.181:
13
C-NMR spectrum of 21 salt
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C.2.18 Salt 22
benzylamidosquaric acid : benzylamine
Fig. C.182: Crystallographic data of 22 salt obtained by SXRD
C.2 Multicomponent solids 269
Fig. C.183: Powder X-ray diractogram of 22 salt
Fig. C.184: DSC thermogram of 22 salt
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C.2.19 Salt of 17:squaric acid
17
Fig. C.185: Crystallographic data of 17 salt obtained by SXRD
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Fig. C.186: Powder X-ray diractogram of 17 salt
Fig. C.187: DSC thermogram of 17 salt
Fig. C.188: TGA thermogram of 17 salt

Appendix D
Resum

Es conegut el fet que les esquaramides presenten una doble capacitat donado-
ra i acceptora d'enllacos d'hidrogen en solucio que les fa interessants en arees
com la qumica supramolecular o la quimica medica. No obstant aixo, la falta
d'informacio sobre les seves propietats en estat solid ens va encoratjar inicial-
ment portar a terme un screening polimorc de diversos compostos model am-
b l'objectiu de coneixer els trets estructurals i les preferencies conformacionals
d'aquesta famlia de compostos. En una segona fase, vam utilitzar aquesta in-
formacio per a dissenyar noves arquitectures supramoleculars a traves d'estrategies
d'enginyeria cristallina. Finalment, l'analisi de les seves estructures cristallines,
en combinacio amb l'estudi d'importants fenomens qumics associats com la coop-
erativitat, la preorganitzacio i la compressio electrostatica ens van ajudar a establir
relacions qumiques i cristallograques entre aquests compostos.
Polimorsme de les esquaramides
En aquesta tesi s'ha estudiat el polimorsme de quatre compostos model els quals
van ser curosament dissenyat amb el seu particular interes: la dibenzilesquarami-
da no conte grups acceptors/donadors d'enllac d'hidrogen addicionals a l'anell es-
quaramdic (1), les dues esquaramides que contenen grups piridina (2 i 3) difereixen
en la llargada de la cadena alqulica i, nalment, la N,N -dimetiletilendiesquaramida
(4) que conte dues amines terciaries i te major exibilitat (Fig. D.1).
Dibenzilesquaramida (1)
L'screening polimorc experimental del compost 1 ha resultat en l'obtencio de tres
formes poli-morques (Fig. D.2), dues de les quals comparteixen una transicio solid-
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Fig. D.1: Compostos model esquaramdics: (1) Dibenzilesquaramida, (2) 3,4-bis-(2-
metilaminopiridil)-1,2-dioxo-3-ciclobute, (3) 3,4-bis-(2-etilaminopiridil)-1,2-dioxo-3-ciclobute, (4)
3,4-bis-(2-dimetilamino-etilamino)-1,2-dioxo-3-ciclobute
solid a la mateixa temperatura cap a la fase de punt de fusio mes elevat (Fig. D.3).
Fig. D.2: Diagrames de DRXP de les formes I, II i III de 1
Fig. D.3: Termogrames de DSC de les formes I, II and III of 1
L'analisi de les seves estructures cristallines revela el mateix motiu estruc-
tural cap i cua en direccions paralleles, antiparalleles i no paralleles dels enl-
lacos d'hidrogen formats entre els NH amdics i els carbonils de les unitats es-
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quaramdiques (Fig. D.4). La forma II es diferencia de les altres dues en el fet que
conte dues molecules en diferent conformacio a la unitat asimetrica (Fig. D.5).
Fig. D.4: Estructures cristallines de les formes I, II and III del compost 1
Fig. D.5: Conformers sobreposats en la unitat asimetrica de la forma II del compost 1
3,4-bis-(2-metilaminopiridil)-1,2-dioxo-3-ciclobute (2)
L'screening polimorc del compost 2 va resultar en l'obtencio de dues formes
(Fig. D.6). La forma I presenta un punt de fusio a 166
Æ
C juntament amb una
cristallitzacio simultania cap a la forma II, la qual fon a 186
Æ
C(Fig. D.7).
Fig. D.6: Diagrames de DRXP de les formes I i II del compost 2
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Fig. D.7: Termogrames de DSC de les formes I i II del compost 2
Ocasionalment, es va observar una transicio solid-solid endotermica per DSC
(Fig. D.8) de la forma I a la forma II a una velocitat d'escalfament lenta (1
Æ
C/min),
revelant una relacio enantiotropica entre ambdos polimorfs, essent la forma I estable
per sota de la temperatura de transicio (ca. 160
Æ
C). Aquest comportament termic
es va corroborar qualitativament per termomicroscopia (Fig. D.9).
Fig. D.8: Termograma de DSC de la forma I del compost 2 mostrant la fusio/cristallitzacio
(vermell) i l'ocasionalment observada transicio solid-solid de la forma I a la II (blau)
L'estructura cristallina de les dues formes (Fig. D.10) presenta el mateix motiu
estructural (parallel i antiparallel) cap i cua que l'observat en el compost 1, junta-
ment amb interaccions secundaries de   stacking que difereixen en les direccions
en ambdues estructures. Tambe s'observen interaccions CH
aril
 N
piridina
.
3,4-bis-(2-etilaminopiridil)-1,2-dioxo-3-ciclobute (3)
Quatre formes polimorques es van obtenir de l'screening experimental del compost
3 (Fig. D.11). Curiosament, la naturalesa del fenomen termic de la forma I no va
poder ser conrmada ja que en l'analisi per DSC sembla una fusio (Fig. D.12), pero
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Fig. D.9: Fotogrames de termomicroscopia del compost 2, mostrant la transicio de fase solida
de la forma I a la II juntament amb la fusio/cristallitzacio durant l'escalfament a 10
Æ
C/min
Fig. D.10: Estructures cristallines i supercies de Hirshfeld de les formes I i II del compost 2
en l'analisi per termomicroscopia s'observa una transicio solid-solid (Fig.D.13). La
fusio de la forma II s'observa a 224
Æ
C. La forma III presenta un punt de fusio a
168
Æ
C i la forma IV fon a 180
Æ
C.
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Fig. D.11: Diagrames de DRXP de les formes I, II, III i IV del compost 3
Fig. D.12: Termogrames de DSC de les formes I, II, III, IV del compost 3
L'estructura cristallina de la forma I (Fig. D.14) presenta el mateix motiu cap
i cua observat en les altres esquaramides en el qual les unitats esquaramdiques
s'uneixen a traves d'enllac d'hidrogen en direccions antiparalleles. Tambe s'observen
interaccions secundaries CH- similars a les descrites per la forma I del compost
2. Els anells piridnics adopten una conformacio de zig-zag i les interaccions dels
grups CH
aril
 N
piridina
tambe s'observen.
3,4-bis-(2-dimethylamino-ethylamino)-1,2-dioxo-3- cyclobutene,
(4)
L'screening polimorc del compost 4 va resultar en diversos polimorfs, no tots en
forma pura (Fig. D.15). Varies indexacions dels difractogrames de la forma I no
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Fig. D.13: Fotogrames de termomicroscopia del compost 3, mostrant la transicio de fase solida
de la forma I a la II i la subsequent fusio durant l'escalfament a 10
Æ
C/min
Fig. D.14: Estructura cristallina de la forma I del compost 3 (hidrogens no presents)
van tenir exit, suggerint una contaminacio d'una altra fase o una resolucio pobre
del difractograma.
L'analisi per DSC de la forma I (+ , hipotetica), presenta una transicio en-
dotermica a 45
Æ
C cap a la forma IV (p.f.=227
Æ
C) durant l'escalfament (conrmat
per DRXP de temperatura variable). Diversos analisis d'escalfament i refredament
amb DSC presenten una transico a la mateixa temperatura amb menor ental-pia
en el refredament, suggerint una transicio de reversibilitat incompleta (Fig. D.17)
i conrmada per termomicroscopia. La forma II presenta una transicio solid-solid
endotermica cap a la forma IV a 150
Æ
C(conrmada per DRXP de temperatura vari-
able). Finalment, l'analisi de DSC de la forma III presenta una transicio solid-solid
a 44
Æ
C cap a la forma d'alta temperatura.
En termes de relacio termodinamica entre les formes d'aquest sistema multi-
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Fig. D.15: DRXP experimentals de les formes I + , II i IV i el DRXP calculat de la forma III
del compost 4
Fig. D.16: Termogrames de DSC de les formes I (+ ), II i III
polimorc es pot concloure que la forma I (+ ) seria enantiotropica amb la forma
IV, aixi com tambe la forma II amb la forma IV. Mostres de forma III mantingudes
a t.a. van transformar irreversiblement cap a la forma I (+ ). Un esquema de la
relacio termodinamica entre les diferents formes es pot observar a la gura D.18.
Les dues estructures cristallines obtingudes de les formes II i III (Fig. D.19)
presenten el tpic motiu cap i cua d'enllac d'hidrogen entre unitats esquaramdiques
amb orientacions paralleles i antiparalleles.
Despres d'estudiar quatre compostos model d'esquaramides secundaries en es-
tat solid, l'existencia d'un sinto supramolecular robust auto-associatiu s'observa en
vuit estructures cristallines resoltes de les tretze formes polimorques obtingudes.
Presenten un mateix motiu estructural imperturbable en forma de cadena en el qual
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Fig. D.17: DSC de la forma I mostrant una transicio reversible cap a la forma IV durant un
experiment d'escalfament-refredament
Fig. D.18: Transformacions polimorques del compost 4
Fig. D.19: Estructures cristallines de les formes II i III del compost 4
agregats d'esquaramida interaccionen a traves d'enllacos d'hidrogen. El seguent es-
quema resumeix les ca-racteristiques polimorques principals dels quatre compostos
model estudiats (Fig. D.20).
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Fig. D.20: Resum dels sistemes polimorcs estudiats
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De la solucio al cristall
En aquesta seccio, les preferencies estructurals d'un model d'esquaramida concret
(2) son analitzades per tal d'entendre la relacio entre l'estructura dels agregats en
solucio i l'estat solid.
Estudis previs en solucio demostren que les esquaramides secundaries presenten
dues conformacions en solucio: anti/anti i anti/sin. Ambdues poden produir un sin-
to R
2
2
(n) amb grups acceptors i donadors d'enllac d'hidrogen apropiats (Fig. D.21).
Fig. D.21: Dues conformacions diferents de les esquaramides secundaries
Inicialment, 2 es va analitzar per
1
H-RMN i el seu espectre en CDCl
3
a baixa
temperatura presenta tres conjunts de senyals N-H, suggerint que 2 esta present com
a mescla de dues conformacions diferents, una simetrica i una asimetrica (anti/anti
(Fig. D.24, 2c) i anti/sin (Fig. D.24, 2a or 2b)) gracies a la rotacio de l'enllac
C-N
amida
que es congela a baixa temperatura (Fig. D.22).
El desplacament qumic observat en experiments de dilucio en base a 2D
1
H-
RMN COSY fa concloure que, dels conformers asimetrics, el dimeric 2b es preferit
(Fig. D.23). Totes les formes conformacionals possibles es relacionen a traves de la
seguent proposta esquematica (Fig. D.24).
Els resultats indiquen que a mesura que s'augmenta la concentracio a 240 K,
la forma auto-associativa preferida es la 2b. Per aquest motiu, en circumstancies
en les quals el mode d'agregat es similar al de l'estructura cristallina es dedueix
que els cristalls haurien de presentar el conformer 2b (contrariament als resultats
obtinguts de l'screening polimorc, que es basen en el 2c). Aquestes observacions
sugereixen que la formacio dels agregats en cadena cap i cua estan afavorits gracies
a la cooperativitat dels enllacos d'hidrogen.
Tenint en compte aquests resultats en solucio, es va estudiar el fenomen de la
cooperativitat i la seva relacio amb la preferencia d'aquests compostos per la confor-
macio en cadena anti/anti en estat solid dissenyant un nou compost model senzill:
la dimetilesquaramida (5). Per fer-ho es va aplicar la teoria desenvolupada per
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Fig. D.22: Equilibri conformacional i espectre de
1
H-RMN del compost 2 en CDCl
3
a 240 K,
260 K i 290 K
Fig. D.23: 2D
1
H-RMN COSY a 240 K del compost 2 durant la dilucio
Chris Hunter, la qual es basa en l'us d'uns parametres que quantiquen el caracter
donador o acceptor d'enllac d'hidrogen d'un grup funcional. Aquests parametres es
calculen a partir de la superfcie de potencial electrostatic (MEPS) de la molecula,
obtenint una energia maxima i mnima que es tradueix en els parametres  i 
(Fig. D.25).
Amb aquest estudi es va observar que l'energia d'interaccio de l'agregat en con-
formacio anti/anti de 5 disminuia dramaticament per efecte de la cooperativitat i,
en canvi, l'energia del sin/sin es mantenia constant (Fig. D.26), suggerint una ex-
plicacio per la qual les diesquaramides, en absencia de grups funcionals addicionals,
presenten nomes el sinto supramolecular anti/anti en estat solid.
Resum 285
Fig. D.24: Cicle termodinamic proposat per a la dimeritzacio del compost 2
Fig. D.25: Superfcies MEP i parametres d'enllac d'hidrogen despres de la primera interaccio
dels conformers anti/anti i sin/sin.
El resultat d'aquest estudi teoric es va contrastar amb un screening polimorc
experimental de 5 a traves del qual nomes es va obtenir una forma polimorca que
presenta el sinto predit anti/anti en cadena (Fig. D.27). La teoria dels parametres
d'enllac d'hidrogen tambe es va aplicar al sistema del compost 2 (estudiat en dis-
solucio) i es van conrmar les observacions experimentals.
Com que la conformacio sin/sin no es va observar en cap dels compostos estu-
diats, es va dissenyar una nova diesquaramida cclica covalentment forcada (6)
per tal d'estudiar les seves caracterstiques estructurals (Fig. D.28, (a)). La seva
estructura cristallina presenta la formacio d'enllacos d'hidrogen esperada entre els
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Fig. D.26: Energies d'interaccio del monomer terminal (anti/anti: blau; sin/sin: vermell) calcu-
lat amb DFT B3LYP 6  31 +G nivell de teoria utilitzant Spartan'10
Fig. D.27: Estructura cristallina del compost 5
NH  OC establerts entre dues molecules adjacents formant cadenes practicament
al mateix pla (Fig. D.28, (b)).
Fig. D.28: (a) Esquema del compost 6 (b) Estructura cristallina i supercie de Hirshfeld del
compost 6 en les quals es mostren les interaccions laterals en vermell
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En el primer estudi de les esquaramides 1, 2 i 3 es va observar que les inter-
accions competitives com el     stacking no afectaven la conformacio anti/anti.
Per tal d'estudiar el seu efecte en la conformacio sin/sin, a priori menys estable,
es va dissenyar una altra esquaramida macrocclica contenint grups aromatics (7,
Fig. D.29, (a)). La seva estructura cristallina presenta la formacio d'enllacos
d'hidrogen entre grups NH  OC distorsionada en el pla en forma de zig-zag i inter-
accions addicionals entre CO  H
aromatic
i     stacking (Fig. D.29, (b)). Aquest
fenomen, observat per primera vegada, suggereix que la cooperativitat estabilitza
els agregats anti/anti superant l'efecte de les interaccions secundaries mentres que
la conformacio no cooperativa sin/sin es menys resistent a la seva presencia.
Fig. D.29: (a) Esquema del compost 7 (b) Estructura cristallina i superfcie de Hirshfeld del
compost 7 en la qual es mostren les interaccions laterals en vermell
Una vegada es va observar la conformacio sin/sin en diesquaramides, ens vam
questionar si les monoesquaramides, les quals estan mes impedides en termes de
cooperativitat, podrien presentar la conformacio sin/sin en estat solid. Per aquest
motiu es va dissenyar una monoesquaramida-ester senzilla (8) (Fig. D.30) i es va
realitzar un screening polimorc experimental. Nomes es va otenir una forma i
la seva estructura cristallina presenta dmers esquaramida/esquaramida fortament
auto-associats interaccionant a traves d'enllacos d'hidrogen en conformacio sin/sin,
com tambe interaccions secundaries CO  H
ethyl
(Fig. D.31).
Aquest resultat suggereix que, en absencia de grups donadors/acceptors com-
petitius, els dimers son mes estables que les cadenes probablement degut al fet que
la cooperativitat es troba impedida per alinear les unitats esquaramdiques en ca-
dena. En aquest sentit, un altre compost model es va dissenyar (9) contenint un
grup piridnic addicional i se'n van calcular els parametres  and  per contrastar-
los amb els resultats experimentals de l'screening (Fig.D.32, (a)). L'estructura
cristallina conrma la prediccio que grups competitius alteren el sinto supramolec-
ular (Fig. D.32, (b)).
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Fig. D.30: Sintons supramoleculars possibles pel compost 8
Fig. D.31: Agregats dimerics observats en l'estructura cristallina del compost 8 juntament amb
la superfcie de Hirshfeld
Fig. D.32: (a) Parametres  i  pel compost 9 (b) Dmers en l'estructura cristallina del compost
9
Enginyeria cristallina: disseny de cocristalls
En la seguent fase d'aquesta tesi es van dissenyar nous materials en base als coneixe-
ments adquirits sobre l'estat solid dels derivats d'acid esquaric. Com s'ha mostrat
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en les seccions anteriors, tots els intents de cristallitzacio de les diferents formes de
les esquaramides van resultar en l'existencia d'una sola conformacio anti/anti cap i
cua, a no ser que la molecula es forces covalentment. Per aquest motiu, una primera
idea va ser dissenyar cocristalls amb coformers donadors/acceptors complementaris
com els fenols i els acids carboxlics apropiats per una conformacio anti/anti i sin/sin
respectivament (Fig. D.33).
Fig. D.33: Esquema dels possibles sintons supramoleculars amb coformers acceptors i donadors
d'enllacos d'hidrogen
Encara que el resorcinol i els acids carboxlics semblessin optims des d'un punt
de vista geometric, els calculs suggerien que no s'obtindrien cocristalls amb les
diesquaramides 5 i 7, degut al fet que les energies d'interaccio d'aquests heterosin-
tons era menor a la dels homosintons (Fig. D.34).
Fig. D.34: Energies d'interaccio estimades dels heterosintons i els homosintons per a les confor-
macions anti/anti i sin/sin dels compostos 5 i 7, respectivament.
Per a corroborar aquesta prediccio, es va portar a terme un screening experi-
mental (extensiu a altres bons grups donadors/acceptors d'enllac d'hidrogen) amb
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els compostos 5 i 7 i no va produir cap cocristall.
1
Aquests resultats reforcen la
teoria que l'autoagregacio dels anells esquaramdics en conformacio anti/anti en
estat solid es robusta i difcil de ser perturbada per altres grups competitius.
Fig. D.35: Coformers utilitzats en l'screening de cocristalls dels compostos 5 i 7
Per aquesta rao, vam dissenyar dues noves estrategies d'enginyeria cristallina: la
primera basada en impedir la conformacio anti/anti en cap i cua a traves d'enllacos
intramoleculars (Fig. D.36 (a)) i la segona, que consisteix en aprotar la conforma-
cio anti/anti i escollir coformers complementaris que interaccionin amb les cadenes
secundaries periferiques funcionalitzades de les esquaramides (Fig. D.36 (b) i (c)).
Primera estrategia: preorganitzacio
En aquesta estrategia es va estudiar l'efecte d'introduir un acceptor d'enllac d'hidrogen
extra a l'esquaramida amb l'objectiu de modicar la preferencia pel model auto-
associatiu cooperatiu observat en les esquaramides estudiades ns el moment i
1
En el cas del compost 7 es van identicar indicis d'una fase nova que no es va poder carac-
teritzar sucientment com per armar la presencia d'un cocristall
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Fig. D.36: Esquema del disseny de cocristalls: (a) via enllacos d'hidrogen intramoleculars i (b,
c) via interaccions periferiques
generar nous sintons supramoleculars. Es van dissenyar els compostos 10 i 11
(Fig. D.37).
Fig. D.37: Esquema dels compostos 10 i 11
Es va realitzar un screening polimorc no exhaustiu pel compost 11 pero de-
safortunadament no es va poder obtenir l'estructura cristallina de l'unica forma
obtinguda.
Encara que les esquaramides son bons donadors/acceptors d'enllac d'hidrogen,
les monoesquaramides poden presentar diversos sintons supramoleculars i per aquest
motiu es va seguir l'estrategia amb el compost 10. Quatre sintons diferents es podien
esperar: la conguracio en anti/anti podia produir dos sintons, el polmer cap i cua
i el monomer intramolecular (Fig. D.38 (a) and (b)), mentres que el la conguracio
en sin/sin podia produir la cadena i el monomer intramolecular (Fig. D.38 (d) and
(c)).
Es va portar a terme un screening polimorc obtenint tres formes: dues anhidres
i un hidrat, de les quals se'n va poder resoldre la seva estructura cristallina a partir
del difractograma de pols, exceptuant l'hidrat (Fig. D.39 i Fig. D.40).
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Fig. D.38: Sintons supramoleculars esperats pel compost 10 amb les seves corresponents de-
scripcions graques
Fig. D.39: Diagrames de DRXP de les formes I, II i III. La forma II es va obtenir amb un
experiment de DRXP de temperatura variable a partir de la forma I (tambe present en la gura)
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Fig. D.40: Estructures cristallines de les formes I i II mostrant interacions d'enllac d'hidrogen
inter i intramoleculars
La forma I presenta un anell de sis membres a traves d'enllacos d'hidrogen
intramoleculars, quasi perpendiculars al pla denit per l'anell de piperazina. Capes
paralleles de molecules s'estabilitzen a traves d'interaccions     stacking entre
els anells de ciclobute i interaccions febles d'enllac d'hidrogen entre els oxgens
carbonlics i els hidrogens de la piperazina. La forma II, en canvi, presenta una
conguracio cap i cua a traves d'enllacos d'hidrogen intermoleculars i els anells de
ciclobute interaccionen via     stacking. En ambdos casos l'anell de piperazina
adopta una conformacio de cadira.
Una vegada conrmada la conformacio intramolecular, vam decidir utilitzar la
preorganitzacio per a dirigir la formacio de cocristalls amb coformers doblement
donadors d'enllac d'hidrogen i es va portar a terme un screening de cocristalls entre
el compost 10 i el resorcinol esperant una estructura similar a la proposada en la
gura D.41.
N
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O
OO
O O
ON
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H
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H
H
R22 (11)
Fig. D.41: Complementarietat acceptor-donador entre el cocristall esperat pel compost 10 i el
resorcinol
Es van obtenir dos cocristalls: un anhidre i un hidrat, amb estequiometries 1:2
(10:resorcinol) i 1:2:2 (10:resorcinol:water), l'estructura dels quals no corresponia a
l'esperada (Fig. D.42). No obstant aixo, es van obtenir evidencies de polimorsme
durant l'screening de cocristalls que no descarten el sinto supramolecular esperat
R
2
2
(10).
En resum, vam estudiar com la formacio d'un enllac d'hidrogen intramolecular
afecta el polimorsme d'una monoesquaramida-ester. No obstant aixo, la preor-
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Fig. D.42: Estructura cristal dels cocristalls amb resorcinol
ganitzacio no ha sigut sucient com per dirigir la formacio d'un cocristall entre un
doble do-nador i un doble acceptor que havem esperat. Per altra banda, s'han
pogut observar tres dels quatre sintons supramoleculars proposats a priori pel com-
post 10.
Segona estrategia: cocristallitzacio amb coformers comple-
mentaris via interaccions periferiques
Totes les dicultats en impedir el sinto cap i cua en anti/anti de les esquaramides
secundaries revela que aquests compostos poden ser molt atractius per ser explotats
com a plantilla estructural en el disseny de noves estructures multicomponents.
Amb una funcionalitzacio adequada dels substituents de les cadenes secundaries,
els coformers complementaris hi poden establir fortes interaccions periferiques.
Cocristalls amb coformers donadors d'enllac d'hidrogen
Es va realitzar un screening de cocristalls entre dos models esquaramdics (2 i 4, Fig.
D.43) que contenen grups piridil i dimetilamino, i un conjunt de coformers donadors
d'enllac d'hidrogen (taula D.1) i el resultat va ser la identicacio de tres i sis formes
solides multicomponents, respectivament, com tambe indicis de l'existencia d'altres
fases. Seguidament es presenten les estructures cristallines obtingudes.
 Cocristall 2 : acid fumaric : ACN
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Fig. D.43: Esquema dels compostos 2 i 4.
Tab. D.1: Experiments de cocristallitzacio dels compostos 2 i 4. -: cap solid obtingut, 0: cap
cocristall, 1: indicis de fases noves, 2: cocristall conrmat per DRXS o DRXP i
1
H-RMN
Coformer Compost 2 Compost 4

Acid fumaric 2 2

Acid p-nitrobenzoic 2 1

Acid glutaric 0 1

Acid glutamic 0 1

Acid oxalic 1 1

Acid ctric 0 1

Acid esquaric 1 2
Resorcinol 0 2
Urea - 1
Nicotinamida 0 1
Fig. D.44: Estructura cristallina del cocristall solvat amb ACN entre el compost 2 i l'acid
fumaric, 1:1:2 (molecules d'ACN no presents)
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 Sal 4 : acid fumaric : MeOH : aigua
Fig. D.45: Estructura cristallina del cocristall solvat amb MeOH/aigua entre el compost 4 i
l'acid fumaric, 2:2:1:3 (molecules d'aigua no presents)
Les estructures cristallines de 2 i 4 amb acid fumaric presenten un tipus de
conformacio cap i cua diferent. Les dues son cadenes, pero el cocristall de
2 presenta un motiu tipus anell R
2
2
(10) format per deu atoms en el qual hi
participen els dos donadors i acceptors d'enllac d'hidrogen. Per altra banda,
el cocristall de 4 cristallitza mitjancant una estructura cap i cua desplacada,
possiblement a causa de les interaccions de l'acid fumaric, formant una ca-
dena (C(6)), en la qual participen nomes un donador i un acceptor d'enllac
d'hidrogen (Fig. D.46).
Fig. D.46: Motius estructurals en cap i cua de les formes multicomponents de (a) 2 i (b) 4 amb
acid fumaric (Coformers no presents)
 Cocristall 4 : resorcinol
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En aquest cas s'han identicat dues formes polimorques anhidres de cocristall
(Fig. D.47) de les quals nomes s'ha pogut resoldre una estructura cristallina
a partir del difractograma de pols (Fig. D.48).
Fig. D.47: Diagrames de DRXP de les dues formes polimorques del cocristall entre 4 i resorcinol
(1:1)
Fig. D.48: Estructura cristallina del cocristall entre 4 i resorcinol, forma I
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 Sal 4 : acid esquaric : aigua
Fig. D.49: Sal hidratada entre 4 i acid esquaric
Cocristalls amb coformers acceptors d'enllac d'hidrogen
En aquest cas es va decidir expandir l'estrategia anterior funcionalitzant els sub-
stituents de les cadenes secundaries de les esquaramides amb donadors d'enllac
d'hidrogen (Fig. D.50) i es va dissenyar el compost 12.
Fig. D.50: Esquema de (a) una diesquaramida general amb grups donadors d'enllac d'hidrogen
periferics i (b) compost 12
El resultat de l'screening de cocristalls realitzat amb un conjunt de coformers
acceptors d'enllac d'hidrogen es resumeix a la seguent taula D.2.
De tots els indicis observats, nomes es van poder obtenir dues estructures cristallines
de solvats del compost 12: en etanol i en DMSO/aigua (Fig. D.51).
Encara que els solvents no es van emprar com a coformers, les dues estruc-
tures cristallines posen de manifest que l'estrategia proposada per a la formacio
de cocristalls amb acceptors d'enllac d'hidrogen via interaccions d'enllac d'hidrogen
periferiques podria funcionar.
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Tab. D.2: Experiments de cocristallitzacio del compost 12. -: cap solid obtingut, 0: cap
cocristall, 1: indicis de fase nova, 2: cocristall conrmat per DRXS o DRXP i
1
H-RMN
Coformer Compost 12
acid oxalic 1
resorcinol 0
nicotinamida 1
isonicotinamida 1
bipiridina 1
piridina 1
Fig. D.51: Estructures cristallines dels solvats de 12 amb (a) etanol i (b) DMSO/aigua
Autoensemblatge i efecte plantilla: arquitectures
helicoidals
Considerant que el motiu estructural cap i cua es pot utilitzar com a plantilla,
vam dissenyar una nova esquaramida asimetrica (13) funcionalitzada amb grups
acceptor i donador d'enllac d'hidrogen al mateix esquelet amb l'objectiu de produir
noves topologies autoensemblades. En un primer moment, es van suggerir dos
tipus d'estructura: (a) cclica i (b) polimerica, que podrien donar lloc a estructures
helicoidals (Fig. D.52).
L'estructura cristallina del compost 13 revela una cadena d'agregats formant
una helix (seguint el model (a) de la gura D.52), i les unitats es connecten entre
elles mitjancant interaccions febles de CH{ (Fig. D.54).

Es una estructura sense
precedent en les esquaramides.
Aquesta estructura es racemica, una combinacio d'una helix en rotacio horaria
i una helix en rotacio antihoraria (Fig. D.55).
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Fig. D.52: Possibles agregats de 13 (a) Cclic i (b) Polimeric
Fig. D.53: Estructura cristallina del compost 13
Fig. D.54: (a) Empaquetament helicoidal via interaccions CH   i (b) interaccions CH  
entre el grup metilamino i l'anell aromatic en el compost 13
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Fig. D.55: Rotacio horaria i antihoraria de les dues helix diferents en el cristall racemic del
compost 13
Derivats d'acid esquaric amb carrega: compressio
electrostatica
Finalment en aquesta tesi, es van estudiar altres derivats d'acid esquaric tenint en
compte efectes com la compressio electrostatica, ja descrita en sals d'acid esquaric
a la bibliograa, i interaccions d'enllac d'hidrogen de carrega assistida.
Amb l'objectiu de combinar les interaccions esmentades es va explorar uns nous
derivats zwitterionics de l'acid esquaric per tal de dissenyar noves estructures supra-
moleculars en l'estat solid. El compost 17 va ser l'objecte d'estudi (Fig. D.56).
Fig. D.56: Sntesis de l'esquaramida zwitterionica 17 i esquema de l'autoensemblatge a traves
de la compressio electrostatica
En principi, dos sintons supramoleculars son geometricament possibles: un anell
R
2
2
(10) (Fig. D.57 (a)) i una cadena C(5) or C(6) (Fig. D.57 (b)).
Per tal d'estudiar aquesta hipotesi, es va realitzar un screening polimorc del
qual se'n van obtenir dues formes anhidres i un hidrat. Les tres formes presenten
dmers electrostaticament comprimits i enllacats entre ells via interaccions de N-
H  O (Fig. D.58).
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Fig. D.57: Motius estructurals d'ensemblatge diferents pel compost 17
Fig. D.58: Dmers en stacking (d
centroides
) per a les formes anhidres I i II del compost 17
La particularitat de cada anhidre es la connexio dels dmers, produint sintons
supramoleculars diferents pels dos polimorfs: anells R
2
2
(10) en la forma I i una
cadena C(5) en la forma II (Fig. D.59).
En el cas de l'hidrat (forma III), s'observa un sinto supramolecular diferent: una
cadena C(6) estabilitzada per molecules d'aigua a traves d'enllacos d'hidrogen (Fig.
D.60).
Per altra banda, durant l'screening polimorc es va obtenir una forma multicom-
ponent degut a l'existencia de traces d'acid esquaric: una sal monosquarat/17. De
la mateixa manera, l'estructura presenta els dmers electrostaticament comprimits
ja observats en les altres formes descrites per aquest compost (Fig. D.61). Una ca-
racterstica important d'aquesta estructura es que els enllacos d'hidrogen entre els
anells d'acid esquaric s'estableixen en forma d'anells R
2
2
(10) previament observada
en l'acid esquaric.
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Fig. D.59: Sintons supramoleculars observats en la forma I (a) i la forma II (b) connectant els
dmers electrostaticament comprimits en el cristall
Fig. D.60: Sinto supramolecular observat juntament amb els dmers en stacking de la forma
hidratada (forma III)
Aquests resultats suggereixen l'us potencial d'estructures zwitterioniques au-
toensemblades com a coformers ecients en la cerca de nous cocristalls amb una
varietat d'acceptors/donadors d'enllac d'hidrogen com acids carboxlics, urees, amides,
etc.
Aquesta tesi es un estudi multidisciplinar de l'estat solid de derivats de l'acid es-
Fig. D.61: Estructura cristallina de la sal monosquarat/17
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quaric, en el qual es combinen arees com l'enginyeria cristallina, la sintesi organica,
la qumica supramolecular i la cristallograa. A mes a mes, s'han utilitzat metodolo-
gies experimentals d'screening tant polimorc com de cocristalls, com tambe varies
tecniques d'analisi. Finalment, el fet que els compostos model son difcils de
cristallitzar en qualitat de monocristalls, ha permes optimitzar un metode de res-
olucio d'estructures cristallines a partir del difractograma de pols.
